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ABSTRACT
FOOD PROTEIN-BASED CORE−SHELL NANOCARRIERS FOR ORAL DRUG
DELIVERY APPLICATIONS: INFLUENCE OF SHELL COMPOSITION ON IN
VITRO AND IN VIVO FUNCTIONAL PERFORMANCE OF ZEIN NANOCARRIERS
MD SAIFUL ISLAM
2017

Oral delivery is the most preferred route for drug administration. Oral drug delivery
is limited by poor physicochemical properties of drugs and physiological barriers in the
gastrointestinal tract. To this end, there is a need for developing new carrier systems to
enhance the oral bioavailability of poorly absorbed molecules. Food-grade biopolymers are
attractive materials for developing drug delivery carriers’ due to their unique properties
and proven safety. Six different core-shell nanocarriers were prepared using food-grade
biopolymers

including

zein-casein

(ZC)

nanoparticles,

zein-lactoferrin

(ZLF)

nanoparticles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate (ZWP)
nanoparticles, zein-pluronic-lecithin (ZPL) nanoparticles and zein-PEG (ZPEG) micelles.
The study was aimed at systematically investigating the influence of shell composition on
the functional performance of core-shell nanocarriers for oral drug delivery applications.
The first goal was to develop and study the structure-function relationship of coreshell nanocarriers for oral drug delivery applications. Nile red (NR) and Cy 5.5 were used
as model dyes for this study. The particle size of the nanocarriers ranged from 100 to 250
nm, and the nanocarrier had a uniform size distribution as evidenced from the low PDI
(0.08 to 0.3). The zeta potential values varied from -10 to 30 mV depending on the shell
composition. The core-shell structure of the nanocarrier was confirmed by Transmission

xxi

Electron Microscopy (TEM). The nanocarriers sustained the release of NR in simulated
gastric and intestinal fluids. NR release from the nanocarriers predominantly followed
Peppas model which indicates the diffusion of NR from nanocarriers by polymer erosion
by hydrolytic or enzymatic cleavage. NR release from ZPEG micelles followed first order
release kinetics. The nanocarriers were taken up by endocytosis in Caco-2 cells, which is
an established model for intestinal permeability studies. ZLG nanocarriers showed the
highest permeability across Caco-2 cell monolayers, while ZC nanoparticles showed the
lowest permeability among the six formulations. ZPEG micelles also showed P-gp
inhibitory activity. All the nanocarriers were found to have bioadhesive properties. Among
the six different nanocarriers, ZLG and ZWP nanocarriers showed significantly higher
bioadhesive property. In-vivo biodistribution of the nanocarriers was studied using Cy 5.5,
a near-IR dye and all the formulations showed longer retention in the rat gastrointestinal
tract compared to the free dye. Among the formulations, ZLG and ZWP nanoparticles were
retained longest in the rat gastrointestinal tract (≥24 hours). All the nanocarriers were found
to be non-immunogenic on oral administration to mice.

The second goal was to investigate the use of core-shell nanocarriers for oral
delivery of a model antiretroviral drug, lopinavir (LPV). LPV is a first-line protease
inhibitor used for the treatment of HIV infections, especially in children. The drug has poor
oral bioavailability due to its poor water solubility, poor membrane permeability and firstpass metabolism in the intestine. LPV is a substrate for the CYP3A4 enzyme and hence is
used in combination with ritonavir (a CYP3A4 inhibitor) to boost the oral bioavailability
of LPV. The current pediatric oral liquid formulation contains LPV and ritonavir (RTV) in

xxii

a mixture of high proportion of propylene glycol and alcohol. The main goal was to test
the feasibility of developing a water dispersible RTV free pediatric formulation of LPV
using zein-based core-shell nanocarriers. The impact of shell composition on the functional
properties of LPV loaded nanocarriers was evaluated in vitro and in vivo. The
encapsulation efficiency for LPV was above 70% in all the nanocarriers, and ZPL
nanoparticles showed the highest encapsulation efficiency (87.92±7.19%). The loading
efficiency ranged from 2 to 5% based on the shell composition. The release of LPV was
sustained both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) for 24
hours. To test the feasibility of developing a food sprinkle formulation, the compatibility
of the nanoformulations with model food matrices were studied. The nanocarriers were
stable when incubated in food matrices (milk and applesauce) and <30% of LPV was
released within first 1 hour followed by sustained release in SGF and SIF for 24 hours. The
nanocarriers increased the permeability coefficient (Papp) of LPV across the Caco-2 cell
monolayers by two to four-fold. The Papp values of LPV loaded nanocarriers decreased in
the following order ZPEG>ZC>ZLF>ZWP>ZLG>ZPL. In vivo pharmacokinetic study in
rats showed that the oral bioavailability of LPV increased by 2-fold compared to marketed
LPV/RTV liquid formulation (Kaletra®). The highest oral bioavailability was obtained
with LPV loaded ZPEG micelles followed by ZWP and ZLG nanoparticles. Highest
plasma concentration (Cmax) of LPV was achieved with ZPEG micelles which was
comparable to Kaletra® formulation. The extent of absorption (AUC) of LPV was in the
following decreasing order of ZPEG>ZWP>ZLG>Kaletra®>free LPV. Multiple dose PK
study further demonstrated that similar or higher steady-state plasma concentration can be
obtained using ZPEG micelles compared to Kaletra®. Findings from this chapter

xxiii

concludes that zein-based nanocarriers can be used to develop ritonavir free LPV
formulation which will ultimately reduce the total drug load and drug-drug interaction in
the treatment of HIV infection.
The last objective was to demonstrate the feasibility of using zein-based core-shell
nanocarriers for oral delivery of fenretinide, an investigational anti-cancer molecule.
Fenretinide has been found to be effective against several cancers including pediatric
neuroblastoma, However, the clinical development of fenretinide is limited by its poor
physicochemical properties. Fenretinide is a poorly soluble and poor permeable anti-cancer
agent. Further, the compound has poor chemical stability. The encapsulation efficiency for
fenretinide was above 70% in all the nanocarriers and zein-β-casein (ZC) nanoparticles
showed the highest encapsulation efficiency (90±0.091%). The release of fenretinide was
sustained both in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) for 24
hours. The nanocarriers were stable when incubated in food matrices (milk and
applesauce), and less than 30% of fenretinide was released after incubation for 1 hour in
food matrices. About 60% of fenretinide was released over 24 hours when the nanocarriers
was transferred from food matrices to SGF and SIF. The nanocarriers enhanced the
permeability of fenretinide across the Caco-2 cell monolayers from 1x10-6 to 72.42x10-6
cm/s. The order of permeability of fenretinide loaded nanocarriers was found to be in the
following decreasing order ZPL>ZLG>ZC>ZWP>ZLF>ZPEG. Among others tested for
single dose PK study of fenretinide, ZLG nanocarriers showed the highest oral
bioavailability of fenretinide (6-fold) compared to free fenretinide suspension.
Nanocarriers increased the elimination half-life (t1/2) by 2- to 4-fold. ZPL nanocarriers
showed the highest Cmax (0.61 μg/mL) of fenretinide, while fenretinide loaded ZC

xxiv

nanocarriers showed the lowest Cmax (0.23 μg/mL). Nanocarriers showed the following
decreasing rank order for relative oral bioavailability, ZWP>ZLG>ZPL>ZC, indicating
that shell composition has a significant influence on the oral bioavailability. Further,
multiple dose pharmacokinetic (PK) studies of fenretinide and fenretinide loaded zeinpluronic-lecithin (ZPL) nanocarriers was performed. The pharmacokinetics of twice a day
free fenretinide suspension was compared with once a fenretinide loaded ZPL nanocarriers.
The steady state concentration of fenretinide and fenretinide loaded ZPL nanocarriers was
achieved at around 50-hours. However, the steady-state plasma concentration of
fenretinide from the ZPL nanocarriers was 5-fold higher compared to free fenretinide
suspension.
Overall, the outcomes from this study demonstrate the structure-function
relationship of core-shell protein nanocarriers for oral drug delivery applications. The
findings from this study can be used to develop food protein based oral drug delivery
systems with specific functional attributes for various oral drug delivery applications.

1

CHAPTER ONE: Introduction
1.1. Oral drug delivery
Oral drug delivery is the preferred route of drug administration due to the ease of
drug administration, cost-effective, and ease of manufacturing. Additionally, oral drug
administration has high patient compliance (Fix 1999). Therefore, 60% of the marketed
formulations are for oral administration (Renukuntla et al. 2013).
Despite the advantages for oral drug administration, the drug delivery by this route
is associated with multiple challenges including varying pH, poor water solubility, poor
membrane permeability, poor stability, and first-pass metabolism.

1.2. Oral drug absorption
1.2.1. Gastrointestinal anatomy and physiology
Human GIT is about 8.35 m long starting from the esophagus followed by the
stomach, small intestine (duodenum, jejunum, and ileum) and large intestine (cecum,
colon, and rectum) (Fig. 1A). Small intestine covers about 81% of the total length of the
GIT and is the major site of drug absorption due to the large surface area (~100 m2)
(DeSesso and Jacobson 2001). The presence of villi and microvilli contributes to the large
surface area of small intestine (Fig. 1B) (Kararli 1995). There are numerous epithelial
projections with lamina propria (villi) in the apical surface (Fig. 1B). Each villus is
subdivided into microvilli and estimated to have 3000-7000 microvilli on each epithelial
cell (Ritschel 1991). This anatomical feasure significantly increase the absorptive surface
area of duodenum and jejunum than ileum in small intestine. Absorbing surface area
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dramaticaly reduced in cecum (0.05 m2), colon (~0.25 m2) and rectum (0.015 m2) due
reduced length and absence microvilli (Kararli 1995).
The epithelial cells are connected to each other by zonula occludens or tight junctions in
the mucosa side. Tight junctions allow only small hydrophilic molecules to through the
aqueous channel (paracellular transport). In addition, the surface of the small intestine is
covered with a thin aqueous mucus layer (around 25 μm thickness) which serves as a
protective barrier against toxins and xenobiotics (Winne 1976; Strocchi et al. 1996).
Various physiological factors including gastrointestinal transit time, variable pH,
enzymatic activity, and metabolism can influence drug absorption from the GI tract.
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Figure 1: Gastrointestinal anatomy showing major regions (A) and microanatomy of digestive tract (B). Reproduced from Remesz et
al. (2004) and http://www.vivo.colostate.edu/hbooks/pathphys/digestion/basics/gi_microanatomy.html.
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1.2.2. Mechanism of oral drug absorption
After oral administration, drug molecules can be transported from the absorption
site to the blood by passive diffusion, facilitated transport, active transport, and
endocytosis. Drug molecules can passively diffuse through the absorption membrane using
transcellular and paracellular route. Facilitated transport is a carrier mediated transport
which is mainly influenced by the concentration gradient. Transmembrane protein (e.g.
vitamin B12 transporter, hexose transporter etc.) facilitates the entry and exit of molecules
(Fig. 2). The active transport is an energy-dependent process and occur through
transporters expressed on the epithelial cells, while vesicular transport (endocytosis) is
dependent on the size (mainly particulates and macromolecules) (Thomas et al. 2006; Hurst
et al. 2007; Varma et al. 2010). The absorption mechanisms are further described in more
detail in subsequent sections.

1.2.2.1. Passive diffusion
Passive diffusion of drug molecules is determined by the physicochemical
properties of compounds such as molecular weight, lipophilicity, and capacity to form
hydrogen bonds (Lipinski 2000; Avdeef 2001). Passive diffusion by transcellular pathway
is limited to small molecules (<500 Da), and rate of absorption or flux (J) is described by
the Fick’s law of diffusion,
J=

DS(Ko/w)(Cg.i.)
h

Where, D is the diffusion coefficient which is influenced by the molecular weight of drug
and the membrane characteristics.
‘S’ is the surface area of the membrane which is influenced by the location in the GI tract.
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‘K’ is the octanol/water (o/w) partition coefficient which is influenced by the lipophilicity
and ionization of drug molecules.
‘C’ is the concentration of drug in the GI lumen which is dependent on the solubility and
dosage form of drugs.
‘h’ is the thickness of the diffusion membrane which varies in different section of GI tract.

The intestinal epithelial layer serve as a protective barrier for the entry of pathogens, toxins,
antigens, and foreign particles from the GI lumen to the systemic circulation (Lee 2015).
The surface of the mucosal layer of the intestine is lined with epithelial cells connected to
each other by the tight junction (Fig. 2). Tight junction is a multiprotein complex and pore
diameter between cells is reported to be <10Å and is hence limited to small molecules
(Takeuchi and Gonda 2004). Hydrophilic drugs and nutrients can be absorbed via an
aqueous channel between the intercellular space of enterocytes (Lennernas 1995). Drug
molecules with molecular weight <500 Da, have been found to be utilized this absorption
pathway (Karlsson et al. 1999; Lee 2015; Turner 2006; Nusrat, Turner, and Madara 2000).
The paracellular transport is also important for the absorption of drugs from GI tract.
Hydrophilic molecules that are restricted to cross the lipid membrane of the epithelial cells
usually absorb via paracellular pathway.
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Figure 2: Various pathways of drug absorption from gastrointestinal lumen to blood
stream. Reproduced from Agrawal et al. (2014).

1.2.2.2. Transporter-mediated uptake and efflux
Intestinal epithelial cells express multiple families of uptake and efflux transporters
which is mainly divided into solute carrier (SLC) transporters and ATP-binding cassette
(ABC) transporters (Fig. 3) (Leibach and Ganapathy 1996; Tamai 2012; Englund et al.
2006; Roth, Obaidat, and Hagenbuch 2012). In general, ABC transporters use ATP as an
energy source and play a major role in intestinal absorption, while SLC utilize H+, Na+,
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Ca++ ion gradient created by Na+/K+-ATPase, or Na+/H+-ATPase (Tsuji and Tamai 1996;
Ogihara, Tamai, and Tsuji 1998).
ABC transporter includes P-glycoprotein (P-gp), breast cancer resistance protein
(BCRP), and multidrug resistance proteins (MRP1-6) (Roth, Obaidat, and Hagenbuch
2012). ABC transporters can be subdivided into uptake and efflux transporters. The uptake
transporters play an important role in the absorption of nutrients such as glucose, amino
acids, and small peptides, while the efflux transporters involve in the removal of absorbed
foreign or toxic substances and return them to GI lumen. The apical membrane also
expresses brush border enzymes for metabolizing macromolecules to small molecules to
facilitate uptake by nutrient transporters (Hamman, Demana, and Olivier 2007). Drugs that
have structural similarity with nutrients can bind with transporters and can be taken up by
epithelial cells. In this regard, peptide transporters, amino acid transporters, and nucleoside
transporters play a major role in the uptake of orally administered drugs (Hamman,
Demana, and Olivier 2007). Peptide transporter 1 (PepT1) can bind and transport diverse
compounds including antibiotics, antivirals, and peptidyl prodrugs (Smith, Clemencon, and
Hediger 2013), while organic anion transporters can interact with statins, angiotensinconverting enzyme inhibitors and other group of drugs (e.g., fexofenadine) (Kalliokoski
and Niemi 2009). Taken together, all these transporters play a significant role in uptake or
efflux, distribution, metabolism, and excretion of administered drugs.
Drugs to overcome numerous barriers after oral administration to achieve
therapeutic concentration in the blood. Figure 3 summarizes different factors that can
influence drug absorption and bioavailability.

8

Figure 3: Schematic diagram of the steps and factors associated with oral drug absorption.
Molecular weight (MW), Unstirred water layer (UWL), Cytochrome P450 (CYP), UDPglucuronosyltransferase (UGT), Glutathione S-transferase (GST), Sulfotransferase
(SULT), apical sodium-dependent bile acid transporter (ASBT), Organic cation transporter
(OCT), Concentrative nucleotide transporter (CNT), Electroneutral organic cation
transporter (OCTN), Organic anion transporting polypeptide (OATP), Peptide transport
protein (PEPT), P-glycoprotein (P-gp), Multidrug resistance protein (MDR), Multidrug
resistance-associated protein (MRP), Breast cancer resistance protein (BCRP),
Monocarboxylate transporter protein (MCT), equilibrative nucleoside transporter (ENT),
(+) and (-) indicates an increase or a decrease in the rate and/or extent of drug absorption,
respectively. Adapted from Huang, Lee, and Yu (2009).
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1.2.2.3. Endocytosis
The uptake of macromolecules and particulate systems occurs by endocytosis. This is
an energy-dependent process which can be divided into receptor-mediated or non-receptor
mediated endocytosis. Vesicular transport mechanisms include clathrin-mediated
endocytosis, caveolae-mediated endocytosis, and macropinocytosis (Fig. 4) (Lundquist
and Artursson 2016). Clathrin-mediated endocytosis involves internalization by ligandbound receptors followed by transport to endosomes and fuse with lysosome for
degradation or recycle back to the cell membrane (Yameen et al. 2014). Clathrin-coated pit
(CCP) is a well-studied mechanism for receptor-mediated endocytosis. The process
includes invagination of the cell membrane and formation of clathrin-coated vesicle
(Somsel Rodman and Wandinger-Ness 2000; Roger et al. 2010; Ford et al. 2002). Clathrinindependent process as shown in figure 4 does not require coat proteins for the formation
vesicles. Instead of coat protein, actin and actin associated proteins is involved in clathrinindependent endocytosis process (Robertson, Smythe, and Ayscough 2009). Clathrinindependent pathway mediate uptake using glycolipids and glycoproteins and are
insensitive to endocytosis inhibitors (Kirkham and Parton 2005). Uptake by clathrin
mediated endocytosis mainly dependent on the size, shape and surface charge (Yameen et
al. 2014). For example, particulate systems prepared using cationic polymers are
predominantly taken up by clathrin-mediated endocytosis by electrostatic interaction with
the negatively charged cell surface (Yameen et al. 2014).
Caveolae-mediated endocytosis process involves the formation of cavities which
are transported to the nucleus by dynamin- and actin-mediated uptake (Lundquist and
Artursson 2016). Caveolae-mediated endocytosis utilizes lipid-raft which is mainly
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composed of cholesterol and sphingolipid for the formation of membrane microdomain
(Conner and Schmid 2003). Caveolae-mediated endocytosis is characterized by the
presence of caveolin protein which leads to the formation of caveosomes (Pelkmans,
Kartenbeck, and Helenius 2001). Negatively charged polymers are generally found to be
internalized via caveolae-mediated endocytosis (Sahay, Alakhova, and Kabanov 2010).
Macropinocytosis also called as fluid-phase endocytosis is mainly dependent on the
concentration of solute around the cells (Adler and Leong 2010). Macropinocytosis is an
actin-driven endocytic process which usually takes up considerable volume of extracellular
fluid into large vesicle known as macropinosomes (Falcone et al. 2006). Unlike the
receptor-mediated endocytosis, the formation of macropinosomes is not activated by direct
interaction of particulate systems (Fig. 4). Tyrosine kinase pathway is involved in the
activation and polymerization of actin (Kerr and Teasdale 2009). Although micron size
particles can be internalized via macropinocytosis, majority of macromolecules and
particulate systems taken up by more than one endocytic process (Gratton et al. 2008;
Zhang et al. 2014).
The particle size of the drug carrier for oral delivery plays a significant role in the
uptake by epithelial cells (Kulkarni and Feng 2013). Particle size of <50 nm diameter is
shown to be transported via the paracellular pathway, while particles in the range of 100500 nm diameter are taken up by endocytosis (Desai et al. 1996). Particle size >1 µm to <5
µm are usually taken up by M-cells in the Peyer’s patches (Desai et al. 1996). In general,
particles around 100 nm diameter were observed to be taken up better by at intestinal
mucosa (Desai et al. 1996; Agrawal et al. 2014). Further, Reineke et al. reported that wide
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range of particles (500 nm to 5 µm) could be absorbed in small intestine via clathrindependent endocytosis (Reineke, Cho, Dingle, Morello, et al. 2013).

Figure 4: Illustration of internalization pathways (phagocytosis, macropinocytosis,
clathrin-dependent endocytosis, clathrin-independent endocytosis, and caveolin-dependent
endocytosis). The fate of internalized cargo and localization to subcellular compartments
are also depicted. ER: endoplasmic reticulum, NLS: nuclear localization signal, NPC:
nuclear pore complex, TPP: triphenylphosphonium cation. Reproduced from Yameen et
al. (2014).
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1.3. Oral drug delivery challenges

Despite many advantages of oral drug delivery, there are several barriers for drugs
absorption. Factors that influence the oral bioavailability of drugs include physiological,
physicochemical, and biopharmaceutical factors (Sabnis 1999; Horter and Dressman 2001;
Kramer and Wunderli-Allenspach 2001; Zhou 2003).

1.3.1. Physiological barriers to oral drug delivery
Multiple physiological factors including variable pH, digestive enzymes, efflux
transporters, GI transit time, mucus layer, and first-pass metabolism influence oral drug
absorption.

1.3.1.1. Variable pH and digestive enzymes
One of the major barriers for oral drug delivery is the variable pH in the GI tract.
The stomach pH ranges from 1.0 to 2.5 (Evans et al. 1988; O'Neill et al. 2011) and
gradually increases to pH 6.6 and pH 7.5 in the proximal portion of intestine, then the pH
decreases to 6.4 close to caecum, and again rises to pH 7.0 in the colon (Table 1). Majority
of the drugs are either weak acid or weak base and the degree of ionization is dependent
on the pKa of the drug molecule and pH of the biological fluid. For example, an acidic
drug is predominantly ionized at a pH two units higher than pKa of the drug while the drug
predominantly remains as unionized, if the pH is two units lower than the pKa (Roche
2007). This is reverse for basic drugs. The unionized and soluble form of the drug is mainly
absorbed by passive diffusion and drugs should remain as ionized to be soluble in GI fluid.
Therefore, a drug which is not completely ionized or unionized at intestinal pH show good
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absorption. (Chawla 2003). In addition to pH, the presence of numerous enzymes (pepsin,
amylase, trypsin, lipases, pancreatin, peptidases, maltase etc.) can also pose an obstacle for
oral delivery of drugs (Table 1).
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Table 1: Anatomical and physiological features of human GI tract. Reproduced from Chawla et al. (2003).
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1.3.1.2. GI transit time and mucus layer
GI transit time is another important factor that influence the drug absorption. GI
transit time is influenced by the individual differences, meals, fluid intake, and disease state
(Davis, Hardy, and Fara 1986; Dressman et al. 1992; Coupe, Davis, and Wilding 1991).
Gastric emptying time for healthy individual varies from 25 minutes to 3 hours, while the
intestinal residence time varies from ~3 to 4 hours. The residence time of drugs in upper
intestine is lower than distal portion, and the movement of drugs gradually slow down
when it reaches to the large intestine. The transit time for large intestine varies from 4 to
20 hours (Table 1) (DeSesso and Jacobson 2001).
Mucus layer in GI tract prevents damage to epithelial surfaces and can limit the oral
drug absorption as the drug has to diffuse through the viscous mucus layer before reaching
the epithelial cells (Ensign, Cone, and Hanes 2012). Mucus is a complex mixture of
proteins (glycosaminoglycans), lipids, carbohydrates, salts, and unidentified materials
(Larhed, Artursson, and Bjork 1998). GI mucus efficiently trap pathogens and foreign
particles and continuous mucus turn-over clears the trapped bacteria and solid particles
(Corfield et al. 2001). The mucus turn-over limits the residence time and prevents the
penetration of particulate systems through the loosely adherent mucus layer (Ensign, Cone,
and Hanes 2012). Drug delivery systems have been designed to enhance the penetration
through loose mucus layer delay the GI transit time to enhance the absorption and oral
bioavailability (Ch'ng et al. 1985; Longer, Ch'ng, and Robinson 1985; Lehr 1994, 2000;
Vasir, Tambwekar, and Garg 2003). One of the commonly used approaches is to
incorporate mucoadhesive materials to enhance residence time in GI tract (Ch'ng et al.
1985; Shaikh et al. 2011). Polymers with high capacity of forming hydrogen, hydrophobic
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or electrostatic interaction with mucus layer showed increased retention after oral delivery
(Lai, Wang, and Hanes 2009; Date, Hanes, and Ensign 2016). Polymers can interact with
the mucus layer by the following mechanisms: i) hydrogen bonding, ii) hydrophobic
interaction, iii) anionic surface charge, and iv) polymer entanglement (Jimenez-Castellanos
1993; Deraguin 1969; Gu, Robinson, and Leung 1988). Particles prepared from polymers
such as poly(lactic acid) (PLA), poly(sebacic acid) (PSA), poly(lactic-co-glycolic acid)
(PLGA) and poly(acrylic acid) (PAA) has been reported to interact with mucus through
one or more of the above mentioned mechanisms (Lai, Wang, and Hanes 2009).

1.3.1.3. GI metabolism and efflux pump
Intestinal metabolic enzymes especially phase-I metabolic enzymes such as
cytochrome P450 (CYP 450) are abundantly expressed in intestinal enterocytes (Chawla
2003). Many orally administered drugs interact with cytochrome P450 (CYP450) enzymes
in the intestine (Watkins 1997). CYP3A is one of the main metabolic enzymes expressed
in human intestine (Bezirtzoglou 2012; Thelen and Dressman 2009). CYP3A activity is
higher in the small intestine and gradually decline in the ilium and colon (Chawla 2003).
In addition to enzymes, efflux pumps can limit drug absorption. P-glycoprotein (Pgp) is an ATP-dependent transmembrane protein expressed in columnar epithelial cells in
the intestine (Loo and Clarke 2005). P-gp composed of 1280 amino acids (170 kDa) and
contains a single chain of two homologous regions. Each region comprises six
transmembrane domains connected by a flexible polypeptide linker (Fig. 5A). The ATPbinding domains are positioned in cytosolic regions which are also known as nucleotidebinding folds (NBFs). The NBFs are responsible for supplying energy for transporting
substrate through the membrane. The Magnesium (Mg2+) ion is reported to play a role in
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stabilizing the ATP-binding site (Tombline et al. 2004). P-gp translocate its substrate from
cytosol of epithelial cells to intestinal lumen and thereby reduces the bioavailability
(Chawla 2003). A wide range of drug molecules (mainly hydrophobic) can interact with Pgp. These drugs include anticancer agents, immunosuppressants, steroid hormones,
calcium channel blockers, beta-adrenoreceptor blockers, cardiac glycosides etc. (Sharom
2011; Varma et al. 2003; Sharom et al. 2001). Most of these drugs are also substrate for
CYP3A4 in the intestinal epithelial cells (Sharom 2011). The P-gp efflux pump along with
CYP3A4 and can limit the oral absorption of these drugs. (Fig. 5B) (Li et al. 2016).
Different classes of P-gp inhibitors have been investigated to overcome the P-gp efflux.
These include small molecule P-gp inhibitors (e.g., Verapamil, Cyclosporin A), polymeric
P-gp inhibitors (e.g. TPGS, pluronics), and natural P-gp inhibitors (e.g. Curcumin,
Grapefruit) (Varma et al. 2003; Liscovitch and Lavie 2002; Kabanov, Batrakova, and
Alakhov 2002; Zhou, Lim, and Chowbay 2004; Deferme, Van Gelder, and Augustijns
2002; Cornaire et al. 2004).
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Figure 5: Structure of P-gp efflux pump and mechanism of inhibition of drug
absorption (A). Functional relationship between P-gp and CYP3A4 (B). Reproduced
from Bansal et al. (2009) and Watkins (1997).
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1.3.2. Influence of physicochemical and biopharmaceutical factors on oral drug
delivery
Oral bioavailability of drugs limited by the physicochemical properties of drugs.
These includes poor solubility and permeability, poor chemical stability, and enzymatic
metabolism in the GI tract (Prabhu, Ortega, and Ma 2005). The poor physicochemical
properties of drug molecules lead to ~40% failure in drug development (Siew et al. 2012).
Lipinski et al. developed ‘Rule of 5’ to guide oral drug development. According to
this rule drugs with molecular weight >500 Da, log P >5, >5 H-bond donors, >10 H-bond
acceptors are less likely to show good absorption after oral administration (Lipinski 2000;
Wenlock et al. 2003). The rate of solubility in the intestinal fluid is one of the important
factors that influence the drug absorption. Noyes-Whitney equation is used to describe the
factors that influences the rate of drug dissolution (Healy 1984; Frenning and Stromme
2003),
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑑𝑖𝑠𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 =

𝐴. 𝐷
(𝐶𝑠 − 𝐶)
ℎ

Where A is the surface area, D is the diffusion coefficient, h is the thickness of the
diffusion layer adjacent to the drug surface, Cs is the saturation solubility of the drug in the
diffusion layer, and C is the concentration of drug in the bulk solution at any time. The
above equation indicates that rate of drug dissolution increases with increase in drug
surface area, which can be achieved by decreasing the particle size. Diffusion coefficient
is dependent on the viscosity of the fluid (solvent) and rate of drug dissolution is inversely
proportional to the viscosity of solvent. Saturation solubility (Cs) is dependent on the
physicochemical characteristics of drug and nature of the fluid (solvent). Therefore, the
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alteration of pH of the solvent can alter the degree of ionization of drug (discussed in
section 1.3.1.1.) and thus can change the drug solubility.
Among all the factors, solubility and permeability are the primary determinants of
oral bioavailability. This lead to the development of Biopharmaceutic Classification
System (BCS) which classifies drugs based on its solubility and permeability (Fig. 6)
(Amidon et al. 1995; Dahan, Miller, and Amidon 2009). According to BCS, a drug is
considered as highly soluble if its highest dose is soluble in 250 mL water over the entire
pH range of 1 to 7.5 (Yu et al. 2002). Similarly, a drug is regarded as highly permeable, if
>90% of its administered dose is biologically available (Lennernas 2007). As shown in
Figure 6, BCS class I drugs are highly soluble and highly permeable. BCS class I drugs
are readily absorbed and are good candidates for oral delivery. BCS Class II drugs are
poorly soluble and highly permeable, while BCS Class III drugs are highly soluble and
poorly permeable. BCS Class IV drugs are poorly soluble and poorly permeable and
require carriers or chemical modification to improve solubility and or permeability (Fig.
6).
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Figure 6: Biopharmaceutics Classification System (BCS). Reproduced from Dahan,
Miller, and Amidon (2009).

Benet et al. further modified BCS by including drug metabolism. This lead to the
development of Biopharmaceutics Drug Disposition Classification System (BDDCS) (Fig.
7) (Wu and Benet 2005). According to BDDCS, highly permeable drugs (class I and class
II) are extensively metabolized, while the poorly permeable drugs (class III and class IV)
are poorly metabolized. For class I and class II drugs, the prmary route of elimination is
metabolism, while for class III and class IV drugs, the primary route of elimination is renal
and biliary excretion (Fig. 7) (Benet et al. 2008; Wu and Benet 2005). In general, BDDCS
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serve as basis for predicting the role of transporters in drug disposition and drug-drug
interactions.

Figure 7: Biopharmaceutic Drug Disposition Classification System (BDDCS).
Reproduced from Wu and Benet (2005).
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1.4. Different approaches for oral drug delivery
Numerous approaches have been used to overcome oral drug delivery challenges.
These can be divided mainly into two categories: i) physical or chemical modification of
drug molecules, and ii) use of drug carriers (Bernkop-Schnurch 2013). The first strategy
involves altering the physical or chemical form to improve the physicochemical
characteristics of the drug. These include micronization, polymorphism, salt formation,
pro-drug, and complexation. The second approach is to using drug carriers with different
types of materials.

1.4.1. Physical or chemical modification of drug molecules
Various physical and chemical modification have been used to enhance aqueous
solubility, intestinal permeability, and bioavailability of drug molecules (Savjani, Gajjar,
and Savjani 2012).
Micronization is one of the well-studied techniques to overcome the limitations
associated with drug dissolution (Blagden et al. 2007). Reducing the particle size of drug
crystals significantly increases the surface area, and rate of dissolution. For example,
micronized formulation of poorly water-soluble glimepiride has been used to enhance the
dissolution rate and to increase the oral bioavailability (Ning et al. 2011). Similarly,
micronized megestrol acetate formulation show enhanced oral bioavailability (Farinha,
Bica, and Tavares 2000).
Drug crystallinity and polymorphisms can influence drug solubility and
bioavailability (Singhal and Curatolo 2004). A drug that can crystallize in more than one
crystal form and is known as polymorphism. Majority of drugs (50-70%) exhibit
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polymorphism, which differ in the internal arrangement and conformations of the
molecules in the crystal lattice (Higuchi et al. 1963; Podaralla 2008). The polymorphs have
distinct chemical and physical properties such as difference in melting point, chemical
reactivity, apparent solubility, dissolution rate, vapor pressure, density, optical and
electrical properties. For example, HIV protease inhibitor ritonavir (Norvir®, Abbott
Laboratories) exist as two polymorphs. Form I of ritonavir is more soluble than form II
(Gardner, Walsh, and Almarsson 2004). An amorphous form of the drug does not have
regular crystal lattice and has a higher solubility in comparison to crystalline form of the
drug (Hancock 2000). Several reports have shown the improved solubility of amorphous
form of the drug compared to the crystalline form (Imaizumi, Nambu, and Nagai 1980; al.
1975). For example, aqueous solubility of amorphous celecoxib was found to be higher
than its crystalline counterpart (Gupta, Chawla, and Bansal 2004).
Salt formation is one of the most commonly used strategies to increase the solubility
of ionic drugs (Berge, Bighley, and Monkhouse 1977; Chowhan 1978). The impact of salt
formation on the rate of drug dissolution was first introduced by Nelson (1957) by
comparing choline and isopropanolamine salts of theophylline with ethylenediamine salts.
Approximately 70% drugs are ionizable and are weakly basic or weakly acidic (Kalepu
and Nekkanti 2015). Therefore, the formation of an appropriate salt of drug molecules
using oppositely charged counter-ions can alter the pH of the diffusion layer resulting
improved solubility. Weakly acidic drugs form salt with strong base (e.g. Phenytoin
sodium) while weakly basic drugs form salt with strong acids (e.g. Atropine sulfate). The
salt formation is dependent on the relative pKa values of the drug and the salt forming

25

species (counter-ion). Table 2 lists commonly used counterions to form pharmaceutical
salts.

Table 2: Common pharmaceutical salts.
Salts class

Examples
Anions

Inorganic acids

Hydrochloride, hydrobromide, sulfate, nitrate, phosphate,

Sulfonic acids

mesylate, esylate, isethionate, tosylate, napsylate, besylate,

Carboxylic acids

acetate, propionate, maleate, benzoate, salicylate, fumarate,

Anionic amino acids

glutamate, aspartate, citrate, lactate, succinate, tartrate, glycolate,

Hydroxyacids

hexanoate, octanoate, decanoate, oleate, stearate, pamoate,

Fatty acids

polystyrene sulfonate (resinate)

Insoluble salts
Cations
Organic amines

Triethylamine, ethanolamine, triethanolamine, meglumine,

Insoluble salts

ethylenediamine,

Metallic

potassium, calcium, magnesium, zinc, arginine, lysine, histidine

choline

procaine,

benzathine,

sodium,

Cationic amino acids

Prodrug approaches has been used to enhance aqueous solubility or permeability of
drugs (Van Gelder et al. 2000). Chemical modification to create prodrug should be
reversible and prodrug should be converted back into parent drug by an in vivo chemical
and/or enzymatic reaction (van De Waterbeemd et al. 2001; Beaumont et al. 2003). For
example, inactive sulindac prodrug derived from sulfinylindene which is 100-times more
water soluble than sulindac drug. The prodrug is converted in vivo to an active sulfide
compound by liver enzyme (Davies and Rampton 1991).
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Complexation of drug molecules with hydrophilic polymers is another approach to
enhance water solubility of lipophilic drugs (Loftsson 1998). Drug complexation with
polymers like cyclodextrin (CD) improve both the pharmaceutical and biological
properties of drug-CD complexes. Cyclodextrins are divided into α-, β-, and γcyclodextrin-based into some D-glucopyranose units. Βeta-cyclodextrin is most commonly
used to entrap and improve the solubility of lipophilic drugs (Fig. 8) (Shimpi, Chauhan,
and Shimpi 2005). Complexation can also be used to increase the stability of compounds,
mask the bitter taste of the drug, and control the drug release (Ranade 1991). Complexation
of drug molecules with cyclodextrin has been used to enhance solubility and oral
bioavailability of several drugs (Loftsson and Brewster 1996; Loftsson and Duchene 2007;
Loftsson and Brewster 2010; Irie and Uekama 1997). For example, complexation of
enalapril (antihypertensive) with beta-cyclodextrin enhanced the solubility, stability, and
bioavailability of enalapril after oral administration (Fig. 8) (al. 2006). Other complexing
agents such as sodium benzoate, caffeine, nicotinamide, and sodium salicylate have also
been used to increase drug solubility.

27

Figure 8: Structure of beta-cyclodextrin-enalapril maleate complex. Reproduced from Ali
et al. (2006).

1.4.2. Drug carriers
Several types of drug carriers have been used to improve the oral drug absorption.
Drug carriers allow the delivery of poorly water-soluble drugs, target the drug release to
specific site in the GI tract, sustain drug release, reduce drug efflux, and transport drugs
through the GI membrane (Fig 9). Various types of drug carriers have been tested for oral
drug delivery applications including micelles, nanospheres, liposomes, nanoemulsions,
solid lipid nanoparticles, polymeric particles (nano and microparticles), and selfemulsifying drug delivery systems (SEDDS) etc. (Fig. 10). Nanoparticles are defined by
the diameter on the order of 100 nm which is comparable to many viral particles
(Pridgen, Langer, and Farokhzad 2007).
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Figure 9: Application of nanocarriers in oral drug delivery applications. Reproduced from Agrawal et al. (2014).
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Figure 10. Different nanocarrier systems investigated for oral drug delivery. Reproduced
from Zhang, Wang, Zhang, et al. (2013).

1.4.2.1. Lipid-based delivery systems
1.4.2.1.1. Liposomes
Liposomes are lipid vesicles with a hydrophilic core and a lipophilic bilayer.
Liposomes can be used to entrap hydrophilic and/or hydrophobic molecules.

Traditional

liposomes are composed of phospholipid and cholesterol. Liposomes are promising drug
carrier. The composition of lipids in the liposomes can be varied to alter the surface charge
and particle size (Wu, Lu, and Qi 2015). The size of liposomes can vary from very small
(25 nm) to large (2.5 µm) vesicles and can be classified as unilamellar and multilamellar
vesicles. In general, liposomes is prepared by dry-film-rehydration method where a thin
lipid film is formed by evaporation of organic solvent followed by hydration of lipid film
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using aqueous drug solution and sonication to encapsulate drug in the core of the liposome
(Akbarzadeh et al. 2013). In this method, primarily form large multilamellar vesicles which
require to either sonicate or extruded to produce small unilamellar vesicles. Alternatively,
ethanol injection method is used prepare liposome. In this method, water injected into a
concentrated lipid-ethanol solution followed by evaporation of ethanol (Maitani et al. 2007;
Maitani et al. 2001; Pons 1993).
Liposome based drug delivery is limited by i) low loading efficiency, ii) poor
stability in GI media, and iii) leakage of entrapped drugs. Lipases can hydrolyze the
liposomes within 2 hours of oral ingestion leading to disruption of bilayer (Liu et al. 2015).
The integrity of liposomes can also be altered in the low gastric pH leading to burst release
of drug in stomach. In this regard, polysaccharides and protein polymers have been used
to improve the stability of liposomes (Manconi et al. 2013; Smistad et al. 2012).
Polymerized liposomes showed enhanced stability in the GI tract and improved oral
absorption. For example, incorporation of sodium glycocholate in liposomal composition
resulted in increased resistance to peptic and tryptic digestion of encapsulated insulin (Niu
et al. 2011). Thiolated chitosan-coated liposomes were found to be stable at low pH with
mucoadhesive properties (Gradauer et al. 2013). Liposomes with multiple layers of
polyelectrolyte have been prepared to achieve higher stability in GI fluid. The multilayer
liposomes were reported to enhance the blood concentration of doxorubicin and paclitaxel
(Thanki et al. 2013; Jain, Patil, et al. 2012; Jain, Kumar, et al. 2012). Lecithin vesicles
achieved >98% encapsulation and enhanced the bioavailability of cyclosporine A
compared to marketed Sandimmune® formulation (Guo, Ping, and Chen 2001; Chen et al.
2003). Further, folic acid coupled phosphatidylcholine-based liposomes was used to
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encapsulate cefotaxime to achieve receptor-mediated endocytosis and achieve higher oral
bioavailability in rats (Ling et al. 2009).

1.4.2.1.2. Solid lipid-based drug carriers
Several solid lipid-based carriers have been investigated to overcome the
limitations such as stability in low pH associated with liposome-based formulations. These
includes solid lipid nanoparticles (SLNs), lipid-drug conjugate nanoparticles (LDC-NPs)
and nanostructured lipid carriers (NLCs). SLNs are promising carriers for compounds with
low water solubility and intestinal permeability (Attama 2011). SLNs are prepared from
lipids with high melting points (Severino et al. 2012; Agrawal et al. 2014). The ease of
scaling up using high-pressure homogenizer and the absence of organic solvents makes it
an attractive drug delivery carrier. Small molecules and peptides have been encapsulated
in SLNs and evaluated for oral delivery (Muller, Mader, and Gohla 2000). Insulin-loaded
SLNs were found to increase their tolerance against peptic enzymes and enhanced the
bioavailability in vivo compared to subcutaneous injection (Zhang et al. 2006).
Incorporation of simvastatin (HMG-CoA reductase and BCS II drug) in SLNs, consisting
of glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate and PEG
glyceride, and enhanced the oral bioavailability (Padhye and Nagarsenker 2013). NLCs are
advantageous over other lipid-based systems in terms of high drug loading, longer shelflife, and feasibility of incorporating both hydrophilic and lipophilic drugs (Poonia et al.
2016). However, SLNs suffer from low drug loading efficiency due to dense pack lipid
molecules and can expel the loaded drug on storage (Muchow, Maincent, and Muller 2008;
Poonia et al. 2016). To address this issue, lipid-drug conjugate (LDCs) nanoparticles have
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been developed. Lipid-drug conjugates are prepared by covalently conjugating drug
molecules with lipids (Irby, Du, and Li 2017). For example, lipid-drug conjugate
nanoparticles (LDC-NPs) of methotrexate (MTX) have been prepared to overcome low
and variable oral bioavailability of this drug (Paliwal, Rai, and Vyas 2011). Nanostructured
lipid carriers (NLCs) have also been tested for oral drug delivery (Poonia et al. 2016). For
example, atorvastatin loaded NLCs demonstrated higher solubility and oral bioavailability
compared to Lipitor® formulation (Elmowafy et al. 2017). NLCs are advantageous over
other lipid-based systems in terms of high drug loading, longer shelf-life, and feasibility of
incorporating both hydrophilic and lipophilic drugs (Poonia et al. 2016). Table 3 lists some
representative examples of lipid nanoparticles used for oral drug delivery.

1.4.2.1.3. Self-emulsifying drug delivery systems
Self-emulsifying drug delivery systems (SEDDS) or self-micro emulsifying drug
delivery systems (SMEDDS) is an isotropic mixture of solvents/co-solvents, lipids/oils,
and surfactants designed to deliver compounds with poor solubility (Gursoy and Benita
2004). Micro or nanoemulsions are thermodynamically stable, an isotropic mixture of oil,
surfactant, water, and co-solvents. Micro or nanoemulsion technology is used to address
the

challenges

associated

with

the

delivery

of

water-insoluble

compounds.

Micro/nanoemulsions are usually prepared using high-pressure homogenizer to reduce the
droplet size in the range of 50-500 nm diameter (Table 3). The microemulsion have been
reported to be effective in protecting the drug from enzymatic attack after oral delivery in
the rabbits (Nicolaos et al. 2003).
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SEDDS/SMEDDS can be placed in soft or hard gelatin capsules for oral
administration and form stable oil-in-water emulsions in the presence of GI fluids (Shao et
al. 2015; Pouton 2000). The lipid content in the formulation can also stimulate the biliary
secretion from the gallbladder (Kalepu, Manthina, and Padavala 2013). In the presence of
bile salts, lipid formulations (e.g., SEDDS or SMEDDS) can be digested leading to the
formation of vesicles, micelles or mixed micelles (Fig. 9). Drug absorption efficiency is
dictated by the physicochemical characteristics of SEDDS/SMEDDS formulations such as
the ratio of oil and surfactant, the concentration of surfactant, polarity, droplet size and
surface charge (Hauss 2007). Taken together, SEDDS/SMEDDS can improve the
solubilization of drugs in the small intestine and enhance bioavailability after oral
administration (McClements and Xiao 2014; Gursoy and Benita 2004). SEDDS have been
efficiently used to enhance the oral bioavailability of BCS class III and class IV drugs.
Currently, there are several SEDDS formulations are available in the market including
Sandimmune®, Sandimmun Neoral® (Cyclosporin A), Norvir® (Ritonavir), and
Fortovase® (Saquinavir).
Lipid-based drug carriers have additional benefit that they mimic chylomicron
pathway and target intestinal lymphatic system after oral delivery (Ahn and Park 2016).
The lymphatic system plays an important role in the uptake and removal of toxins and
foreign materials from the body (Longmire, Choyke, and Kobayashi 2008). Lymphatic
systems are also responsible for maintaining the fluid balance in the body by removing
interstitial fluid and return to blood after filtering damaged cells, cancer cells, bacteria, and
viruses (Dixon 2010). Furthermore, lymphatic system plays an important role in the
absorption and distribution of fat and fat-soluble vitamins from the GI tract (Dixon 2010).
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Targeting lymphatic systems using lipid-based formulations (liposomes, SLNs, NLCs,
SEDDS) is especially useful for treatment of diseases like lymphoma and HIV (Kalepu,
Manthina, and Padavala 2013). Figure 11 shows the mechanism of drug absorption of drug
from SEDDS formulation. The lipid-based drug delivery system can mimic the
chylomicron pathway to improve the bioavailability and by-pass the first-pass metabolism
(Chaudhary et al. 2014). Further, the lipid based delivery system can facilitate transcellular
absorption due to increased membrane fluidity, allow paracellular transport by opening
tight junctions, and increase epithelial cell uptake by inhibiting P-gp/CYP450 (Zeng et al.
2012; O'Driscoll 2002; Frazer 1955).
However, SEDDS formulations suffer from limitation such as i) migration of
volatile co-solvents to capsule shell, ii) lack of good predictive in vitro models for
assessment of formulations, and iii) high concentration of surfactants in SEDDS can be
toxic to the epithelial membrane.
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Table 3: Lipid nanoparticles used for oral drug delivery applications.
Drug

Excipients

Type

Outcome

References

Cefotaxime

Unsaturated soybean

Liposomes

At 90% confidence interval, the value for

Ling et al. (2009)

phosphatidylcholine

AUC0–∞ was 1.4–2-times higher and the value
for Cmax was 1.2–1.8-times higher for the folic
acid coupled liposomes compared with folic
acid-free liposomes.

Testosterone

Dynasan 118, stearic acid, NLC

Facilitated administration of a single dose of Muchow

undecanoate

Tween 80, carnauba wax

testosterone undecanoate in a unit oral dosage

et

al.

(2011)

form and reduced variation in bioavailability in
the fed and fasted states
Pentoxifylline

Lecithin,

cetyl

alcohol, SLN

Tween 20

SLN prepared by homogenization followed by
sonication. The system enhanced the

Varshosaz,
Minayian,

bioavailability of the drug (5.23-fold higher in
comparison with the suspension) by avoidance

Moazen (2010)

of the first-pass metabolism
Crypto

Glyceryl

monostearate, SLN

Incorporation of the drug into a solid lipid Hu et al. (2010)

tanshinone

Compritol ATO,

matrix altered the in vivo metabolic behavior of

Tween 80, soy lecithin,

the drug, thereby increasing the bioavailability.

sodium

Incorporation of sodium dihydrofolate into

and
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dihydrofolate

SLNs

significantly

enhanced

the

oral

bioavailability
Buspirone

Poloxamer, soy lecithin, SLN

SLNs enhanced the bioavailability of the drug Varshosaz,

spermaceti, Polysorbate 80,

2.53-fold by avoiding the pre-systemic hepatic

cetyl alcohol

metabolism.

Tabbakhian,

and

Mohammadi (2010)
Vinpocetine

Compritol ATO, Solutol NLC

Nanostructured lipid carriers showed sustained Zhuang et al. (2010)

HS 15, Poloxamer, Miglyol

release of the drug, with a remarkable increment

812N, monostearate

in bioavailability (322 %) in comparison to a
drug suspension. Application of Solutol HS 15
as a surfactant in the NLC altered the integrity
of intestinal epithelial cells and increased the
permeability.

Lopinavir

Stearic acid

SLN

The SLN showed a biphasic sustained drug Ravi et al. (2014)
release,

which

led

to

enhanced

oral

bioavailability (5- fold) and improved the
distribution of the drug to HIV reservoirs. The
report suggested this is a better an alternative to
the

marketed

formulation.

lopinavir/ritonavir

co-
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Saquinavir

Dextran protamine, Precirol NLC

The permeability of saquinavir loaded into Beloqui et al. (2014)

ATO15,

812,

dextran protamine-coated nanostructured lipid

Polysorbate 80, Poloxamer,

carriers was increased ninefold in comparison

protamine sulfate, dextran

with uncoated NLC.

Miglyol

Cyclosporin A Olive oil, polyglycolyzed SEDDS

Ritonavir

Increased solubility and oral bioavailability of Gursoy and Benita

glycerides, ethanol

Cyclosporin A.

Oleic acid, Polyoxyl 35 SEDDS

Improved oral bioavailability of ritonavir.

(2004)
FDA (2006)

castor oil, ethanol
Paclitaxel

dl-α-tocopherol,

TPGS, SMEDDS

paclitaxel.

Tyloxapol
Cefpodoxime

Medium-chain

proxetil

triglycerides,

Enhanced solubility and oral bioavailability of Gursoy and Benita

Microemulsion
Soybean

(2004)

Enhancement of the absolute bioavailability of Nicolaos
cefpodoxime proxetil.

et

al.

(2003)

Lecithin, Polysorbate 80,
HIV: human immunodeficiency virus, NLC: nanostructured lipidic carrier, SLN: solid lipid nanoparticle, AUC: Area under the plasma
concentration-time curve, NLCs: Nanostructured lipid carriers, SLN: Solid lipid nanoparticles, SEDDS: Self-emulsifying drug
delivery system, SMEDDS: Self-microemulsifying drug delivery system, Cmax: Maximum plasma drug concentration.
Reproduced from Pathak and Raghuvanshi (2015) and Gursoy and Benita (2004).
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Figure 11: Schematic representation of mechanisms of intestinal drug transport from
SEDDS formulations. Reproduced from Kalepu, Manthina, and Padavala (2013).
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1.4.2.2. Polymeric nanocarriers
Polymeric materials have been extensively investigated for the development of
drug carriers (Galindo-Rodriguez et al. 2005; Pridgen, Alexis, and Farokhzad 2014, 2015).
A variety of synthetic and natural polymers have been tested for their potential to overcome
barriers associated with oral drug delivery (Table 4) (Agrawal et al. 2014). Drug molecules
are encapsulated inside the polymeric matrix or dispersed, adsorbed, complexed within the
polymeric matrix (Huang and Dai 2014).
Various techniques have been used to prepare polymeric nanocarriers, which
mainly fall into top-down and bottom-up processes (Fig. 10). The top-down method is
based the reduction of particle size using various techniques such as ultrasonication,
cavitation, homogenization, microfluidization, milling and spray drying (Reis et al. 2006).
On the otherhand, the bottom-up technique is based on particle growth from individual
particles such as phase separation method including controlled crystallization during
freeze-drying or technologies that use supercritical fluid (de Waard, Frijlink, and Hinrichs
2011).
Polymeric microparticles exhibit higher stability in GI tract, encapsulate both
hydrophilic and hydrophobic molecules (Vilos and Velasquez 2012). Different types of
polymers have been used to prepare nanoparticles or microparticles (Table 5) (Chawla,
Sharma, and Pawar 2012; Rahman et al. 2006; Hsu, Yu, and Huang 2013; Patel et al. 2016;
Simonoska Crcarevska, Glavas Dodov, and Goracinova 2008). For example, alginate and
chitosan are widely used natural polymers to develop nanoparticles and microparticles.
These polymers found to reduce drug release in stomach, increase stability, and sustain
drug release at higher pH in intestine (Calija et al. 2013).
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Nanoparticles are defined by the diameter on the order of 100 nm which is
comparable to many viral particles (Pridgen, Langer, and Farokhzad 2007). Polymeric
nanoparticles have also been studied for oral drug delivery applications and drug molecules
can be entrapped in the core of the nanoparticles during the preparation (Mo et al. 2014;
Galindo-Rodriguez et al. 2005). The surface of polymeric nanoparticles can be modulated
by utilizing the polymeric end groups or by conjugating another polymer to the surface of
nanoparticles (Valencia et al. 2013).
Polymeric micelles are relatively small, spherical structure composed of
amphiphilic polymers (Croy and Kwon 2006). The polymers used in the micelle helps to
orient lipophilic hydrocarbon chain towards center leaving aqueous groups in contact to
aqueous medium. The concentration of polymers at which micelles are formed is known
as critical micelle concentration (CMC). Polymeric micelles have been investigated for
improving oral bioavailability of hydrophobic drugs molecules (Francis, Piredda, and
Winnik 2003; Dabholkar et al. 2006; Pierri and Avgoustakis 2005). Polymeric micelles
have been tested to increase aqueous solubility of cyclosporin A (Francis, Cristea, and
Winnik 2005; Francis et al. 2005; Francis et al. 2003). Further, pH-sensitive polymeric
micelles have also been tested to enhance intestinal absorption of hydrophobic compounds
(Pierri and Avgoustakis 2005; Ould-Ouali et al. 2005). Polyethylene glycol (PEG)-bP(alkyl(meth)acrylate-co-methacrylic acid)s (PEG-b-P(Al(M)Aco-MAA)s) is a diblock
copolymer and shows pH-dependent micellization in aqueous media. Polymeric micelles
formed from this diblock copolymers have been studied for the delivery of several
hydrophobic drugs. Several studies shown that fluid phase endocytosis pathway is the
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major cell uptake mechanism for polymeric micelles (Allen et al. 1999; Luo et al. 2002).
Table 5 lists some representative examples polymeric micelles used for oral drug delivery.

Table 4: Representative synthetic and natural polymers for oral drug delivery.
Class of polymers
Polyesters

Examples
Poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA),
polyglycolic acid (PGA), and poly(ɛ-caprolactone).

Polyanhydrides

Poly(sebacic acid), poly(adipic acid), poly(terephthalic acid), and
their copolymers)

Polyamides

Poly(imino carbonates) and polyamino acids)

Polyethers

Polyethylene glycol (PEG) and polypropylene glycol

Cellulose

Carboxymethyl

derivatives

(HPMC), ethyl cellulose, hydroxypropyl methyl cellulose acetate

cellulose,

hydroxypropyl

methyl

cellulose

succinate (HPMC-AS), and cellulose acetate succinate (CAS)
Protein

Collagen, gelatin, and albumin

Polysaccharides

Chitosan, alginate, carrageenan, cyclodextrin, and hyaluronic acid

Reproduced from Kapoor et al. (2015) and De Jong and Borm (2008).
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Figure 12: Different techniques used for the preparation of polymeric nanocarriers. Adapted from Bennet and Kim (2014).
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Table 5: Representative list of polymeric nanocarriers used for oral drug delivery.
Polymers

Drug

Key findings

Reference

PEG-b-PCL NHS-PEGb- PCL solution of Coumarin 6

The functional nanocarriers specifically interact Du et al. (2013)

7pep (Transferrin receptor (TfR) specific

with gastrointestinal epithelial cells and increased

7peptide nanocarrier)

drug transport.

Tocopherol succinate glycol chitosan (GC- Ketoconazole

GC-TOS increased the solubility of ketoconazole Duhem et al.

TOS) conjugates (Micelles)

(BCS class II drug) and enhanced the intestinal (2012)
permeation.

Pluronic copolymers and LHR conjugate Paclitaxel

Pluronic/ LHR micelles enhanced the oral Dahmani et al.

(Mixed polymeric micelles)

bioavailability of paclitaxel.

Alginate-oligochitosan-Eudragit(®) L100-

NSAIDs

55 (ALG-OCH-EL) (Microparticles)
Alginate coated chitosan core-shell
(Nanoparticles)
Vitamin B12-Chitosan (Nanoparticles)

Improved the stability and reduced drug release in Calija et al.
acidic pH (stomach).

Naringenin

Scutellarin

(2012)

(2013)

Effective in the treatment of dyslipidemia,
hyperglycemia compared to free Naringenin

Maity et al.

2-3 fold greater oral bioavailability than free

Wang et al.

scutellarin

(2017)

(2017)
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N-trimethyl chitosan-palmitic acid

Resveratrol

3.8-fold increase in oral bioavailability

(Micelles)
PLGA (Nanoparticles)

Ramalingam
and Ko (2016)

Lopinavir

13.9-fold increase in oral bioavailability

Joshi, Kumar,
and Sawant
(2016)

PEG-PLGA (Nanoparticles)

Ginsenoside

3 to 9-fold increase in oral bioavailability

Voruganti et al.
(2015)

Methacrylate copolymer (Eudragit 100)

Efavirenz

Higher serum drug concentration than free drug

(Nanoparticles)
sericin/poly(ethylcyanoacrylate)

(2016)
Fenofibrate

70% increase in oral absorption

(Nanospheres)
Gelatin-pluronic F68 (Nanoparticles)

Hari et al.

Parisi et al.
(2015)

Acyclovir

2-fold increase in drug exposure

Kharia and
Singhai (2015)

PEG-PAMAM dendrimer (Nanoparticles)

Probucol

Increased plasma concentration and lipid-

Qi et al. (2015)

lowering effect when delivered using
nanoparticles
Basic methacrylate copolymer
RL100 (Nanoparticles)

Atazanavir

2.91-fold increase in drug exposure

Singh and Pai
(2016)
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Increased the mice survival rate against advanced
Poly(butyl cyanoacrylate) and Poly(ε-

5-Fluorouracil or recurrent colon cancer compared to free 5-

Caprolactone) (Nanoparticles)
Mucoadhesive dendrimer (Nanoparticles)

Fluorouracil.
Albendazole

2.4-fold increase in Cmax.

Ortiz et al.
(2015)
Mansuri et al.
(2016)

Poly(amido

amine)

dendrimers Camptothecin

(Nanoparticles)

Cationic and anionic PAMAM dendrimers were Sadekar et al.
effective in enhancing the oral absorption of

(2013)

camptothecin.
Poly(ethylene glycol)-bpoly(alkyl(meth)acrylate-co-

Candesartan
cilexetil

pH-dependent

micellization

loading.

and

high

drug Satturwar et al.
(2007)

methacrylic acid) micelles
Poly(lactide)-poly(ethylene glycol) micelles

Griseofulvin

High drug loading, stable micelle in simulated Pierri and
gastrointestinal fluid.

Avgoustakis
(2005)

PMMMA-PLGA:poly[(methyl methacrylate)-co-(methyl acrylate)-co-(methacrylic acid)]-poly(D,L-lactide-co-glycolide), PAMAM:
Poly(amidoamine), PCL: Poly(caprolactone).

46

1.5. Natural polymers
Natural polymers are attractive materials for developing nanoparticulate based oral
drug delivery systems due to their biocompatibility. Natural polymers are derived from
plant sources like corn, cellulose, potato, soybean, or animal sources or synthesized by
bacteria (Nair and Laurencin 2007). The characteristics of natural polymers can be
improved by changing the surface chemistry such as dextran, cyclodextrins, and derivatives
of starch, cellulose, chitosan (Cumpstey 2013). These polymers have been widely
investigated for their application in drug delivery (Mogosanu and Grumezescu 2014). For
example, characteristics of cyclodextrins have been further improved by the substitution of
some of the hydrogen bonds with methyl groups result in increased solubility, stability, and
bioavailability, while decreasing the toxicity of polymer or drug (Figueiras et al. 2007).
Several research groups have studied natural polymers to develop nanocarriers for
oral delivery of drugs (Alqahtani et al. 2017; Hu et al. 2015; Bagre, Jain, and Jain 2013;
Huang et al. 2015; Santipanichwong et al. 2008).
Both polysaccharide and protein-based natural polymers have been investigated for
oral drug delivery applications.

1.5.1. Polysaccharide-based polymers
Polysaccharide-based polymers are ubiquitous and mainly obtained from algae,
plants, microbes, and animals. These polymers have been studied for drug delivery
applications (Cumpstey 2013). The diversity of structure and availability of derivable
functional groups provide enormous potential for the development of non-toxic, safe, and
cost-effective nanocarriers (Zhang, 2013). Polysaccharides are mainly divided into
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polyelectrolyte and non-polyelectrolyte polymers (dextran, dextrin, pullulan, etc.).
Polyelectrolyte polysaccharides can also be divided into positively charged (chitosan) and
negatively charged (heparin, hyaluronic acid) polymers (Sinha and Kumria 2001).
Electrostatic interaction of oppositely charged polymers have been used for the formation
of polysaccharide-based nanocarriers (Boddohi et al. 2009; Boddohi et al. 2010). Some
polysaccharide polymers such as chitosan exhibit efficient mucoadhesion due to the
formation of non-covalent bonds with intestinal mucosa and modifies the GI transit time
(Guggi, Krauland, and Bernkop-Schnurch 2003). Alginate, chitosan, guar gum, pectin,
xanthan gum, gellan gum and carrageenan based nanocarriers have been investigated for
oral drug delivery applications (Bhatia 2016; Jana 2011). Alginate has been used in
combination with other synthetic or natural polymer to modulate the functional
performance (Bacon 2002). Chitosan is a cationic, biodegradable, and non-toxic polymer
and has been extensively investigated alone or in combination with other polymers for oral
drug delivery applications (George and Abraham 2006). Alginate can be modified by crosslinking to control the release of encapsulated drugs (Pillay et al. 1998). Alginate has also
been grafted with albumin, PLGA, PEG, heparin, and guar gum to control the drug release
from polymer matrix (Hauptstein et al. 2015; Moebus, Siepmann, and Bodmeier 2009;
Davidovich-Pinhas, Harari, and Bianco-Peled 2009; El-Sherbiny et al. 2011; Mennini et
al. 2012; Pongjanyakul and Puttipipatkhachorn 2007; Wells and Sheardown 2011). For
example, rifampicin loaded PLGA-alginate core-sehll microsphere was shown to modify
drug release kinetics and achieved near zero-order release pattern (Wu et al. 2013).
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1.5.2. Protein polymers
Protein polymers are versatile class of biopolymers with a wide-range of amino
acid composition and varying physicochemical properties, which in-turn can influence its
functional performance (Podaralla 2009). The protein polymers have gained increased
attention due to the following advantages such as i) availability of various modifiable
functional groups (-NH2, -COOH and -SH), ii) renewable source and low cost, iii) protein
polymers are obtained from natural source and do not require initiators for synthesis, and
iv) proven biocompatibility compared to some of the synthetic polymers (Mukherjee et al.
2014). The formation of nanocarriers using protein polymers is mainly dictated by the
protein structure and subsequent intra- or inter-molecular interaction. (Ko and
Gunasekaran 2006).
However, the purity of protein polymers is difficult to control compared to synthetic
polymers. In addition, immunogenicity is one of the major concerns with protein polymers
(Podaralla 2009). The major limitation of natural protein polymers is batch-to-batch
variation (Podaralla 2009). Table 6 lists the physicochemical properties of some of the
protein polymers used for drug delivery.
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Table 6: Physicochemical properties of protein polymers.
Protein

Gelatin

Source

Collagen

Composition

4-hydroxylysine,

Molecular

Isoelectric

weight

point

15-250 KDa

7-9 (Type

hydroxyproline, glycine,

A), 4-5

alanine, and proline
Albumin

Whey

Plasma

Single polypeptide with 585

protein

amino acids

Milk protein

protein

(Type B)
66 KDa

4.7

α-lactoglobulin (LG), β-LG,

β-LG-18 KDa

3.5-5.2

lactalbumin,

α-LG-14 KDa

immunoglobulin, lactoferrin.
Casein

Milk protein

Proline- α s1, α s2, β and k

α s1-23 KDa

subunits

α s2- 25 KDa

4.6

β – 24 KDa
k – 19 KDa
Zein

Zea mays L.

High proportion of glutamine

α-zein-22-24

and proline

KDa, β-zein-

5.0-9.0

44 KDa, γzein-14 KDa
Gliadin

Wheat flour

Glutamine, Proline

Reproduced from Podaralla (2009).

28-55 KDa

6.8
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1.5.2.1. Animal proteins
1.5.2.1.1. Gelatin
Gelatin is the hydrolytic product of collagen and has a long history of use in
pharmaceutical industry as gelatin capsules (Marty, Oppenheim, and Speiser 1978; Ziv,
Avtalion, and Margel 2008). Gelatin is non-toxic, non-immunogenic, cost-effective and
can be easily modified to develop nanocarriers (Jahanshahi, Sanati, and Babaei 2008;
Boulle et al. 2008). The presence of multiple ionizable functional groups in gelatin (COOH, -NH2, phenol, guanidine, imidazole) favors conjugation of a variety of molecules
(Saxena et al. 2005; Shutava et al. 2009). However, unmodified gelatin is less stable and is
water insoluble (Lohcharoenkal et al. 2014). Addition of cross-linking agent such as
glutaraldehyde can overcome the limitations associated with gelatin’s stability and can be
used to control the release of encapsulated drugs (Jameela and Jayakrishnan 1995). For
example, glutaraldehyde cross-linked gelatin microsphere coated with alginate or chitosan
improved the stability of gelatin microsphere and controlled the release of methotrexate
after oral administration in rats (Narayani 1995).

1.5.2.1.2. Albumin
Albumin (66 kDa) can be obtained from different sources such as egg white, bovine
serum albumin (BSA), and human serum albumin (HSA). Albumin maintains the osmotic
pressure in human blood and is responsible for binding of nutrients. Albumin is highly
soluble at physiological pH and is an attractive carrier due to its ability to bind to various
molecules (Peters 1985). The reactive functional groups in albumin can be manipulated to
conjugate drug molecules depending on the application (Casi and Neri 2012). For example,
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emulsion solidification method has been used to prepare fluorouracil loaded BSA-alginate.
The nanoparticles were found to be distributed in liver, kidneys, lungs and brain after oral
delivery in rat (Yi, Yang, and Pan 1999). The major limitation of natural protein polymers
is batch-to-batch variation and may hinder the scaling-up for industrial application
(Elzoghby, Samy, and Elgindy 2012). HSA is obtained by fractionation of human plasma
and can carry bloodborne pathogens. However, recombinant HSA can overcome these
limitations (Chuang, Kragh-Hansen, and Otagiri 2002). It is important to note that human
serum albumin-bound paclitaxel (Abraxane®) is currently in clinical use for the treatment
of breast cancer, lung cancer and pancreatic cancer.

1.5.2.1.3. Milk proteins
Milk proteins include casein (80%) and whey proteins (20%). (Livney 2010) Casein
is a mixture of α-, β-, γ-, and κ-casein. Sodium caseinate is widely used as a stabilizer and
emulsifier in dairy and food products (Kimpel and Schmitt 2015). Beta-casein is a globular
protein and has been explored for oral delivery of hydrophobic molecules (Kytariolos et
al. 2013; Bachar et al. 2012; Shapira et al. 2010).
Whey protein is isolated from bovine milk has several proteins including βlactoglobulin, α-lactalbumin, lactoferrin, bovine serum albumin, immunoglobulins,
glycomacropeptide, and enzymes. It is widely used for its nutritional value in infants and
children due to the presence of essential amino acids (Baer et al. 2011; Coker et al. 2012;
Miller, Alexander, and Perez 2014). β-lactoglobulin (LG) is a major protein in the whey
protein and has been investigated as a carrier for drug and nutraceuticals, because of its
ability to bind with lipophilic molecules (Dufour, Genot, and Haertle 1994) such as
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retinoids (Collini, D'Alfonso, and Baldini 2000), hemin (Frapin, Dufour, and Haertle
1993), aromatic and carcinogenic hydrocarbons (Farrell, Behe, and Enyeart 1987; Tavel et
al. 2010), palmitic acids (Ragona et al. 2000; Wu et al. 1999), cholesterol and tocopherol
(Wang, Allen, and Swaisgood 1997), omega-3-fatty acids (Zimet and Livney 2009), and
anti-neoplastic agents (Eberini et al. 2008). β-lactoglobulin is relatively less affected by
peptic enzymes and is a promising vehicle for oral delivery of therapeutics (Miranda and
Pelissier 1983; Yvon et al. 1985).
Lactoferrin is an iron-binding glycoprotein which possesses multiple biological
activities including antibacterial, antiviral, antioxidant and anticancer activity (Baker and
Baker 2009). Lactoferrin acts as a natural iron transporter and has been investigated as a
ligand for targeting blood-brain barrier and intestinal epithelium through the transferrin
receptors (Zhang, Wang, Ayman, et al. 2013; Singh et al. 2016).

1.5.2.2. Plant proteins
1.5.2.2.1. Gliadin
Gliadin is a gluten protein found in wheat and is water-insoluble due to the presence
of high proportions of glutamine and proline residues (Thewissen et al. 2011; Delcour et
al. 2012). Gliadin proteins are divided into two groups based on solubility. These includes
monomeric gliadin (soluble in 70% alcohol) and polymeric glutenin (insoluble precipitate).
The presence of neutral and hydrophobic amino acids in gliadin favors interaction with the
epithelium by forming hydrogen and hydrophobic bonds (Ramteke and Jain 2008). Gliadin
can also interact with mucin due to the presence of disulfide groups (Arangoa et al. 2001;
Gulfam et al. 2012). Gliadin based nanoparticles have been tested for oral delivery of
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retinoic acid and vitamin E (Duclairoir et al. 2003). However, some individuals with gluten
intolerance can be sensitive to gliadin, thus limiting its application as a drug carrier
(Ciclitira et al. 2005; Dewar, Pereira, and Ciclitira 2004; Friis 1996; Joye, Nelis, and
McClements 2015).

1.5.2.2.2. Zein
Zein is one of the few water-insoluble natural proteins with a high proportion
(>50%) of hydrophobic amino acids (proline, alanine, and leucine). It is the major storage
protein in corn and is composed of α, β, γ, and δ zein, classified based on the solubility in
hydroalcoholic solvents (Joshi et al. 2015). Commercial zein is mainly composed of α-zein
(22−27 kDa). Zein is a US-FDA approved Generally recognized as safe (GRAS) material
and is widely used in the food and packaging industries to provide an impervious moisture
barrier (Corradini et al. 2014). Zein has also been used to encapsulate hydrophobic
compounds and sustain the release from microspheres, nanoparticles, and nanofibers
(Table 7) (Zhang, Cui, Che, et al. 2015; Gong et al. 2011; Hashem et al. 2015; Zhang, Cui,
Chen, et al. 2015; Zhang et al. 2016). However, Zein nanoparticles exhibit poor colloidal
stability leading to particle aggregation and thus require additional polymer or other
materials to form stable nanoparticles (Joye, Davidov-Pardo, and McClements 2015; Chen
and Zhong 2014).

1.5.2.2.3. Soy proteins
Soy protein isolate (SPI) contains a high concentration of protein rich in essential
amino acids. Glycinin and β-conglycinin constitutes the major portion of SPI (Yaklich
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2001). The presence of polar, non-polar and charged amino groups facilitates the
incorporation of a variety of drug molecules (Teng, Luo, and Wang 2012). The globular
protein forms a hydrophobic core in the presence of water and the addition of crosslinking
agent leads to aggregation and formation of microspheres (Lazko, Popineau, and Legrand
2004). Curcumin nanocomplexation with SPI significantly enhanced the solubility of
curcumin and stability in GI tract (Table 7) (Chen, Li, and Tang 2015). The
physicochemical properties of SPI are variable and dependent on nature and composition
of starting materials (defatted soy flour or flakes), processing and preparation procedure
used, and environmental conditions (Liu and Tang 2013; Keerati and Corredig 2009). In
addition, some portion of SPI remains as aggregated particles during the process of
isolation of SPI from its starting materials, and the surface hydrophobicity significantly
increases with heat treatment (Keerati and Corredig 2009; Liu and Tang 2013).
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Table 7: Natural protein polymers for oral drug delivery applications.
Protein polymers

Drugs

Findings

Reference

Zein nanoparticles

Folic acid

Two-times higher oral
bioavailability of folic acid
compared to free folic acid.

Peñalva (2015)

Zein-alginate nanoparticles

Superoxide
Dismutase

Reduced intracellular reactive
oxygen species.

Lee, Kim, and Park (2016)

Zein nanoparticles

Quercetin

Sustained plasma level of
quercetin and anti-inflammatory
activity.

Penalva et al. (2017)

Compressed zein microsphere

Ivermectin

Increased oral bioavailability of
ivermectin in dogs.

Gong et al. (2011)

Zein microsphere

Aceclofenac
sodium

Sustained release oral drug
delivery system.

Karthikeyan et al. (2012)

Casein nanoparticles

Cisplatin

Increased oral absorption of
cisplatin.

Zhen et al. (2013)

Casein nanoparticles

Flutamide

Enhanced oral bioavailability of
flutamide for the treatment of
prostate cancer.

(Elzoghby, Helmy, et al. 2013b,
2013a; Elzoghby, Saad, et al.
2013)

Bovine Lactoferrin

Doxorubicin

Increased doxorubicin
bioavailability in hepatic tumor
model.

Golla et al. (2012)
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β-Casein Nanomicelles

Paclitaxel

Increased stability and availability
of paclitaxel in gastric carcinoma
animal model.

Bar-Zeev, Assaraf, and Livney
(2016)

β-Casein micelle

Curcumin

Increased solubility and cell
uptake of curcumin in human
leukemia cells.

Esmaili et al. (2011)

β-Lactoglobulin nanoparticles

Epigallocatechin
gallate (EGCG)

Prevent oxidation and degradation
of EGCG

(Li et al. 2012; Shpigelman,
Cohen, and Livney 2012)

β-Lactoglobulin nanoparticles

Curcumin

Enhanced Solubility of curcumin

Teng, Li, and Wang (2014)

Nanocomplexation of curcumin with

Curcumin

Enhanced antioxidant properties of

Tapal (2012)

soy protein isolate nanoparticles
Nanocomplexation of curcumin with
Soy Protein Isolate nanoparticles

curcumin
Curcumin

Significantly enhanced solubility
and permeability of of curcumin

Chen, Li, and Tang (2015)
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1.6. Scope and objectives
Food-grade polymers are promising materials for developing oral drug delivery
systems due to their biocompatibility and proven safety. This study focuses on the use of
food protein-based nanoparticles/micelles for oral drug delivery applications.
Zein has been used to form nanoparticles for various drug delivery applications
(Penalva et al. 2017; Irache and Gonzalez-Navarro 2017; Penalva et al. 2015; Luo et al.
2013; Podaralla and Perumal 2012). However, in the absence of a stabilizer, zein
nanoparticles tend to aggregate (Davidov-Pardo et al. 2015; Chen and Zhong 2014). To
this end, the goal of this study is to develop stable core-shell nanocarriers using other
proteins or polymers as shell. The overall goal of this study was to systematically study the
influence of shell composition on the physicochemical and functional performances of zein
nanocarriers for oral drug delivery applications. The study was based on the hypothesis
that the hydrophobic core can be used to encapsulate water-insoluble compounds and
achieve sustained release, while the shell biopolymer can be used to provide unique
functional characteristics and good sensory properties for oral drug delivery applications.
Six different core−shell nanocarriers were prepared including zein-β-casein (ZC)
nanoparticles, zein-lactoferrin (ZLF) nanoparticles, zein-polyethylene glycol (ZPEG)
micelles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate (ZWP)
nanoparticles and zein-pluronic-lecithin (ZPL) nanoparticles. The core-shell nanocarriers
in addition to stabilizing the zein core, offers the following advantages i) enhanced
dispersibility and enzymatic stability, ii) sustained drug release, and iii) enhanced
permeability and bioavailability of encapsulated drugs.
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The overall goal is to demonstrate the feasibility and application of core-shell
nanocarriers for oral drug delivery.

To achieve this goal, following were the specific aims of this study:
Objective 1: Preparation and study of the structure-function relationship of core-shell zein
nanocarriers for oral drug delivery applications.

Objective 2: Use of core-shell nanocarriers for oral delivery of a model antiretroviral
drug.

Objective 3: Use of core-shell nanocarriers for oral delivery of an investigational anticancer drug molecule.
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CHAPTER TWO
PREPARATION AND STUDY OF THE STRUCTURE-FUNCTION
RELATIONSHIP OF CORE-SHELL NANOCARRIERS
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2.1. Introduction

Given that oral delivery is the most common and convenient route of drug
administration with high patient compliance, several strategies (nanoparticles, micelles,
emulsions, and lipid-based carriers) have been explored to address the oral delivery
challenges (Agrawal et al. 2014; Zhang, Wang, Zhang, et al. 2013; Kohli et al. 2010;
Simoes et al. 2015). Considering the versatility of nanocarriers for oral drug delivery
applications, a wide range of materials (natural and synthetic polymers) have been tested
for developing nanoformulations (Agrawal et al. 2014; Zhang, Wang, Zhang, et al. 2013).
However, very limited studies have focused on the development of nanocarriers for
pediatric oral drug delivery. The major concern in developing nanocarriers in general and
pediatric in particular to ensure that excipients are safe.
Given the dynamic change in physiology from birth through adolescence,
development of medicines for pediatrics remains a challenge in formulation development
(Ivanovska et al. 2014; Nahata 1999). The Pediatric Research Equity Act (PREA) was
introduced in 2012 (Christensen 2012; Ren and Zajicek 2015). The Best Pharmaceuticals
for Children Act (BPCA) and Pediatric Research Equity Act (PREA) together was
introduced to develop safe and effective medicines for pediatric patients (Ren and Zajicek
2015; Christensen 2012). Formulations developed for adult per say may not suitable for
pediatric patients. The excipients that are suitable for adults may not necessarily be safe
for pediatrics. Therefore, a comprehensive assessment of the excipients is essential before
in pediatric drug formulations (Schmitt 2015; Salunke et al. 2013; Salunke, Giacoia, and
Tuleu 2012). There have been some efforts to develop easy, reliable, and flexible pediatric
formulations such as minitablets, pellets, orally dispersible tablets, chewable tablets,
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powders for reconstitutions, liquid syrup, and suspension (Ivanovska et al. 2014).
However, there is an unmet need especially to improve the oral bioavailability of drugs
with poor physicochemical properties.
In this regard, food-grade biopolymers especially protein polymers are promising
for developing oral drug delivery vehicles since they are edible, safe and biocompatible.
Protein polymers that have been explored for oral drug delivery applications include
gelatin, casein, whey proteins, soy proteins, zein, and wheat proteins (Arangoa et al. 2001;
Liu et al. 2005). Zein is a water-insoluble protein GRAS protein polymer that is widely
used in food and packaging industry (Corradini et al. 2014). Zein has been used to
encapsulate hydrophobic compounds and sustain the release from microspheres,
nanoparticles, and nanofibers (Zhang, Cui, Che, et al. 2015; Gong et al. 2011; Hashem et
al. 2015; Zhang, Cui, Chen, et al. 2015; Zhang et al. 2016). However, zein nanoparticles
exhibit poor colloidal stability leading to particle aggregation (Joye, Davidov-Pardo, and
McClements 2015; Chen and Zhong 2014). To this end, the main goal of this study is to
develop zein-based nanocarriers using different food-grade biocompatible polymers as
stabilizers on the outer shell of the nanocarrier. The focus of this study is to systematically
investigate the influence of shell composition on the physicochemical and functional
performance of core-shell zein nanocarriers for oral delivery applications.
In this study, milk proteins including casein whey protein as a whole or individual
proteins ( (lactoglobulin and lactoferrin which differ in their physicochemical properties
were used (Livney 2010). Beta-casein can form microsphere and micelles, and it has been
explored as an oral drug delivery vehicle for hydrophobic compounds (Willmott et al.
1992). Beta-casein is comparatively more hydrophobic among the milk proteins and
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therefore can stabilize zein nanoparticles by utilizing hydrophobic interaction between zein
and casein. Whey protein which is isolated from bovine milk has several proteins (βlactoglobulin, α-lactalbumin, lactoferrin, bovine serum albumin, immunoglobulins,
glycomacropeptide, and enzymes) and is widely used for its nutritional value in infants and
children due to the presence of essential amino acids (Coker et al. 2012; Miller, Alexander,
and Perez 2014). β-lactoglobulin (LG) is the major portion of Whey protein and has been
investigated as drug or nutraceutical carrier for its binding capacity with lipophilic
molecules (Dufour, Genot, and Haertle 1994; Collini, D'Alfonso, and Baldini 2000; Frapin,
Dufour, and Haertle 1993; Farrell, Behe, and Enyeart 1987; Tavel et al. 2010; Ragona et
al. 2000; Wu et al. 1999; Wang, Allen, and Swaisgood 1997; Zimet and Livney 2009;
Eberini et al. 2008). β-lactoglobulin was less affected by peptic enzymes and is a promising
vehicle for oral delivery of therapeutics. (Miranda and Pelissier 1983; Yvon et al. 1985).
Lactoferrin (LF) is an iron-binding glycoprotein that belongs to the transferrin family
(Baker and Baker 2009). Lactoferrin has a high nutritional value for infants and children
as an iron transporter. (Manzoni 2016). It also has been used as targeting ligand for
improving the delivery across the blood−brain barrier and intestinal epithelial barrier
through lactoferrin receptors. (Singh et al. 2016; Zhang, Wang, Ayman, et al. 2013).
Nanoparticles prepared using zein per se results in larger particles with wide size
distribution, particle aggregation, and low drug encapsulation. Our lab previously has
reported the use of pluronic F68 and lecithin to stabilize zein nanoparticles and achieve
higher drug encapsulation (Podaralla and Perumal 2010). A combination of pluronic F68
and lecithin in 2:1 ratio stabilized the zein nanoparticles (Podaralla and Perumal 2010,
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2012). In this study, we will explore the use of zein-pluronic-lecithin (ZPL) nanoparticles
for oral drug delivery.
Polyethylene glycol (PEG) is an FDA approved biocompatible polymer that has
been used to modify the surface of nanoparticles and proteins (D'Souza A and Shegokar
2016). Further, PEG is a widely used water-soluble excipient in oral and other formulations
(D'Souza A and Shegokar 2016). Earlier research from our group has demonstrated the
ability of PEGylated zein to form self-assembled micelles with hydrophobic zein as the
core and hydrophilic PEG chain as the shell (Podaralla et al. 2012). The PEG-zein (ZPEG)
micelles enhanced the aqueous solubility and chemical stability of curcumin, a waterinsoluble anticancer agent. Further, the curcumin-loaded PEG-zein micelles showed higher
cell uptake than free curcumin in drug-resistant cancer cells and reduced the IC50 value of
curcumin by 3-fold (Podaralla et al. 2012). However, the ZPEG micelles is yet to be
investigated for oral drug delivery.
In this study, six different core−shell nanocarriers were prepared including zein-βcasein (ZC) nanoparticles, zein-lactoferrin (ZLF) nanoparticles, zein-polyethylene glycol
(ZPEG) micelles, zein-β-lactoglobulin (ZLG) nanoparticles, zein-whey protein isolate
(ZWP) nanoparticles and zein-pluronic-lecithin (ZPL) nanoparticles. The six nanocarriers
differ in their surface charge and hydrophilicity. The influence of shell composition on the
physical stability, enzymatic stability, release kinetics, cell/tissue uptake, intestinal
permeability, and in vivo biodistribution of zein nanocarriers was evaluated. Nile red (NR)
was used as a model hydrophobic compound for in vitro studies, while Cy 5.5, a nearinfrared dye, was used for the in vivo imaging studies.
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Specific aims of this study were:
i)

To develop and characterize zein-based core-shell nanocarriers.

ii)

To test the release of encapsulated Nile Red (NR) from the nanocarriers in
simulated gastrointestinal fluids.

iii)

In vitro cell uptake studies in Caco-2 cells to determine the kinetics and the
mechanism of cell uptake of the nanocarriers.

iv)

Test the bioadhesive properties of the core-shell nanocarriers.

v)

Oral immunogenic studies of core-shell nanocarriers in mice.

vi)

Oral biodistribution of core-shell nanocarriers in rats.
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2.2. MATERIALS AND METHODS
2.2.1. Materials
White zein (Zein F-4000) was purchased from Freeman Industries Inc, (Tuckahole,
NY, USA). Nile red, β-casein, β-lactoglobulin, and D-α-Tocopherol polyethylene glycol
1000 succinate (TPGS 1000) were purchased from Sigma-Aldrich Company (St. Louis,
MO, USA). Bovine lactoferrin and whey protein isolate were provided by Dr. Hasmukh
Patel from the Department of Dairy Science, South Dakota State University. Trehalose was
obtained from Acros Organics (Bridgewater, NJ, USA). Precast-Gels and reagents for
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were purchased
from Bio-Rad (Hercules, CA). Pepsin, trypsin, sodium azide and Dulbecco’s Modified
Eagle Medium were purchased from Fisher Scientific (Bridgewater, NJ, USA). Dialysis
membrane (MWCO 10 kDa) was purchased from Spectrapor (Houston, TX, USA).
ProLong Gold Antifade mounting medium with DAPI was purchased from InvitrogenMolecular Probes (Eugene, OR, USA). Polyethylene glycol (PEG, 5kDa) was purchased
from Jenkem Technology (Plano, TX, USA). Cyanine 5.5 NHS ester dye was purchased
from Lumiprobe (Hallandale Beach, FL, USA).

2.2.2. Preparation of zein-based core-shell nanocarriers
The core-shell nanoparticles were prepared using the phase separation method
based on differential solubility of zein and milk proteins (Alqahtani et al. 2017; Podaralla
et al. 2012). Briefly, 15 mg of zein was dissolved in 2 mL of 90% ethanol containing 1 mg
of Nile red (NR) or Cy5.5 dye. The alcoholic phase was added dropwise under probe
sonication (Sonics & Materials, Inc., Danbury, CT, USA) to the aqueous phase consisting
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of 15 mL 0.1 M citrate buffer (pH 7.4) and 0.2% w/v of milk protein (β-casein or
lactoferrin) or pluronic (0.9%, w/v)-lecithin (0.45%, w/v) (PL).
Zein-β-lactoglobulin (ZLG) and zein-whey protein isolate (ZWP) nanoparticles
were prepared by preheating 15 mg of β-lactoglobulin (LG) or whey protein isolate (WP)
in 15 mL of 0.1 M citrate buffer (pH 6.8) for 30 minutes at 60°C before adding in zein
hydroalcoholic solution. The resulting colloidal dispersion was placed on a magnetic stirrer
(200 rpm) for 3 hours to evaporate the ethanol. The nanoparticles were separated using
centrifugal filter (10 kDa MWCO) (EMD Millipore, Billerica, MA, USA) at 4000 rpm and
washed with deionized water to remove the free NR or Cy 5.5. Trehalose (30 mg) was
added as a cryoprotectant before lyophilization. The lyophilized formulations were stored
in a desiccator at 4°C until further use.

Polyethylene glycol (PEG5000) was conjugated to zein to prepare PEGylated zein
micelles as reported earlier (Podaralla et al. 2012). Briefly, zein and methoxy PEGsuccinimidyl succinate (5KDa) in the weight ratio of 1:2 (zein: mPEG ester) were dissolved
in 90% ethanol and incubated overnight. The reaction was stopped by adding 1 M of
glycine followed by dialysis (10 kDa MWCO) for 24 h against water to remove the free
PEG. To prepare the micelles, NR or Cy 5.5 was dissolved in 20 mL of 90% alcohol along
with zein-PEG (5.5 × 10−2 g/L), and the mixture was stirred overnight in a magnetic stirrer
to allow for partitioning of the dye into the hydrophobic zein core. Ethanol was removed
using a rotary evaporator, and the resultant film was hydrated with citrate buffer (pH 7.4)
to form ZPEG micelles. The mixture was dialyzed (10 kDa MWCO) against deionized
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water (100 mL) to remove the free dye. The dye-loaded ZPEG micelles was lyophilized
and stored in a desiccator at 4°C until further use.
2.2.3. In vitro characterization and optimization
The particle size, size distribution, and zeta potential were determined using the
Malvern Zetasizer Nano-ZS (Malvern Instruments Inc., Southborough, MA) by dispersing
lyophilized nanoparticles in deionized water (0.1 mg/mL). For morphological analysis, the
nanocarriers were visualized by transmission electron microscopy (TEM). The specimen
was prepared by placing a dilute dispersion of the nanoparticles on carbon-coated 200 mesh
copper grid and the sample was evaporated overnight. TEM images were acquired using a
Tecnai Spirit G2 TEM (FEI, Hillsboro, OR, USA), operated at an accelerating voltage of
120 kV. The electron micrographs were recorded using Orius SC200 CCD camera coupled
to TEM. Image analysis was performed using Digital Micrograph software.

2.2.4. Determination of Nile Red (NR) encapsulation efficiency
Briefly, 5 mg of NR loaded lyophilized particles was dispersed in deionized water
and centrifuged at 14000 rpm for 10 minutes. After decanting the supernatant, the
nanoparticles were digested in 90% alcohol to extract the encapsulated NR. The
concentration of NR was determined using a calibration curve (0.2 to 5µg/ml) of NR in
90% alcohol. The samples were analyzed by spectrofluorimetry (SpectromaxM2,
Molecular Devices, Sunnyvale, CA) using the excitation and emission wavelength of 559
and 629 nm respectively. The encapsulation efficiency (EE%) was calculated using the
following equation
NR Encapsulation Efficiency (%) =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑅 𝑖𝑛 𝑁𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑎𝑑𝑑𝑒𝑑 𝑁𝑅

x 100
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2.2.5. In vitro Release of NR
The in vitro release of NR from the nanocarriers was determined in simulated
gastric (SGF) and intestinal fluid (SIF). SGF was prepared using 0.1 M HCl and 0.32%
w/v pepsin (pH 1.2), while SIF was prepared using 0.05M KH2PO4 with 0.1 M NaOH (pH
7.5) and 1% w/v pancreatin. For release studies, 20 mg of NR loaded nanocarriers (ZC,
ZLF, ZLG, ZWP, ZPL, and ZPEG) was suspended in 5 ml release medium and placed in
a dialysis cassette (EMD Millipore, 10KDa MWCO). The cassette was placed in 200 ml
release medium containing Tween 80 (0.1% v/v) to maintain sink conditions. At predetermined intervals, 1 ml of the release medium was removed and replaced with an equal
volume of release medium. The sample was mixed with 1ml of ethanol, and the
concentration of NR was determined by spectrofluorimetry as described earlier.

2.2.6. Enzymatic degradation of core-shell nanocarriers
The degradation profile of nanoparticles was determined by incubating the
nanoparticles in simulated gastric fluid (SGF) and intestinal fluid (SIF) for up to 4 hours.
The samples were analyzed by SDS-PAGE gel electrophoresis (12%). ZC and ZLF was
stained with Coomassie blue, while for ZPEG, ZLG, and ZWP the gels were stained with
Gel Code Blue Staining Reagent (Life Technologies).

2.2.7. Influence of pH and ionic strength on nanoparticle stability
To determine the effect of pH on particle size and zeta potential, lyophilized blank
nanocarriers were dispersed in solution varying in pH from 2 to 10. The pH was adjusted
using 0.1 M HCl or 0.1 M NaOH. Similarly, the effect of salt concentrations (0-200 mM
of NaCl) on particle size and zeta potential of the nanocarriers were also determined.
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2.2.8. Cell culture
Caco-2 cells (ATCC, Rockville, MD, USA) cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) (4.5 g/L glucose) supplemented with 20% FBS
(HyClone; Thermo Scientiﬁc, Waltham, MA, USA), 1% non-essential amino acids, 1% Lglutamine, 1% streptomycin (100 μg/ml) and penicillin (100 IU/ml). The growth medium
was changed every day in the first two weeks followed by replacement of the medium three
times a week.

2.2.9. Mechanism of cellular uptake of NR loaded nanocarriers
Caco-2 cells were seeded in a 12-well plate at a concentration of 1 x 105 cells/well
(passage number 10-15). Next day, the culture medium was removed, and the cells were
treated with one µg of NR loaded different nanocarriers in Hank’s Balanced Salt Solution
(HBSS) for 30 minutes to 2 hours at 37°C. At the end of the treatment period, the cells
were washed with HBSS three times followed by trypsinization. The cells were washed
with ice-cold HBSS and fixed using 2% paraformaldehyde. The mean fluorescence
intensity was analyzed by flow cytometry (FACS, BD Biosciences, San Jose, CA). To
understand the mechanism of cell uptake of the nanoparticles, the experiments were
performed at 4°C and compared with the cell uptake at 37°C.
In a separate set of experiments, Caco-2 cells were pre-incubated with endocytosis
inhibitors including 1µM phenyl arsine oxide (PAO), 4µM Filipin and 10 µM Cytochalasin
D for 30 minutes, followed by cell uptake experiment using 1 µg NR loaded nanocarriers
for 2 hours.
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2.2.10. Calcein uptake assay
For P-gp- inihibition assay, Caco-2 cells were seeded in a 96-well plate (1x104
cells/mL) 24 hours before treatment with nanocarriers. Blank nanocarriers were dispersed
in HBSS buffer (1 mg/mL) and cells were incubated with 50 μL of blank nanocarriers for
30 minutes. Cells were washed three times with HBSS buffer followed by addition of 200
μL of 0.5 μM calcein AM, a P-gp substrate (Molecular Probes, Eugene, OR, USA) and
incubated for 2 hours. Cells were washed three times with ice-cold HBSS and lysed using
0.5% Triton X-100. A control experiment was performed following the same procedure,
but without the addition of nanocarriers. Calcein uptake was measured by
spectrofluorimetric analysis using 485 and 530 nm as excitation and emission wavelengths
respectively. To determine P-gp inhibition, the relative calcein fluorescence (FL) was
calculated for the nanocarrier treated and non-treated groups using the following equation,
𝐹𝐿 (𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) − 𝐹𝐿(𝑛𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
]𝑥100
𝐹𝐿 (𝑛𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑)

% 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 = [

2.2.11. In vitro transepithelial transport of core-shell nanocarriers
Caco-2 cells (1×105 cells/well) were seeded onto Transwell polyester insert (pore
size 3.0 µm, surface area 1.12 cm2) in a 12-well plate (Transwell®, Corning Costar Corp.,
Cambridge, MA, USA). The cells were grown in an atmosphere of 5% CO2 and 95% air
with 95% relative humidity at 37°C. The cells were allowed to grow for three weeks, and
the formation of a monolayer was confirmed by measuring the transepithelial electrical
resistance (TEER) using EVOM meter (Sarasota, FL). Before starting the experiment, the
medium in the apical side was replaced with 2mg/ml of nanoparticle dispersion in Hank’s
balanced salt solution (HBSS), and the permeability of NR loaded nanoparticles was
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determined for 4 hours. Samples (200µl) were withdrawn from the basolateral
compartment at pre-determined time points and replaced with an equal volume of fresh and
pre-warmed HBSS buffer solution. The apparent permeability coefficient (Papp) was
calculated using the following equation

Papp (cm/s) =

[

(dQ/dt)

𝐴𝐶𝑜

] x 100

Where dQ/dt is the flux of NR across Caco-2 monolayer, C0 is the initial concentration of
NR in the apical chamber, and A is the surface area of the 12-well plate Transwell insert
(1.12 cm2).

2.2.12. Cell uptake studies using confocal laser scanning microscopy
To visualize the cell uptake of core-shell nanocarriers, Caco-2 cells (5x104
cells/well) were seeded in a chamber slide (Nunc Lab-TEK®II Chamber SlideTM system,
Thermo Scientific, Waltham, MA) and was incubated overnight. Next day, the growth
medium was replaced with HBSS buffer (pH 7.4) and equilibrated for 30 min at 37°C.
Then, the nanoparticle dispersion (500µg/mL) was added to the wells and incubated for
30-60 min. At the end of treatment period, cells were washed three times with cold HBSS
to remove the surface adsorbed nanoparticles. Cells were then fixed using 4%
paraformaldehyde for 20 min at room temperature followed by staining F-actin with Alexa
Fluor 488-Phalloidin (Life Technologies, Carlsbad, CA). DAPI containing mounting
medium (Vector Labs) was used to stain the nucleus. Images were taken using Olympus
FluoView 1200 (FV 1200) confocal laser scanning microscope (CLSM) at a 60x
magnification.
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2.2.13. Ex vivo adhesion assay
2.2.13.1. Everted sac method
To determine the mucoadhesive properties of core-shell nanoparticles, everted sac
method was used (Reineke, Cho, Dingle, Cheifetz, et al. 2013). Pig jejunum was procured
from the Department of Animal Science at South Dakota State University. Briefly, a
section of freshly collected pig jejunum (6 cm length) was everted using a glass rod to
expose the mucosal side, and the open ends were tied to form a sac (Fig. 11). The loose
mucus was removed from the intestine. The sac was filled with phosphate buffered saline
glucose (PBSG). The everted sac was placed in NR loaded nanoparticle suspension (100
mg/ml) in PBSG and incubated at 37˚C in a shaker water bath for 1 hour to allow time for
the nanoparticles to adhere to the tissue. Fluorescent-labeled polystyrene nanoparticles
(200nm, Phosphorex, Hopkinton, MA, USA) were used as a positive control. Following
incubation, the everted sac was removed and processed (adherent mucus and remaining
suspension collected as bound and unbound fractions, respectively) for determining the NR
concentration by spectrofluorimetry. The ratio of NR concentration in the bound and
unbound nanoparticles was used to calculate the percent adhesion.
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Figure 13: Schematic presentation of everted sac method to test the bioadhesion of
nanocarriers on the mucosal surface. Reproduced from Alam, Al-Jenoobi, and Al-Mohizea
(2012).

2.2.13.2. Determination of bioadhesive property of nanocarriers using Texture
Analyzer
The bioadhesive property of the nanocarriers was further determined using a texture
(Reineke, Cho, Dingle, Cheifetz, et al. 2013). Bioadhesive property of the nanocarriers was
determined by measuring the maximum force required to separate the nanocarriers from
mucosal surface of the intestinal tissue (Thirawong et al. 2007). Polystyrene nanoparticles
(PS) (Phosphorex Inc., Hopkinton, MA, USA) of 200 nm size was used as a positive

74

control. Briefly, ‘T’ shapped metal-head probe was coated by dip and dry method using
5% (w/v) aqueous nanoparticle dispersion. A thin uniform layer of the coat was obtained
by repeated cycles of dipping and drying the metal head for eight times. The coated probe
was then fitted in the loading arm of the texture analyzer. Freshly collected piglet jejunum
was washed with pre-warmed oxygenated PBS (pH 7.4) and placed below the probe. The
coated metal probe was programmed to descend at 0.5 mm/s until a final force of 5 g was
achieved between the coated probe and the intestinal tissue. The probe was incubated for
7 minutes to allow for interaction (Mathiowitz et al. 1997; Santos et al. 1999; Reineke,
Cho, Dingle, Cheifetz, et al. 2013; Thanos et al. 2003) between the coated probe and
intestinal tissue. Then the probe was ascended with the same speed, and the peak loads
were recorded during start of the fracture between tissue and probe. The fracture strength
was calculated and normalized using projected surface area (PSA). The following equation
was used for calculation of PSA (Reineke, Cho, Dingle, Cheifetz, et al. 2013):
1

PSA = 2 × 6 × 𝑎 × ℎ
Where, a is the length of each side of the hexagon and h is the radius of the probe surface.
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Figure 14: Texture analyzer set up to determine the force required to remove nanoparticle
coated probe from the excised intestinal tissue. Modified from Shaikh et al. (2011).

2.2.14. Ex vivo tissue uptake studies in pig jejunum
To determine the tissue uptake of NR loaded nanocarriers, pig jejunum was used.
The jejunum was collected from 11-day old pig and maintained in Krebs buffer at 37°C. A
6 cm jejunum was flushed with buffer, tied open ends, and filled with NR loaded
nanocarriers (10µg/ml) followed by incubation in HBSS (pH 7.4) for 2 hours at 100rpm
(37°C). At the end of the treatment, the jejunum was washed and fixed with 4%
paraformaldehyde overnight at 4°C. The fixed tissue was embedded using optimal cutting
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temperature medium (OCT), and 10µm sections were prepared using a cryo microtome
(Leica, Buffalo Grove, IL). F-actin was stained with Alexa Fluor 488-Phalloidin and the
nucleus was stained with DAPI. The images were taken at 20x magnification.

2.2.15. Animal studies
2.2.15.1. Immunogenicity studies
Female Balb/c mice (4 weeks old) were used for the immunogenicity study. The
experiments were conducted according to the approved protocol by the Institutional
Animal Care and Use Committee (IACUC) at SDSU. Mice were randomly divided into
five groups with four animals in each group. Nanocarriers (100µg of total protein) was
administered by oral gavage at 0 and 3rd week (booster dose). Blood samples were collected
from the retro-orbital plexus at 0, 3rd and 5th week. The samples were then processed to
separate the serum and analyzed for IgG antibody titers. Intestinal contents were also
collected and processed (Kim et al. 2002; Pecquet et al. 2000). to determine the mucosal
IgA levels. Briefly, freshly collected intestinal contents were diluted in 1:32 (w/v) ratio of
intestinal content and chilled PBS containing 50mM EDTA and 0.1mg/mL trypsin
inhibitor. The samples vortex vigorously to disperse the tissue contents. Then the sample
was centrifuged at 650g for 10 minutes. The supernatant was separated and mixed with
0.03 mL of 100 mM phenyl methyl sulfonyl fluoride (PMSF). Then the sample was
centrifuged at 27000xg for 20 minutes at 4°C to further clarify the secretions. Another 0.02
mL of PMSF and 0.02 mL of sodium azide was added to each of the 2 mL clarified
solutions. The solution was incubated for 15 minutes and 0.2 mL of fetal bovine serum
(FBS) as added as substrate. The final samples were stored in -80°C until further analysis.
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All the samples were analyzed for anti-zein, anti-ZC, anti-ZLF, anti-ZLG, antiZWP and anti-ZPEG IgG and IgA antibodies by Enzyme-linked Immunosorbent Assay
(ELISA). Briefly, 96-well plates were coated with 200ul of 0.1% (w/v) total protein
(nanocarriers). After overnight incubation at 4°C, the plates were washed with buffer (PBS
in 1% Tween 20) and blocked with 3% normal goat serum for 1 hour at 37°C. A second
washing step was done with PBS buffer (pH 7.4), followed by incubation with 1/16 diluted
mouse serum for 2 hours at room temperature. The intestinal samples were also analyzed
to determine the level of IgA antibody. The plate was washed with PBS buffer (4 times)
and incubated with Horse Reddish Peroxidase (HRP) conjugated goat anti-mouse IgG or
anti-mouse IgA for 1 hour. Then the plate was washed for four times using PBS buffer and
incubated with 100µL TMB (3, 3’, 5, 5’-tetramethylbenzidine) substrate. The reaction was
stopped after 10 minutes using 50µL 1M H2SO4. The optical density was recorded at 450
nm in a plate reader (SpectraMax2, microplate reader, Molecular Devices, Sunnyvale, CA).

2.2.15.2. In vivo biodistribution
To determine the in vivo oral biodistribution of core-shell nanocarriers, Cy 5.5, a
near infra-red dye was used. Male Sprague-Dawley rats (6–8 weeks of age, 200-250 g)
were used for the study. The animal studies were conducted after approval from IACUC at
SDSU. The animals were acclimatized one week before the start of the study and had free
access to water and food. Cy 5.5 loaded nanoparticles (50µg) were dispersed in water (2ml)
and administered using a flexible oral gavage tube under mild isoflurane anesthesia. The
time-dependent biodistribution (2, 6, 12, and 24 hrs) of nanocarriers was determined using
the in-vivo imaging system (Xtreme, Bruker, Billerica, MA, USA). The free dye was used
as a control. The animal was placed in the imaging chamber, and a short exposure of x-ray
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was used to record the anatomy followed by determination of fluorescence. After 6 and 24
hours, the animals were sacrificed, and the gastrointestinal tract (GIT) was separated, and
the fluorescence was recorded using the in-vivo imaging system. All images were captured
at 0.1-second exposure using the excitation and emission wavelengths as 690 and 750 nm
respectively. Bruker MI software was used to process the images.

2.2.15.3. In vivo tissue uptake studies through rat jejunum
To determine the tissue uptake of Cy 5.5 loaded nanocarriers, the jejunum was
collected at 6 hours after oral administration of nanocarriers and the tissue was fixed with
4% paraformaldehyde overnight at 4°C. The fixed tissue was embedded using optimal
cutting temperature medium (OCT), and 10µm sections were prepared using a cryomicrotome (Leica, Buffalo Grove, IL). F-actin was stained with Alexa Fluor 488Phalloidin and the nucleus was stained with DAPI. The images were taken at 20x
magnification.

2.3. Statistical analysis
All the experiments were conducted in triplicate. Data is represented as the mean ±
standard deviation. Statistical evaluation was performed by one-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc test using Minitab® statistical software (Minitab
Inc., State College, PA) at a significance level of p < 0.05.
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2.4. RESULTS AND DISCUSSION

Core-shell nanocarriers were developed using zein, a hydrophobic plant protein as
the core and milk proteins (β-casein or lactoferrin or β-lactoglobulin or whey protein
isolate), polyethylene glycol or pluronic-lecithin as the shell. The physicochemical
characteristics of the six nanocarrier formulations is shown in Table 8. Part of the work
related to zein-β-casein (ZC) nanoparticles, zein-lactoferrin (ZLF) nanoparticles and
PEGylated zein (ZPEG) micelles was previously reported by us and reproduced here for
comparison.

2.4.1. Characteristics and Stability of core-shell nanocarriers
All the three nanocarriers had a particle size in the range of 100-200 nm with a
uniform size distribution, as seen from the low polydispersity index (Table 8). The
nanoparticles in this size range have been reported to increase drug solubility and
permeability through the membrane (Desai et al. 1996; Win and Feng 2005).
The shell composition influenced the NR encapsulation efficiency in the
nanocarriers (Table 8). Encapsulation efficiency was relatively high with ZLF followed by
ZLG, ZPL, ZWP, ZC nanoparticles and ZPEG micelles (Table 8). The properties of the
shell polymer and the kinetics of nanoparticle formation can influence the encapsulation
efficiency of nanoparticles (Joye, Davidov-Pardo, and McClements 2015). On the other
hand, similar loading efficiency with all the six formulations indicate that the loading
efficiency is mainly influenced by the affinity of NR with hydrophobic zein core.
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Table 8: Characteristics of NR loaded nanocarriers.
Zeta

NR Encapsulation

potential (mV)

Efficiency (%)

Formulation

Size (d.nm)

PDI

ZC nanoparticles

118.6 ±6.3

0.180 ±0.05

-36.3 ±4.5

71.6 ±9

ZLF nanoparticles

175.2 ±6.8

0.251 ±0.02

28.6 ± 3.12

82.5 ±7

ZPEG micelle

102.3 ±8.2

0.233 ±0.014

-1.63 ±4.3

56.1 ±4

ZLG nanoparticles

222.7±14.0

0.09±0.019

-35.5±1.83

78.51±3.68

ZWP nanoparticles

248.9±0.14

0.29±0.01

-29.7±1.55

74.68±1.04

ZPL nanoparticles

291.86±2.89

0.34±0.065

-49.68±3.13

76.3±3.4

PDI: Polydispersity Index; NR: Nile Red; ZC: Zein-β-casein nanoparticles; ZLF: ZeinLactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-β-Lactoglobulin
nanoparticles; ZWP: Zein-whey protein isolate nanoparticles; ZPL: Zein-Pluronic-Lecithin
nanoparticles; Each value represents mean±SD (n= three different batches). Data for ZC,
ZLF, and ZPEG is reproduced from our earlier study (Alqahtani et al. 2017) and included
here for comparison.
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The spherical morphology and the core-shell structure of the nanocarriers was
confirmed from the TEM images (Fig. 15). The formation of core-shell architecture was
further confirmed by the zeta potential values (Table 8). The negative zeta potential of ZC,
ZLG, ZWP, and ZPL nanoparticles is attributed to β-casein, β-lactoglobulin, whey protein
isolate, and lecithin respectively, while lactoferrin imparted a positive charge to the ZLF
nanoparticles. The ZPEG micelles had a very weak negative charge and was close to zero.
ZPEG micelles was characterized by MALDI-TOF analysis to determine the degree of
PEGylation. The PEG is covalently conjugated to zein. MALDI-TOF analysis (Fig. 16)
indicated that one PEG molecule covalently conjugated with zein where PEG provides a
steric barrier against particle aggregation.
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Figure 15: TEM images of blank nanocarriers. ZC: Zein-β-casein nanoparticles; ZLF:
As can be seen from the TEM images, the nanocarriers were spherical with a
Zein-Lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-βLactoglobulin nanoparticles; ZWP: Zein-whey protein isolate nanoparticles; ZPL: ZeinPluronic-Lecithin nanoparticles; Representative images are presented here. TEM images
for ZC and ZLF nanoparticles are reproduced from our earlier study (Alqahtani et al.
2017) and is included here for comparison. Scale bar for ZC, ZLF is 100 nm, for ZPEG,
ZLG, ZWP scale bar is 200 nm and for ZPL scale bar showing 500 nm.
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Figure 16: MALDI-TOF analysis of free zein and ZPEG.
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The nanocarriers were found to be stable at different pH encountered in the
gastrointestinal tract and there was no significant particle aggregation (Table 9, 10 11, 12,
13, and 14). Casein (pI= 4.6) is positively charged at acidic pH in the stomach and is
negatively charged in the alkaline pH of the intestine (Tavares et al. 2014). Earlier studies
have used sodium casein to stabilize zein nanoparticles, but significant aggregation was
observed at pH close to the isoelectric point of casein (pH 3-5) (Joye, Davidov-Pardo, and
McClements 2015; Patel, Bouwens, and Velikov 2010). Sodium casein contains a mixture
of caseins (α, β and κ caseins) with different physicochemical characteristics (Cross et al.
2005). The caseins differ in the number of hydrophilic and hydrophobic domains which in
turn influences the interaction with zein (Cross et al. 2005). Patel et al. formed zein-sodium
casein nanoparticles through electrostatic interaction between the zein and sodium casein
by controlling the pH of the solution (Patel, Bouwens, and Velikov 2010). Unlike sodium
casein, β-casein used in the present study stabilized the zein nanoparticles mainly through
hydrophobic interactions.
Lactoferrin (pI=8.7) is positively charged throughout the entire pH range of the
gastrointestinal tract (Tavares et al. 2014). Zein, which is negatively charged at pH 7.4
(pI=6.8), is stabilized through electrostatic interaction with the positively charged
lactoferrin (Podaralla and Perumal 2012). However, there was a slight increase in the
particle size of ZC and ZLF nanoparticles closer to the isoelectric pH of casein and
lactoferrin respectively, as a result of a reduction in the electrostatic charge on the
nanocarriers (Table 9 and 10).
ZLG and ZWP nanoparticles has negative surface charge and the electrostatic
repulsive force can prevent particle aggregation (Xiong 1992; Zhang and Zhong 2009).
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ZLG and ZWP nanoparticles nanoparticles were found to be stable with respect to size,
PDI and zeta potential when exposed to a wide range of pH (2-9) (Table 11 and Table
12). β-Lactoglobulin is the major protein in whey protein isolate, and its isoelectric point
is 5.3. (Aich, Batabyal, and Joardar 2015) Below the isoelectric point (pH 2.0) the surface
zeta potential of both of ZLG and ZWP nanoparticles shifted towards positive zeta potential
with less impact on particle size (Table 11 and Table 12). At lower pH (pH <4), the
proteins used in our study are expected to be positively charged. This can lead to
electrostatic repulsion resulting in desorption of the shell protein and particle aggregation.
The fact that the nanocarriers did not aggregate signify that hydrophobic interactions and
steric repulsion play a major role in preventing particle aggregation (Tokle, Mao, and
McClements 2013).
In case of ZPL nanoparticles, the particle size, PDI and zeta potential did not change
at different pH (Table 13). The isoelectric point of lecithin is 4 and the presence of pluronic
may reduce the influence of pH on size and surface charge of nanoparticles by providing a
steric barrier (Chain and Kemp 1934).
In case of ZPEG micelles, the particle size remains unchanged, except at pH 2,
where the particle size increased (Table 14). Zein is known to undergo structural changes
in acidic pH to form aggregates (Cabra et al. 2006). However, the zeta potential of ZPEG
micelles did not change much with an increase in pH and stayed close to zero (Table 14).
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Table 9. Influence of pH on particle size and PDI of zein-casein (ZC) nanoparticles.
pH

Particle size (nm)

PDI

2

146.7 ±12.27

0.110 ±0.008

3

156.1 ±18.32

0.184 ±0.125

4

179.9 ±11.23

0.128 ±0.058

5
138.6 ±9.23
0.113 ±0.014
6
135.8 ±8.91
0.095 ±0.014
7
130.6 ±11.10
0.097 ±0.009
8
132.7 ±11.31
0.093 ±0.011
9
130.4 ±13.82
0.103 ±0.016
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced
from our earlier study (Alqahtani et al. 2017) and is included here for comparison.

Table 10. Influence of pH on particle size and PDI of zein-lactoferrin (ZLF)
nanoparticles.
pH
Particle size (nm)
PDI
2
157.21 ±12.24
0.194 ±0.012
3
179.55 ±7.93
0.189 ±0.035
4
165.32 ±9.43
0.188 ±0.018
5
181.63 ±8.71
0.167 ±0.018
6
165.91 ±5.65
0.188 ±0.005
7
175.21 ±6.8
0.251 ±0.02
8
201.35 ±19.11
0.247 ±0.021
9
202.15 ±17.29
0.289 ±0.013
PDI: Polydispersity Index Each value represents mean±SD (n= 3). This data is reproduced
from our earlier study (Alqahtani et al. 2017) and is included here for comparison.
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Table 11. Influence of pH on particle size and PDI of zein-β-lactoglobulin (ZLG)
nanoparticles.
Particle Size
pH
PDI
Zeta Potential (mV)
(d.nm)
2
248.43±3.36
0.18±0.01
-25.7±1.47
3
248.66±2.80
0.12±0.03
-38.1±1.91
4
263.42±3.94
0.189±0.02
-40.7±1.25
5
268.17±8.78
0.20±0.025
-40.13±1.06
6
251.7±9.79
0.13±0.05
-40.73±1.45
7
242.5±5.28
0.064±0.04
-36.9±1.65
8
251.63±6.08
0.12±0.02
-37.4±0.95
9
270.1±17.74
0.26±0.02
-34.93±2.03
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).

Table 12. Influence of pH on the mean particle size and PDI of zein-whey protein isolate
(ZWP) nanoparticles.
Particle Size
pH
PDI
Zeta Potential (mV)
(d.nm)
2
219.33±2.11
0.10±0.05
-27.43±1.79
3
234.9±4.51
0.19±0.02
-36.53±1.95
4
239.63±4.95
0.19±0.05
-35.5±1.56
5
236.93±4.13
0.16±0.02
-36.9±1.44
6
235.03±4.38
0.17±0.01
-36.16±1.66
7
235.2±3.56
0.10±0.03
-33.8±3.17
8
244.01±4.16
0.20±0.01
-34.7±1.3
9
271.76±27.73
0.27±0.08
-32.43±2.87
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).
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Table 13. Influence of pH on mean particle size and PDI of zein-pluronic-lecithin (ZPL)
nanoparticles.
pH
Particle size (nm)
PDI
Zeta potential (mV)
-49.68±3.13
2
291.86±2.89
0.34±0.06
-45.05±1.25
3
286.12±3.43
0.20±0.07
-50.58±3.24
4
292.12±5.15
0.3±0.026
299.05±9.07
0.2±0.01
-52.34±1.26
5
-42.89±5.32
6
291.71±5.04
0.20±0.04
296.61±10.23
0.25±0.02
-48.87±3.56
7
-46.57±6.89
8
299.66±3.87
0.26±0.03
287.75±3.90
0.25±0.01
-53.66±4.98
9
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).

Table 14. Influence of pH on the mean particle size and PDI of PEGylated zein (ZPEG)
micelles.
pH
Particle size (nm)
PDI
2
161.76±6.98
0.25±0.012
3
86.12±3.43
0.23±0.073
4
92.12±9.15
0.25±0.026
99.05±7.87
0.23±0.015
5
6
91.71±8.14
0.23±0.043
96.61±13.23
0.23±0.024
7
8
99.66±3.87
0.21±0.031
87.75±5.76
0.24±0.011
9
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).
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Nanocarriers were also stable at different ionic strength (Table 15, 16, 17, 18, 19,
and 20). There was no significant change in the particle size of ZC and ZLF nanoparticles
when exposed to ionic strength (10-200 mM), typically encountered in the gastrointestinal
tract. However, the magnitude of the zeta potential decreased with increase in ionic strength
for ZC and ZLF nanoparticles can be attributed to the electrostatic screening effect from
the adsorption of counterions (sodium or chloride ions) around the charged nanoparticles
(Table 15 and 16) (Tokle, Mao, and McClements 2013).
ZLG and ZWP nanoparticles have negative surface charge and which prevented
aggregation by electro repulsion. ZLG and ZWP nanoparticles were found to be stable at
different ionic strength (10-500 mM). There was a change in surface charge with the
increase in ionic strength (Table 17 and 18). The magnitude of change of zeta potential
was higher for ZLG nanoparticles (-32.06 mV to -5.8 mV) compared to ZWP nanoparticles
(-30.55 mV to -15.2 mV). This variation may arise from the presence of other proteins in
whey protein isolate. A higher change in surface charge with higher ionic strength may be
attributed to the adsorption of counterions on the nanoparticles (Tokle, Mao, and
McClements 2013). Similar to the impact of pH, particle size and surface charge of ZPL
nanoparticles remained unchanged at different ionic strength of the dispersing medium
(Table 19).
For ZPEG micelles, the particle size was relatively small at higher ionic strength
(≥100 mM) (Table 20). Given that PEG-zein micelles has a weak charge, the adsorption
of ions at higher ionic strength provided a charge barrier to prevent aggregation. However,
no specific trend was observed in the zeta potential of ZPEG micelles with change in the
ionic strength.
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Table 15. Influence of ionic strength on particle characteristics of zein-casein (ZC)
nanoparticles.
Ionic strength
Particle size (nm)
PDI
Zeta potential (mV)
(mM)
0
118.6 ± 6.3
0.18 ± 0.05
-36.3 ± 4.5
10
131.7 ±13.29
0.085 ±0.025
-35.25 ±2.495
20
134.2 ±12.02
0.115 ±0.015
-30.8 ±3.414
50
128.9 ±13.15
0.105 ±0.016
-22.15 ±3.909
100
130.7 ±14.35
0.106 ±0.018
-20.05 ±2.281
150
128.8 ±12.73
0.108 ±0.021
-17.6 ±1.849
200
133.4 ±12.15
0.092 ±0.018
-14.15 ±2.201
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced
from our earlier study (Alqahtani et al. 2017) and is included here for comparison.
Table 16. Influence of ionic strength on particle characteristics of zein-lactoferrin (ZLF)
nanoparticles.
Ionic strength (mM)

Particle size
PDI
Zeta potential (mV)
(nm)
0
175.2 ±6.8
0.251 ±0.02
28.6 ± 3.12
10
187.95 ±24.4
0.188 ±0.018
32.21 ±2.838
20
174.35 ±27.08
0.197 ±016
26.85 ±4.849
50
183.9 ±29.6
0.184 ±045
20.32 ±3.788
100
175.35 ±24.11
0.187 ±0.021
14.85 ±2.758
150
169.25 ±14.21
0.183 ±0.017
9.55 ±3.869
200
175.1 ±32.9
0.191 ±0.030
6.19 ±2.687
PDI: Polydispersity Index; Each value represents mean±SD (n= 3). This data is reproduced
from our earlier study (Alqahtani et al. 2017) and is included here for comparison.
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Table 17. Influence of ionic strength on particle characteristics of zein-β-lactoglobulin
(ZLG) nanoparticles.
Ionic Strength (mM)
Particle Size
PDI
Zeta Potential
(d.nm)
(mV)
10
256.7±7.85
0.07±0.03
-32.06±4.81
20
260.26±7.23
0.14±0.005
-19.9±0.65
50
257.66±3.84
0.12±0.02
-17.06±0.37
100
270.56±2.11
0.15±0.02
-14.8±0.85
250
249.43±2.65
0.09±0.07
-11.93±1.30
500
258.43±2.63
0.16±0.04
-5.8±2.98
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).

Table 18. Influence of ionic strength on particle characteristics of zein-whey protein isolate
(ZWP) nanoparticles.
Ionic Strength (mM)
Particle Size
PDI
Zeta Potential
(d.nm)
(mV)
10
280.9±3.93
0.23±0.047
-30.55±3.04
20
264.63±2.3
0.15±0.057
-28.2±1.55
50
260.1±6.18
0.19±0.078
-18.45±1.76
100
253.66±6.68
0.08±0.039
-17.35±0.91
250
257.1±3.11
0.17±0.036
-12.15±0.77
500
267.7±4.10
0.11±0.066
-15.2±2.82
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).
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Table 19. Influence of ionic strength on mean particle size and PDI of zein-pluroniclecithin (ZPL) nanoparticles.
Ionic strength (mM)

Particle size
PDI
(nm)
0
289.81±2.12
0.31±0.06
10
280.02±5.65
0.25±0.17
20
288.12±6.54
0.3±0.06
50
290.5±8.70
0.3±0.01
100
292.70±6.14
0.30±0.05
150
300.61±8.93
0.26±0.01
200
296.06±5.80
0.27±0.02
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).

Zeta potential
(mV)
-58.60±3.02
-55.01±3.65
-55.12±2.35
-50.02±5.45
-45.09±1.32
-45.80±2.50
-56.51±6.50

Table 20. Influence of ionic strength on particle characteristics of PEGylated zein (ZPEG)
micelles.
Ionic strength (mM)

Particle size
PDI
Zeta potential
(nm)
(mV)
0
102.3 ±8.2
0.233 ±0.014
-1.63 ±4.3
10
125.16±29.17
0.26±0.053
-4.21±1.67
20
130.34±30.55
0.29±0.050
-0.85±0.37
50
131.33±24.30
0.25±0.024
-2.30±2.33
100
91.30±2.54
0.26±0.012
-1.26±0.233
150
92.86±9.56
0.25±0.042
-1.07±1.43
200
91.10±6.36
0.25±0.039
-0.96±0.83
PDI: Polydispersity Index; Each value represents mean±SD (n= 3).

The enzymatic stability of the core-shell nanocarriers was tested in SGF and SIF in
presence of pepsin and pancreatin respectively. In general, all the six formulations were
enzymatically more stable in SGF compared to SIF (Fig. 17 and 18). SDS-PAGE analysis
indicating that nanocarriers are relatively stable in SGF in presence of pepsin (Fig. 17)
while slow degradation was observed in SIF in presence of pancreatin (except ZPEG) (Fig.
18).
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This is in agreement with the reported enzymatic stability of the proteins used in
our study (Hurtado-Lopez and Murdan 2006; Luo, Pan, and Zhong 2015; Lonnerdal, Jiang,
and Du 2011). SDS-PAGE analysis indicating that nanocarriers are relatively stable in SGF
in presence of pepsin (Fig. 17) while slow degradation observed in SIF in presence of
pancreatin (Fig. 18).

Figure 17: Enzymatic Stability of nanocarriers in Simulated Gastric Fluid (SGF) with
pepsin after incubation for different time points and analyzed by SDS-PAGE. ZC and
ZLF data is reproduced from our earlier study (Alqahtani et al. 2017) and included for
comparison.
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Figure 18: Enzymatic Stability of nanocarriers in Simulated Intestinal Fluid (SIF) with
pancreatin after incubation for different time points and analyzed by SDS-PAGE. ZC and
ZLF data is reproduced from our earlier study (Alqahtani et al. 2017) and included here for
comparison.
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2.4.2. In vitro release of NR from core-shell nanocarriers
The in-vitro release of NR from the nanocarriers was tested in simulated gastric
fluid (SGF) and simulated intestinal fluid (SIF). As can be seen from Fig. 19, the NR
release was sustained from all the six nanocarriers, but the release kinetics was strongly
influenced by the shell composition. PEG, which is the most hydrophilic polymer among
the six formulations showed faster release (Fig. 19) and significantly higher burst release
(20% within the first few hours). ZPL nanoparticles showed the slowest release of NR in
both SGF and SIF. The release was relatively high in SIF compared to SGF for ZC
nanoparticles, while the release was high in SGF for ZLF, ZPEG and ZLG formulations
(Fig. 19). The low solubility of casein in acidic pH resulted in slow release in SGF
compared to the release in SIF. Unlike ZLG, ZWP nanoparticles released less NR in SGF
than in SIF.
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Figure 19: Cumulative percent of NR release from different nanocarriers in presence of
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). ZC: Zein-β-casein, ZLF:
Zein-lactoferrin, ZPEG: PEGylated zein, ZLG: Zein-β-lactoglobulin, ZWP: Zein-whey
protein isolate. Each value represents mean±SD (n=3). Data for ZC, ZLF and ZPEG is
reproduced from our earlier study (Alqahtani et al. 2017) and included for comparison.
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To understand the release kinetics and to guide future formulation optimization, the
data was fitted to different release kinetic models. The release of NR from the nanocarriers
followed mixed order kinetics that was a combination of diffusion and erosion (Table 21).
The release of the entrapped hydrophobic compounds from the zein matrix has been
reported to occur through the diffusion-degradation mediated process (Liu et al. 2010;
Parris, Cooke, and Hicks 2005). During the early phases, the drug release occurs mainly
by diffusion through the protein matrix, while in the later phases; release is mediated by
both diffusions of the entrapped molecule and enzymatic degradation of the protein itself
(Parris, Cooke, and Hicks 2005). The release kinetics was influenced by the shell
composition including the molecular weight, enzymatic stability, and hydrophobicity of
the polymer. The initial release is controlled by the polymer swelling and diffusion through
the swollen matrix, while erosion of the polymer controls the release at later time points
(Hu et al. 2012). The release of NR from ZC nanoparticles showed a good fit to the Peppas
model, indicating initial zero-order kinetics (by diffusion) followed by first-order kinetics
(polymer erosion by hydrolytic and enzymatic degradation) in both SGF and SIF (Table
21). ZLF nanoparticles showed a biphasic release with an initial burst release (~10%) from
the NR trapped in the shell, followed by sustained drug release at later time points (Table
21). In case of ZPEG micelles, the release followed first-order kinetics (Table 21) by
hydrolytic and enzymatic degradation of zein. The release of NR from ZLG, ZWP and ZPL
nanoparticles showed mixed order kinetics. However, ZLG, ZWP and ZPL nanoparticles
showed a better fit to Peppas model indicating that NR release was diffusion controlled at
the early phases followed by polymer erosion at later time points. The mixed order kinetics
observed in this study agrees with reported studies for zein particulate systems in the
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literature (Hu et al. 2012; Mehta, Kaur, and Verma 2011). The release did not directly
correlate with the enzymatic stability of the core-shell matrix in SGF and SIF (Fig. 17 and
18) This is because other factors (pH, ionic strength, etc.) may influence the release of NR
from nanoparticles.
The chemical properties of both the core and the shell dictate the extent of water
diffusion and polymer erosion. For casein, which is relatively more hydrophobic of the
among the milk protein-based shell composition, in the early stage of drug release the
diffusion of water through the nanoparticle matrix appears to be the rate-limiting step,
while for PEG-zein micelles, the polymer erosion appears to influence the release. On the
other hand, ZLF nanoparticles appeared to show varying extent of diffusion-erosion to
sustain the release of NR. For ZLG and ZWP nanocarriers, the relatively higher enzymatic
stability causes slower surface erosion and controlled the release of encapsulated NR. In
ZPL nanocarriers, the hydrophobic lecithin has a role in controlling the release of NR in
SGF and SIF. In addition to polymer characteristics, the relative binding affinity of the
encapsulant and the encapsulation/loading efficiency also can influence the release.
Overall, results from this study demonstrate that the shell matrix has a strong influence on
the drug release kinetics from the core-shell zein nanocarriers.
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Table 21: Summary of nonlinear fit of NR release kinetics using different models.
Formulation
(Medium)

R2

Peppas
Hixson-Crowell
Zero Order
First Order
Higuchi
𝑛
C=C0-K0t
F=100*(1-exp(-k*t)) F = k ∗ sqrt(t)
𝐹 = 𝐾∗𝑡
𝐹 = 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3)
ZC (SGF)
0.9758
0.8992
0.9233
0.8780
0.7007
ZC (SIF)
0.9903
0.9902
0.9884
0.9903
0.8929
ZLF (SGF)
0.9573
0.5202
0.7661
0.5976
0.9114
ZLF (SIF)
0.9682
-0.4053
0.6926
-0.3524
0.6320
ZPEG (SGF)
0.8146
0.4173
0.4368
0.9718
0.4450
ZPEG (SIF)
0.8940
0.7376
0.6169
0.9501
0.7049
ZLG (SGF)
0.9906
0.9838
0.9923
0.9771
0.8252
ZLG (SIF)
0.9986
0.9238
0.9604
0.9212
0.6669
ZWP (SGF)
0.9845
0.7870
0.9095
0.8157
0.9845
ZWP (SIF)
0.9728
0.9729
0.9717
0.9655
0.8435
ZPL (SGF)
0.976
0.972
0.970
0.974
0.852
ZPL (SIF)
0.980
0.980
0.984
0.980
0.800
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF:
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model.

100

2.4.3. In vitro transepithelial transport and cell uptake of nanocarriers
Caco-2 cells, a well-established model for oral drug transport was used to study the
influence of shell composition on the in-vitro transepithelial transport and cell uptake of
nanocarriers. The permeability of NR loaded nanoparticles was determined using polarized
Caco-2 monolayers, and the formation of a polarized monolayer was confirmed from
TEER measurements (>400 ohms/cm2). There was a time-dependent increase in the apical
to basolateral transport of NR loaded nanoparticles (Fig. 20). ZPL nanoparticles showed
the highest permeability, while ZC nanoparticles showed the lowest permeability among
the six formulations. ZWP showed faster cell uptake than other nanocarriers. (Fig. 20) In
general, the apparent permeability (Papp) increased over time for all the six nanocarriers.
All the six nanocarriers increased the permeability of NR, and there was no detectable
permeation of free NR under the experimental conditions. Apparent permeability of
nanocarriers

was

in

the

following

decreasing

ranks

order:

ZPL>ZLG>ZPEG>ZWP≥ZLF>ZC (Fig 20). The nanocarriers did not affect the cell
viability of Caco-2 cells (data not shown).
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Figure 20: Transepithelial permeability of NR loaded nanocarriers across Caco-2 cell
monolayers. Apparent Permeability coefficient (Papp) from apical to basolateral chamber
(A→B) was determined at different time points. Each value represents mean±SD (n=4),
*P<0.05 compared to free NR permeability. ZC, ZLF and ZPEG data is reproduced
from our earlier study (Alqahtani et al. 2017) and included for comparison.
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To confirm the transcellular uptake of the nanoparticles, the cell uptake studies
were conducted using sub-confluent culture of Caco-2 cells. As shown in Figure 21, there
was a time-dependent increase in the uptake of NR loaded nanoparticles. Unlike the
transepithelial transport studies shown in Figure 21, ZWP nanoparticles showed the
highest cell uptake, while ZC nanoparticles showed the lowest cell uptake among the six
formulations (Fig. 21). This is contrary to the Papp values which may be attributed by the
presence of minor proteins in whey protein isolate. For example, the presence of positively
charged lactoferrin in whey protein isolate may favor the interaction with negatively charge
cell membrane. In addition, lactoferrin receptor may also be involved in higher cell uptake.
minor proteins in whey protein isolate may synergistically work with lactoglobulin for
enhancing cell uptake, while delayed exocytosis due to minor proteins may explain the
lower permeability in first two hours (Fig. 25). Further studies are required to understand
the differences in cell uptake between the nanocarriers.
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Figure 21. Flow cytometry analysis of time dependent cell uptake of free NR or NR
loaded nanocarriers in Caco-2 cells. Each value represents mean±SD (n=3), *P<0.05.
ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG
micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey protein nanoparticles;
ZPL, Zein-pluronic-lecithin nanoparticles. NR, ZC, ZLF and ZPEG data is from our
earlier study (Alqahtani et al. 2017) and included for comparison.
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There was less than 10% release of NR from the nanocarriers under the
experimental conditions (data not shown here), signifying that most of the cell uptake is
attributed to the encapsulated NR. The cell uptake decreased by 50% when the temperature
was reduced to 4oC indicating that nanocarriers were taken up by energy-dependent process
(Fig. 22).

Figure 22: Cell uptake of NR loaded nanocarriers at 4°C and 37°C after incubation for
2 hours. Each value represents mean±SD (n=4). ZC and ZLF data is reproduced from
our earlier study (Alqahtani et al. 2017) and included for comparison.
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To determine the mechanism of cell uptake, different endocytosis inhibitors were
used. When phenyl arsine oxide (PAO) was used as an inhibitor for clathrin-dependent
endocytosis, the cell uptake of ZLF, ZPEG, ZLG, ZWP, and ZPL nanocarriers decreased
by 50%, 36%, 39%, 52% and 65% respectively (Fig 23). On the other hand, there was only
a slight decrease in the uptake of ZC nanoparticles. In presence of filipin, an inhibitor for
lipid raft-mediated endocytosis, there was minimal decrease in the cell uptake of ZC, ZLF
and ZPEG nanocarriers (12-25%), while cell uptake of ZLG, ZWP and ZPL nanocarriers
significantly decreased (45-55%). Cytochalasin-D, an inhibitor for macropinocytosis,
reduced the uptake of ZPEG, ZC, ZLG, ZWP and ZPL nanocarriers by 64%, 42%, 43%,
32% and 31% respectively, while the uptake of ZLF nanoparticles was reduced by 20%
(Fig 23).
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Figure 23: Mechanism of in vitro cell uptake of NR loaded nanocarriers by Caco-2
cells. Cells were treated with different endocytosis inhibitors for 30 minutes followed
by cell uptake studies using different NR loaded nanocarriers. Each value represents
mean ± SD (n=4). ZC, ZLF and ZPEG data is reproduced from our earlier study
(Alqahtani et al. 2017) and included for comparison.

The fluorescence microscopy studies showed that the nanoparticles were taken up
by endocytosis, as evidenced from the punctuated fluorescence of NR loaded nanoparticles
(Fig. 24). Images from confocal microscopy showed that all nanocarriers enhanced cell
uptake compared to free NR control. The images are consistent with flow cytometry data
indicating that ZWP and ZLG nanocarriers showed higher cell uptake among the six
nanocarriers. ZC, ZLF, ZPEG and ZPL nanocarriers showed comparable cell uptake after
incubation for 30 minutes (Fig. 24).
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Figure 24. Confocal microscopy images of polarized Caco-2 cells showing the
internalization of Nile red (NR) loaded nanocarriers after 30 min incubation. Blue is
nucleus stained with DAPI, green is Alexa Fluor 488 labeled with Phalloidin for F-actin,
and red is NR loaded nanoparticles (magnification 60x). ZC, zein-casein nanoparticles;
ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin
nanoparticles; ZWP, zein-whey protein nanoparticles; ZPL, Zein-pluronic-lecithin
nanoparticles. Free NR, ZC, ZLF and ZPEG images are reproduced from our earlier
study (Alqahtani et al. 2017) and included for comparison.
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The cell uptake is strongly influenced by the particle size, surface charge and
surface hydrophobicity of the nanoparticles (Bannunah et al. 2014). Nanoparticles can be
taken up by non-specific and specific endocytosis pathways (Bannunah et al. 2014; He et
al. 2013). Lactoferrin receptor is expressed in the intestinal epithelial cells, and they are
mainly found in the clathrin vesicles (Jiang et al. 2011). The results from the competitive
uptake studies and endocytosis inhibitor studies suggest that ZLF nanoparticles are taken
up predominantly through lactoferrin receptor (Alqahtani et al. 2017). Nevertheless, the
ZLF nanoparticles can also be taken up by non-specific endocytosis pathways. The
positively charged ZLF nanoparticles can be taken up through adsorptive endocytosis by
binding to the negative charge glycocalyx in the cell membrane (Bannunah et al. 2014). In
contrast, the cell uptake of negatively charged ZC nanoparticles can be limited by the
charge repulsion from the cell membrane. Macropinocytosis is a nonspecific process for
the uptake of fluid and particles into the cells (He et al. 2013). The results from the
endocytosis inhibitor studies suggest that both ZC nanoparticles and ZPEG micelles are
predominantly taken up by macropinocytosis. Similarly, ZLG and ZWP nanoparticles are
also predominantly taken up by macropinocytosis pathway. Our results are in agreement
with the non-specific uptake of nanoparticles reported in the literature (Luo et al. 2013;
Song et al. 2013). The formulations used in the present study showed 3 to 8-fold higher
permeability compared to the permeability reported for zein-sodium casein nanoparticles
(Luo et al. 2013). The β-casein unlike the sodium casein does not cause charge-induced the
aggregation of zein particles, which may be attributed to the enhanced cell uptake of ZC
nanoparticles (Alqahtani et al. 2017).
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In case of beta-lactoglobulin, the amino acid sequence has similarity with lipocalin1 (Lcn-1), a ligand of lipocalin-interacting membrane receptor (LIMR) which is highly
expressed in intestine (Fluckinger et al. 2008; Sawyer and Kontopidis 2000; Kontopidis,
Holt, and Sawyer 2002). The presence of only beta-lactoglobulin on the surface of ZLG
nanoparticles may favor the uptake by its receptor, although this was not investigated in
this study. Unlike, ZLG, ZWP nanoparticles may be taken taken up by additional nonspecific endocytosis pathway, thus contributing to the higher uptake of ZWP nanoparticles
(Fig 22 and Fig.23). ZPL nanoparticles was found to be taken up by both clathrin and
caveolae-mediated endocytosis indicating that the shell components (pluronic and lecithin)
in ZPL favored the interaction with clathrin-coated pit as well as lipid-rafts (Gu et al. 2016;
Batzri and Korn 1975; Pagano, Huang, and Wey 1974). The difference in the transepithelial
transport of the nanoparticles is influenced by the kinetics of the different endocytosis
processes and the intracellular release of cargo from the nanocarriers.
The efflux proteins expressed in the intestinal epithelial cells can prevent uptake of
drug or nanocarriers. Previous results support our findings that PEG can inhibit P-gp
activity although the mechanism remains to be elucidated (Shen et al. 2008). Pluronic F127
was reported to inhibit P-gp (Wei et al. 2013) and used as positive control (Fig. 25).
However, in spite of having pluronic F127 in ZPL nanoparticles, the presence of lecithin
might be a contributing factor in the lower P-gp inhibitory activity of ZPL nanoparticles.
(Fig. 25). Further studies are required to clarify the mechanism. ZLG and ZWP
nanoparticles did not show P-gp inhibitory activity (Fig. 25). ZC and ZLF nanoparticles
showed small increase in calcein uptake with the increase in concentration of nanoparticles
used for the treatment of cells.
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Overall, the difference in the transepithelial transport of the nanoparticles is
influenced by the kinetics of the different endocytosis processes and the intracellular
release of cargo from the nanocarriers.
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Figure 25. P-gp inhibition activity of nanocarriers by calcein AM uptake assay. Each
value represents mean±SD (n=3). ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin
nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP,
zein-whey protein nanoparticles; ZPL, Zein-pluronic-lecithin nanoparticles. Pluronic
F127 used as positive control. Data for ZC, ZLF and ZPEG P-gp iniibition assay is
reproduced from our earlier study (Alqahtani et al. 2017) and included for comparison.
X-axis represents nanocarrier concentration, Y-axis represents fluorescence intensity
from calcein.
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2.4.4. Oral biodistribution of nanocarriers
The in-vivo oral biodistribution of core-shell nanoparticles was studied in rats using
Cy 5.5, a near-IR dye. The nanocarriers prolonged the retention of the Cy 5.5 dye up to 1224 hrs, while the free dye was cleared within 6 hrs. ZC, ZLG, ZWP and ZPL nanoparticles
were found to be retained in the gastrointestinal tract for 24 hours, while the other two
formulations (ZPEG and ZLF) were retained only up to 12 hours (Fig. 26 and 27). To
confirm these results, the animals were sacrificed at 6 and 24 hours after oral administration
to image the gastrointestinal tract. At 6 hours, all the six formulations were retained in the
small intestine, with ZC, ZLG and ZWP nanoparticles compared to the other three
formulations (Fig. 28). At 24 hours, there was still a strong signal from ZC, ZLG, ZWP
and ZPL nanoparticles in the caecum and colon, while there was only a faint signal from
the other two formulations (Fig 26). The tissue sections taken from the rat jejunum at 6
hours showed that the nanocarriers were taken up by the epithelial cells in the villi through
endocytosis, as evidenced from the punctuated fluorescence (Fig. 29). These results were
consistent with ex-vivo tissue uptake studies in pig jejunum (Fig. 30). Among the six
nanocarriers, ZPL and ZPEG nanocarriers showed higher uptake in intestinal epithelial
tissue (Fig. 30).
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Figure 26. Biodistribution of Cy 5.5 loaded nanocarriers after oral administration.
Whole body image of rats at different time points and rat gastrointestinal tract 24 h after
oral administration of nanocarriers. This is a representative image of four animals in
each treatment

group. ZC, zein-casein nanoparticles;

ZLF, zein-lactoferrin

nanoparticles; ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP,
zein-whey protein nanoparticles.
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Figure 27. Biodistribution of Cy 5.5 loaded nanoparticles after oral administration in rats.
Images shows the fluorescence in rat gastro-intestinal tract 24 hrs after oral administration
of nanoparticles. This is a representative image of four animals in each treatment group.
ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zein-PEG
micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey protein nanoparticles;
ZPL, Zein-pluronic-lecithin nanoparticles.
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ZC

ZLF

ZLG

ZWP

ZPEG

ZPL

Figure 28. Biodistribution of Cy 5.5 loaded nanoparticles after oral administration in
rats. Images shows the fluorescence in rat gastro-intestinal tract 6 hrs after oral
administration of nanoparticles. This is a representative image of four animals in each
treatment group. ZC, zein-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles;
ZPEG, zein-PEG micelles; ZLG, zein-lactoglobulin nanoparticles; ZWP, zein-whey
protein nanoparticles.
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Figure 29: In vivo distribution of Cy 5.5 loaded nanocarriers in rat jejunum. Rats were
sacrificed at 6 hours after oral delivery of nanocarriers. The jejunum was separated,
washed, fixed with 4% paraformaldehyde and sectioned for imaging by confocal
microscopy. Magnification is 20X.
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Figure 30: Ex vivo uptake of NR loaded nanocarriers in pig jejunum. Magnification is
20X.
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2.4.5. Ex vivo bioadhesion assay
Since the nanocarriers were retained for a prolonged period in the gastrointestinal
tract, the mucoadhesive properties were evaluated using everted pig jejunum and texture
analyzer. All the six formulations were found to be mucoadhesive (Fig. 31 and 32) and
were comparable to polystyrene nanoparticles, a known mucoadhesive polymer (Reineke,
Cho, Dingle, Cheifetz, et al. 2013). ZLG and ZWP nanoparticles showed significant
bioadhesive/mucoadhesive property among the six formulations (Fig. 31 and 32).
Bioadhesion can occur through intermolecular interaction such as electrostatic attraction,
hydrophobic interactions, hydrogen or disulfide bonding (Andrews, Laverty, and Jones
2009; Sosnik A. 2014). Increased interaction of cationic polymers such as chitosan,
lactoferrin and polylysine with anionic glycoproteins or glycolipids (abundant in small
intestinal membrane) resulted in enhanced mucoadhesion and cell uptake (Liu 2012;
Thongborisute and Takeuchi 2008; Bengoechea 2011; Tang et al. 2012). Cationization of
beta-lactoglobulin was also reported to enhance interaction with negatively charged mucus
(Teng et al. 2016; Teng et al. 2014; Teng et al. 2013). In addition, thermal denaturation of
whey protein has previously been reported to show increased interaction with mucin by
hydrogen and disulfide bonding (Hsein et al. 2015). ZLG and ZWP nanocarriers were
prepared by pre-heating β-LG and WP which results in unfolding the protein and exposure
of hydrophobic regions or thiol groups resulting in hydrophobic interaction with mucus
layer. Further, zein nanoparticles have been reported to show increased interaction with
mucus layer by hydrophobic interaction (González-Navarro 2017; Penalva et al. 2015).
Taken together, enhanced bioadhesive/mucoadhesive of ZLG and ZWP nanocarriers may
be attributed to prolonged in vivo retention after oral delivery in rats.
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Figure 31. Ex vivo mucoadhesion of Nile red (NR) loaded nanocarriers to pig jejunum
after 1 h treatment. Y-axis represents the percentage of nanocarriers bound to the
tissue. Each value represents mean ± SD of four independent experiments, *P<0.05
compared to PS nanoparticles. PS, polystyrene nanoparticles used as positive control;
ZC. zein-β-casein nanoparticles; ZLF, zein-lactoferrin nanoparticles; ZPEG, zeinPEG micelles; ZLG. Zein-β-lactoglobulin nanoparticles; ZWP. Zein-whey protein
nanoparticles; ZPL, Zein-pluronic-lecithin nanoparticles.
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Figure 32. Ex vivo mucoadhesion of Nile red (NR) loaded nanocarriers using Texture
Analyzer to determine fracture strength (mN) between Piglet jejunum and nanoparticle
coated probes. Each value represents mean ± SD of four independent experiments,
*P<0.05 compared to PS nanoparticles. PS, polystyrene nanoparticles used as positive
control; ZC. zein-β-casein nanoparticles; ZLF. zein-lactoferrin nanoparticles; ZPEG,
zein-PEG micelles; ZLG. Zein-β-lactoglobulin nanoparticles; ZWP. Zein-whey
protein nanoparticles; ZPL. Zein-pluronic-lecithin nanoparticles.
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2.4.6. Immunogenicity of core-shell nanocarriers
The nanocarriers were found to be non-immunogenic when orally administered to
mice. The nanoparticles were administered during the first week followed by a second dose
on the third week. There was no significant change in the serum IgG levels compared to
the saline-treated group (Fig. 33).

Figure 33: Oral immunogenicity of nanoparticles in mice. Serum IgG level determined
after oral delivery of blank nanoparticles to Balb/c mice at 0 and 3rd week. Serum IgG
was measured at 0, 3rd and 5 weeks. Each value represents mean±SD (n=4), *P<0.05.
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The nanoparticles can be taken up by multiple pathways from the GIT. The
intestinal epithelium consists of different cell types including enterocytes, mucin-secreting
goblet cells, and M-cells. (Pridgen, Alexis, and Farokhzad 2015) The M-cells are
associated with Peyer’s patches, which is part of the gut-associated lymphoid tissue
(GALT). The M-cells in the intestine can take up the nanoparticles based on their charge,
surface hydrophobicity and the presence of specific ligands (Beloqui, des Rieux, and Preat
2016). The protein biopolymers used in this study are GRAS food proteins that are used
for daily consumption. In general, there is oral immune tolerance to commonly used food
proteins (Pabst and Mowat 2012; Paula-Silva et al. 2015). Furthermore, the denaturation
of the protein during the preparation of the nanoparticles can also reduce the
allergenicity/immunogenicity of protein biopolymers (Livney 2010). Given that the Mcells make up only 5-10% of the epithelium, the enterocytes serve as the major absorptive
cell population in the intestine for endocytosis of nanoparticles (Pridgen, Alexis, and
Farokhzad 2015; Beloqui, des Rieux, and Preat 2016; Sass, Dreyer, and Seifert 1990).
However, the mucus covering the surface of the nanoparticles can limit drug absorption
through the enterocytes (Lai, Wang, and Hanes 2009; Ensign, Cone, and Hanes 2012). To
this end, the mucoadhesive polymers can interact with the intestinal mucus layer to increase
the retention and absorption of encapsulated drug at the site of absorption (Smart 2005).
As discussed in section 2.4.5., different shell structure can interact differently with the
mucus in GI tract. Although, zein protein has mucoadhesive property (Irache and
Gonzalez-Navarro 2017), the presence of LG and WP in the shell enhanced the
mucoadhesiveness. The differences in the mechanism of mucoadhesion of the core-shell
nanoparticles can be attributed to the observed differences in the in-vivo retention of
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nanoparticles. Further studies are required to understand the mechanism of mucoadhesion
of the core-shell nanoparticles in different regions of the GIT.
The shell composition can be varied to develop nanocarriers with specific
functional attributes. ZC nanoparticles in addition to provid a sustained drug release for
systemic drug absorption. The ZPEG micelles can be especially useful for improving the
oral bioavailability of drugs that are susceptible to P-gp efflux (Alqahtani et al. 2017). ZLF
nanoparticles can be used to increase the drug absorption through receptor-mediated
endocytosis. The ZLG and ZWPO nanocarriers can be a potential delivery vehicle for colon
diseases. Taken together, the findings from this study demonstrate that the functional
properties of the protein biopolymers can be used for rational development of core-shell
nanocarriers for various oral drug delivery applications.

2.5. Conclusions
The findings from this study demonstrate the influence of shell composition on the
physicochemical, biological, and functional characteristics of zein nanocarriers for oral
drug delivery applications. The shell composition influenced the drug release kinetics, cell
uptake, permeability, retention, and absorption through the oral route. ZC nanoparticles
showed the slowest release of NR, while ZWP nanoparticles showed the highest cell
uptake. Among six nanocarriers, ZPL nanoparticles showed the highest apparent
permeability across Caco-2 cell monolayer. ZPEG micelles inhibited P-gp efflux. ZLF
nanoparticles were taken up by lactoferrin receptors in the intestinal cells. All the six
formulations were mucoadhesive and increased the retention of the dye in the
gastrointestinal tract of rats. ZWP and ZPL nanocarriers showed the longest retention (>24
hours) in GI tract. Although, all six nanocarriers have higher bioadhesive/mucoadhesive
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property compared to polystyrene nanoparticles, ZLG and ZWP nanocarriers showed the
highest bioadhesive property. Overall, the results demonstrate the potential of using food
protein based core-shell nanocarriers to develop a safe and effective oral drug delivery
vehicle in general and pediatric formulations in particular.
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CHAPTER THREE
USE OF CORE-SHELL NANOCARRIERS FOR ORAL DELIVERY OF A
MODEL ANTIRETROVIRAL DRUG
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3.1. Introduction
Acquired immune deficiency syndrome (AIDS) is a disease of human immune
system caused by human immunodeficiency virus (HIV) (Tuset 1935). HIV infection
gradually reduce the effectiveness of human immune system leading the individuals
susceptible to opportunistic infections (Freed 2001). As per the latest estimates, about 36.7
million people are living with HIV infection including 1.8 million children (WHO 2016).
Despite significant progress in the diagnosis and treatment, the number of newly infected
people (especially children) remains unacceptably high. The rate of progression of the
disease is higher in infants than adults at the developmental stages of the immune system.
(Newell et al. 2004). Further, treatment of HIV infection in young patients hindered by the
delayed diagnosis, lack of a reliable marker to predict rapid disease progression, lack of
evidence-based treatment guidance, and more importantly lack of child friendly drug
formulations (Coovadia et al. 2010; Kuhn et al. 2012; Palumbo et al. 2010; Violari et al.
2008; Prendergast et al. 2012). The standard treatment for HIV infection consists of a
combination of at least three different class of anti-retroviral drugs known as highly active
anti-retroviral therapy (HART) (Althoff et al. 2012). These anti-retroviral drug classes
include protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase
inhibitors (NTRTIs), and integrase strand transfer inhibitors (INSTIs) (Viswanathan et al.
2015). A typical HAART combination includes two NRTIs and one PI, NNRTI, INSTI, or
NNRTI. HAART combination is effective in lowering viral load by interfering at the
different stages of viral life-cycle, and significantly improves patients’ quality of life
(Thompson et al. 2012; Gunthard et al. 2014; Piacenti 2006; Vadlapatla et al. 2014).
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Among the anti-retroviral drugs, majority of the regimen include PI as one of the main
class of drugs.
PIs suppress HIV protease enzymes, responsible for the progression and maturation
of viral gag and gag-pol polyproteins. (Vadlapatla et al. 2014) Inhibition of these protein
results in immature and non-infectious viral particles. First generation PIs include
saquinavir, ritonavir, nelfinavir, indinavir, and fosamprenavir, while the second-generation
PIs are lopinavir, darunavir, atazanavir, and tipranavir. All PIs administered suffer from
porr oral bioavailability with values ranging from 4% (saquinavir) to 70% (nelfinavir)
(Vadlapatla et al. 2014). The poor oral bioavailability of PIs attributed to the poor water
solubility, poor membrane permeability and first-pass metabolism in the intestine
(Williams and Sinko 1999). Ritonavir is a potent inhibitor for CYP3A4 and serve as
pharmacokinetic enhancer for other PIs. As a result, all PIs (except nelfinavir), is used in
combination with low dose ritonavir to improve the oral bioavailability of PIs. (Vadlapatla
et al. 2014)
Lopinavir (LPV) is a first-line PI used for the treatment of HIV infections,
especially in children. LPV is coformulated withritonavir (LPV/r). The current pediatric
oral liquid formulation contains LPV and ritonavir in a mixture of propylene glycol and
alcohol (42.4%, v/v). Both lopinavir and ritonavir are very bitter, which results in poor
patient compliance of this formulation (Pham et al. 2016). Further, high alcohol
concentration has the potential for toxicity in younger children (Marek and Kraft 2014).
Addition of ritonavir in the formulation causes the multiple drug interactions leading to
adverse effects (Pandie et al. 2016).
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Figure 34: Chemical structure of lopinavir Stoll et al. (2002).

To this end, the goal of this chapter is to use zein based nanocarriers for improving
the oral bioavailability of LPV and test the feasibility of developing a ritonavoir free LPV
pediatric formulation. The impact of shell composition on the functional properties of LPV
loaded nanocarriers was evaluated in vitro and in vivo.

The specific aims of the study are as follows:
i)

Preparation and characterization of LPV loaded nanocarriers.

ii)

Determination of in vitro release of LPV from the nanocarriers in simulated GI
fluids and food matrices (milk and applesauce).

iii)

Determination of in vitro enzymatic stability of LPV loaded nanoparticles.

iv)

Determination of apparent permeability (Papp) of LPV loaded nanocarriers in
Caco-2 cell monolayers.

v)

Determine the pharmacokinetics LPV loaded nanocarriers in rats.
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3.2. MATERIALS AND METHODS
3.2.1. MATERIALS
Lopinavir was purchased from AvaChem Scientific (San Antonio, TX, USA).
Ritonavir was obtained from Selleckchem (Houston, TX, USA). 2% milk and applesauce
were purchased from Hyvee Supermarket (Brookings, South Dakota, USA). Sterile saline
and heparin lock flush syringes, and 23G syringe with blunt needles were purchased from
SAI Technologies (Lake Villa, Illinois, USA). Acetonitrile and glacial acetic acid were
obtained from Fisher Scientific (Hampton, NH, USA). All other chemicals and reagents
were similar to the ones used in chapter two.

3.2.2. METHODS
3.2.2.1. Preparation of nanocarriers
Nanocarriers were prepared by phase separation method as described in the earlier
chapter (Section 2.2.2.). Briefly, 1 mg of LPV was dissolved in 1 mL of 90% ethanol and
mixed with 15 mL hydroalcoholic solution of zein. LPV containing zein solution was
added dropwise to the aqueous phase to form core-shell nanocarriers. LPV (1mg) loaded
ZPEG micelles was prepared using the method reported in the earlier chapter (section
2.2.2) All the other steps were similar to the ones mentioned in chapter two. Loading
efficiency of LPV further optimized based the ratio of drug to polymer, ratio of core to
shell and alcohol concentration. Drug to core polymer (zein) ratio was found to be an
important parameter for drug loading and therefore different drug/polymer ratio was varied
from 1 mg to 5 mg to achieve higher LPV loading.
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3.2.2.2. Characterization of LPV loaded nanocarriers
LPV loaded nanocarriers were characterized for particle size and zeta potential
using Malvern Zeta Sizer Nano ZS (Malvern Instrument Inc., Southborough, MA). The
morphology of LPV loaded nanocarriers was visualized by TEM as described in chapter
two (Section 2.2.3.).

3.2.2.3. Differential Scanning Calorimetry (DSC)
Thermal analysis of free LPV and LPV loaded nanocarriers was performed by
Differential Scanning Calorimetry (DSC Q200, TA Instruments Inc., USA). Three to five
mg of LPV loaded nanocarriers was placed in an aluminum pan in DSC (T zero Lid #
T100819), and the heat flow was maintained at 10°C/minutes from 25 to 300°C under
nitrogen gas ( 20 mL/minute). The Thermograms were processed using TA Universal
software (TA Instruments Inc., USA).

3.2.2.4. HPLC analysis of LPV
HPLC analysis of LPV was performed on a Waters system (Milford, MA)
equipped with an isocratic pump, a degasser, an autosampler and data processing software
(Breeze version 3.30 SPA). LPV was separated on a symmetry® C18 Column (Waters
Corporation, Milford, USA) (5 µm, 4.6 mm X 150 mm). The mobile phase was a mixture
of 10 mM ammonium acetate (pH 6.5) and acetonitrile (35:65 v/v).(Vats, Murthy, and Ravi
2011) The mobile phase was pumped at a flow-rate of 1.0 mL/min. LPV was monitored at
a wavelength of 210 nm. The calibration curve (peak area versus drug concentration) was
linear (R2=0.999) in the LPV concentration range of 0.39–2.5 μg/mL.
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3.2.2.5. Determination of encapsulation and loading efficiency of LPV
To determine the encapsulation/loading efficiency, around 2 mg LPV loaded
lyophilized nanocarriers was dispersed in 1 mL of water and centrifuged at 1000 rpm for
10 minutes. The supernatant was discarded, and the nanocarriers was dispersed in 1 mL of
90% ethanol to digest the nanocarrier. The LPV extracted from the nanocarrier was filtered
through 0.2 µm syringe filter, and 50 µL was injected into HPLC column. Encapsulation
efficiency (EE%) and loading efficiency (LE%) was calculated using the following
equations:
EE% =
LE% =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐿𝑃𝑉 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠

x 100
x 100

3.2.2.6. In vitro release of LPV from nanocarriers
The release of LPV from nanocarriers was performed using dialysis method in
simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) in the presence of pepsin
and pancreatin enzymes respectively (as described in section 2.2.5.). Briefly, 50 mg of LPV
loaded nanocarrier was dispersed in 5mL of SGF or SIF and placed inside the dialysis tube
(Snakeskin dialysis membrane, 10 kDa molecular weight cutoff). The dialysis sac was
placed in a beaker containing 25 mL SGF or SIF. 0.1% (w/v) Tween 80 mixed with release
medium to maintain sink condition. The beaker was placed in a temperature controlled
shaker at 37°C and agitated at 100 rpm. Around 400 µL of sample was withdrawn at
predetermined time points up to 24 hours, and an equal volume of pre-warmed SGF or SIF
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was replaced in the beaker. The sample was diluted with equal volume of ethanol and
analyzed by HPLC.
Sequential release of LPV was determined by incubating LPV loaded nanocarriers
in food matrices (2% milk or applesauce) and transferred to SGF followed by SIF. Briefly,
50 mg LPV nanocarriers was dispersed in 5 mL of 2% milk or 5 mL apple sauce (diluted
2 times using water) and transferred into a dialysis sac (10 kDa molecular weight cutoff).
Nanocarrier containing dialysis sac placed in a beaker containing 25 mL of 2% milk or
apple sauce and was incubated for 1 hour. After 1 hour, the dialysis sac was placed in equal
volume of SGF containing 0.32% pepsin and in a separate beaker containing 25 mL SGF
with 0.1% Tween 80 and 0.32% pepsin. At the end of 2 hours, in the dialysis sac was placed
in 10 mL SIF containing 1% pancreatin in a separate beaker containing 30 mL SIF with
0.1% Tween 80 and 1% pancreatin. About 400 µL of the sample was withdrawn at predetermined time points (1, 2, 4, 8, 12, and 24 h) and was mixed with equal volume of
ethanol followed by analysis in HPLC.

3.2.2.7. Solid state stability of free LPV and LPV in nanocarriers

The solid-state stability of free and encapsulated LPV in nanocarriers was evaluated
for three months according to the ICH guidelines. Briefly, 5 mg of LPV loaded nanocarriers
was placed in a constant climate chamber (Binder, Tuttlingen,

Germany) at

30°C±2°C/65% RH±5% RH for three months. At predetermined time points, particle size,
PDI and zeta potential of LPV nanocarriers were measured and the LPV content in the
nanocarriers was determined using HPLC.

133

3.2.2.8. Transepithelial permeability of LPV nanocarriers
The transepithelial permeability of 10 µg/mL free LPV, 10 µg/mL LPV with low
dose of ritonavir (2.5 mg/mL) and 10 µg/ml of LPV loaded nanocarriers was studied using
Caco-2 cell monolayer. Caco-2 cells (Passage number # 20-25) was maintained in Eagle’s
Minimum Essential Medium (EMEM from ATCC: American Type Cell Culture
Collection, Manassas, VA, USA) with 10% FBS, 1% streptomycin/penicillin antibiotic and
placed in incubator with 5% CO2. Briefly, 5x104 cells were seeded in collagen-coated 12well plate transwell inserts (3 µm pore size) with an area of 1.12 cm2 (Transwell®, Corning
Costar Corp. Cambridge, MA, USA). The growth medium was changed every two days
for 15 days. The integrity of the Caco-2 cell monolayers was determined by measuring the
transepithelial electrical resistance (TEER) using EVOM instrument (World Precision
Instrument, Sarasota, FL, USA). Cell monolayers with TEER value >400 Ω.cm2 was used
for the permeability study. Cell monolayers were incubated with 0.5 mL of Hank’s
Balanced Salt Solution (HBSS) in the apical chamber and 1 mL of HBSS in the basolateral
compartment for 30 minutes at 37°C. For permeability studies, the donor solution was
replaced with 500 μL of free LPV suspension (10 μg/mL) or equivalent LPV in LPV/r
combination (2.5 μg/mL ritonavir) or equivalent LPV loaded nanocarriers dispersed in
HBSS buffer. Around 100 μL of the sample was collected at each time point (0h, 1h, 2h
and four h) from the basolateral chamber. An equal volume of pre-warmed HBSS buffer
was added to the basolateral chamber to maintain the volume. The samples were mixed
with equal volume of ethanol for analysis by HPLC. The apparent permeability coefficient
(Papp) of free LPV, LPV/r, and LPV loaded nanocarriers across Caco-2 cell monolayers
was calculated using the following equation
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Papp (cm/s) =

[

(dQ/dt)

𝐴𝐶𝑜

] x 100

Where dQ/dt is the flux of LPV across Caco-2 monolayer, C0 is the initial concentration of
LPV in the apical chamber, and A is the surface area of the 12-well plate Transwell insert
(1.12 cm2).

3.2.2.9. Enzymatic metabolism studies
To determine the metabolic stability of LPV, human intestinal microsomes was
purchased from Sekisui Xenotech, LLC (Kansas City, KS, USA) and incubated with LPV
nanoformulations. The microsomal protein was diluted with rapid start solution (5mM
magnesium chloride, 5mM glucose-6-phosphate, 1mM b-NADPI, and 1U/mL glucose-6phosphate dehydrogenase) supplied by Sekisui Xenotech, LLC (Kansas City, KS, USA).
Briefly, 0.3 mg/mL of microsomal protein was incubated with 10 μg/mL of LPV, LPV/r,
and LPV loaded nanocarriers. The study was performed for 30 minutes at 37°C under 100
rpm. Around 50 μL of the reaction mixture was collected at 15 and 30 minutes followed
by mixing with equal volume of cold acetonitrile to stop the reaction. The LPV content
was determined by HPLC.

3.2.2.10. Pharmacokinetic studies in Rats
Based on the results from in vitro permeability study, LPV loaded ZPEG, ZLG and
ZWP nanocarriers were selected for pharmacokinetic studies in the rat. Free LPV and
marketed liquid LPV formulation (Kaletra®) were used as controls. All animal
experiments were carried out after approval from the IACUC at SDSU. Male Sprague
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Dawley rats (3–4 weeks of age) weighing 115-150g were used for the study. Rats with
surgically placed jugular vein catheter were purchased from Charles River (Wilmington,
MA) and acclimatized for one week. After fasting for 12 hours, free LPV or LPV/r in water
with 2% Tween 20, LPV loaded ZPEG and ZPL nanoparticles in water (LPV: 52 mg/kg
body weight) were administered by oral gavage to rats. Blood samples (200 µL) were
collected at 0, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 15 h, 18 h and 24 h in heparinized tubes.
After centrifugation (15 minutes, 4000 rpm), the plasma was collected and stored at -80 °C
until further analysis by HPLC. LPV concentration in the plasma samples was determined
by HPLC using a calibration plot prepared by spiking known amount of LPV in rat plasma.
The LPV was extracted from the plasma by liquid-liquid extraction method using a mixture
of ethyl acetate and n-hexane (50:50, v/v). An equal volume of the organic solvent mixture
was added to plasma and centrifuged to separate the organic LPV layer. The extraction was
repeated for three times to ensure complete LPV extraction from the plasma. The organic
solvent was evaporated under dry nitrogen atmosphere. The residue was reconstituted in
90% ethanol and used for HPLC analysis. The lower limit for the detection of LPV was
found to be 50 ng/mL, and the extraction efficiency was 90.96±4.36%. The
pharmacokinetic parameters such as peak concentration (Cmax), time to reach peak
concentration (Tmax), area under the plasma concentration-time (AUC), and half-life (t1/2)
were calculated by non-compartmental analysis using PK-solution software. Percent
relative bioavailability (Frel%) of LPV was calculated using the following formula,

Frel (%) =

𝐴𝑈𝐶 (𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠)
𝐴𝑈𝐶 (𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛)

𝑋100
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Based on the AUC values obtained after single dose PK study, the multiple dose
pharmacokinetics of ZPEG micelle was studied. In the multiple dose study, 52 mg/kg
(similar to the single dose study) LPV containing Kaletra® liquid formulation and ZPEG
micelle were orally administered twice a day for 2 days. Blood samples were collected
from the jugular vein catheter at 0, 0.5, 1, 3, and every 3 hours up to 48 hours. All the blood
samples were processed as described above and the plasma concentration of LPV was
determined by HPLC. Steady state PK parameters such as Css

max,

Css

min,

AUCss 0-t were

calculated using PK-solution software. Average steady state plasma concentration (Cavg ss)
was calculated using the following equation,
Cavg ss =

𝐴𝑈𝐶0−𝜏
𝜏

Where, τ is the dose interval (12 hours).

3.3. Statistical analysis
All the experiments were conducted in triplicate using three independent batches
of nanoparticles. The data is represented as a mean ± standard deviation. Student t-test and
analysis of variance (ANOVA) was performed to determine statistical significance at p <
0.05.
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3.4. Results
3.4.1. Development and characterization of LPV loaded nanocarriers
The particle size of the nanocarriers was in the range of 100 to 250 nm with a
uniform size distribution (PDI 0.1 to 0.36) (Table 22). ZPEG micelles showed the smallest
in size (97 nm), while ZLG nanoparticles was was relatively the largest nanoparticles (251
nm) among the six formulations. The zeta potential of the nanocarriers varied from 30 to 58 mV based on the shell composition. The LPV loaded nanocarriers had a spherical
morphology as was visualized by TEM (Fig. 35). The encapsulation efficiency of LPV was
above 65% for all nanocarriers and zein-pluronic-lecithin (ZPL) nanoparticles showed the
highest encapsulation efficiency (Table 22). The loading efficiency was optimized and
increasing drug to core polymer (zein) ratio was found to increase the loading efficiency.
The loading efficiency of LPV varied from 2.14% to 5.3% depending on the shell
composition (Table 22). ZPL and ZC nanocarriers showed the highest loading efficiency,
while ZLF nanoparticles showed the lowest loading efficiency. LPV was entrapped in the
nanocarriers and was confirmed by thermal analysis (DSC) (Fig. 36). DSC thermogram
showed the presence of melting peak for free LPV at around 100°C and absence of LPV
peak in LPV loaded nanocarriers confirmed the encapsulation of LPV in the nanocarriers
(Fig. 36).
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Table 22: Characteristics of LPV loaded nanocarriers.
Nanoparticle

Particle size

PDI

Zeta

(d.nm)

EE (%)

LE (%)

Potential
(mV)

ZC

130.25±0.070

0.18±0.06

-29.3±1.93

70.47±2.15

5.12±0.20

ZLF

185.12±4.32

0.27±0.25

30.24±4.58

64.86±1.84

2.14±0.19

ZPEG

97.56±7.26

0.15±0.012

-3.12±2.23

71.56±4.21

4.58±0.15

ZLG

251.36±3.52

0.093±0.07

-29.6±3.34

84.46±1.62

3.08±0.25

ZWP

215.03±10.94

0.24±0.06

-21.3±1.28

81.36±0.57

3.32±0.22

ZPL

247.5±1.13

0.36±0.02

-58.45±0.49

87.92±7.19

5.31±0.38

EE%: Encapsulation efficiency in percent; LE%: Loading efficiency in percent; ZC: Zeinβ-casein nanoparticles; ZLF: Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein
micelles;

ZLG:

Zein-β-lactoglobulin

nanoparticles;

ZWP:

Zein-whey

protein

nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value represents mean±SD
(n=3).
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Figure 35: TEM images of lopinavir loaded nanocarriers. ZC: Zein-β-casein
nanoparticles; ZLF: Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein micelles;
ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein nanoparticles; ZPL:
Zein-pluronic-lecithin nanoparticles.
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Figure 36: DSC thermograms of free lopinavir and lopinavir loaded nanocarriers. ZC.
Zein-β-casein nanoparticles, ZLF. Zein-lactoferrin nanoparticles, ZPEG. PEGylated zein
micelles,

ZLG.

Zein-β-lactoglobulin

nanoparticles,

ZWP.

Zein-whey

protein

nanoparticles, ZPL. Zein-pluronic-lecithin nanoparticles. X-axis shows the Temperature
(°C) and Y-axis shows the Heat Flow (W/g). Red line: Free LPV; blue line: LPV loaded
nanocarriers; black line: blank nanocarriers.
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3.4.2. In vitro release of LPV from nanocarriers
All six nanocarriers showed sustained release of LPV in simulated gastric fluid
(SGF) and simulated intestinal fluid (SIF) for 24 hours. ZPEG micelles showed the slowest
release (<30%), while relatively faster (~80%) release was seen with ZPL nanoparticles
(Fig. 37). ZC, ZLF, ZLG and ZWP nanocarriers released 40% to 65% of LPV in both SGF
and SIF within 24 hours. ZLG nanocarriers showed relatively faster release of LPV in SGF
than SIF, due to the higher solubility of β-lactoglobulin in acidic pH (Taulier and Chalikian
2001). There was no significant difference in LPV release between SGF and SIF for other
nanocarriers (Fig. 37).
To understand the mechanism of LPV release, the data was fitted to different
empirical release kinetic models (Table 23). The release of LPV from the nanocarriers
followed Peppas model in both SGF and SIF, except for ZLG nanocarriers. This is
indicative of polymer swelling and diffusion from polymer matrix followed by surface
erosion of polymer due to hydrolytic cleavage (Sivakumar and Rao 2003). In case of ZLG
nanocarriers, the release of LPV in SGF followed first-order kinetics which was consistent
with NR release shown in second chapter (Section 2.4.2.). LPV release from ZLG
nanocarriers in SIF followed Hixon-Crowell model indicating that the release is dissolution
limited. In case of ZWP and ZPL nanocarriers, LPV release in SGF followed Peppas
model, while in the presence of SIF followed mixed order kinetics (Table 24).
The nanocarriers was stable when incubated with food matrices (milk and
applesauce). In general, less than 40% of LPV was released within two hours when
incubated with food matrices and less than 80% of LPV was released from the nanocarriers
in 24 hours after transferring to SGF followed by SIF (Fig. 38). ZPEG micelles showed
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slowest release of LPV in both milk and applesauce, while ZLG and ZWP nanocarriers
released LPV faster in milk and applesauce. However, the release of LPV in SGF and SIF
(Fig. 37) did not change much after treating the nanoparticles with milk or applesauce,
which indicates that there was no influence of the presence of food matrices on the release
of LPV from the nanocarriers. This property concludes that nanocarriers have the potential
to use as food sprinkle.
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Figure 37: Cumulative percent of lopinavir released from different zein-based
nanocarriers in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF).
ZC: Zein-β-casein nanoparticles, ZLF: Zein-lactoferrin nanoparticles, ZPEG:
PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey
protein isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value
represents mean±SD (n=3).
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Table 23: Summary of nonlinear fit of LPV release kinetics using different models.
Formulation
(Medium)

R2

Peppas
Hixson-Crowell
Zero Order
First Order
Higuchi
C=C0-K0t
F=100*(1-exp(-k*t))
𝐹 = 𝐾 ∗ 𝑡 𝑛 𝐹 = 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3)
F = k ∗ sqrt(t)
ZC (SGF)
0.909
0.853
0.820
0.890
0.900
ZC (SIF)
0.957
0.907
0.904
0.932
0.939
ZLF (SGF)
0.983
0.790
0.859
0.839
0.982
ZLF (SIF)
0.994
0.920
0.945
0.941
0.976
ZPEG (SGF)
0.924
0.307
0.665
0.354
0.862
ZPEG (SIF)
0.994
0.896
0.946
0.910
0.975
ZLG (SGF)
0.891
0.906
0.853
0.919
0.860
ZLG (SIF)
-0.717
0.843
0.890
0.822
0.629
ZWP (SGF)
0.981
0.873
0.905
0.905
0.979
ZWP (SIF)
0.970
0.969
0.972
0.966
0.820
ZPL (SGF)
0.982
0.824
0.925
0.877
0.979
ZPL (SIF)
0.981
0.951
0.984
0.957
0.960
2
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles,
ZLF: Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zeinwhey protein isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. The highlighted value indicates the best fit model.
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Figure 38: Sequential release of LPV from different zein nanocarriers in food matrices
(milk or apple sauce) for 1 h followed by 1 h in SGF and up to 24 h in SIF. Zein-β-casein
nanoparticles, ZLF: Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles,
ZLG:

Zein-β-lactoglobulin

nanoparticles;

ZWP:

Zein-whey

protein

isolate

nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Each value represents
mean±SD (n=3).
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Table 24: Summary of non-linear fit of lopinavir sequential release kinetics using different models.
R2

Formulation (Medium)
Peppas
𝐹 = 𝐾 ∗ 𝑡𝑛

Hixson-Crowell
Zero
First Order
Higuchi
Order
F=
𝐹=
F = k ∗ sqrt(t)
100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3) C=C0-K0t 100*(1-exp(-k*t))
ZC (milk to SGF to SIF)
0.969
0.910
0.888
0.942
0.969
ZC (apple sauce to SGF to SIF)
0.981
0.915
0.933
0.943
0.980
ZLF (milk to SGF to SIF)
0.987
0.961
0.962
0.977
0.964
ZLF (applesauce to SGF to SIF)
0.977
0.931
0.937
0.949
0.975
ZPEG (milk to SGF to SIF)
0.995
0.989
0.977
0.992
0.949
ZPEG (applesauce to SGF to SIF)
0.989
0.826
0.913
0.856
0.989
ZLG (milk to SGF to SIF)
0.942
-6.67
0.500
0.130
0.643
ZLG (applesauce to SGF to SIF)
0.969
-0.230
0.571
-0.161
0.579
ZWP (milk to SGF to SIF)
0.941
0.0065
0.490
0.157
0.636
ZWP (applesauce to SGF to SIF)
0.973
-0.235
0.549
-0.136
0.547
ZPL (milk to SGF to SIF)
0.975
0.464
0.671
0.591
0.842
ZPL (applesauce to SGF to SIF)
0.958
0.138
0.688
0.201
0.746
2
SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF:
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model.
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3.4.3. Stability of LPV loaded nanocarriers
Solid state stability of LPV in ZC and ZLG nanoformulations was determined by
storing the formulation at 30°C±2°C/65% RH±5% RH for three months (according to ICH
guidelines) (ICH 2013). More than 90% of LPV remained at the end of 3 months and there
was no significant difference in the stability of free LPV and LPV loaded nanoformulations
(Fig. 39a). However, the particle size of ZLG nanoparticles increased after two months
indicating, aggregation of particles (Fig. 39b). On the other hand, the physicochemical
characteristics of ZC nanocarriers did not change over time (Fig. 39c and Fig. 39d).

Figure 39: Solid state stability of free LPV and LPV loaded ZC and ZLG nanoparticles.
Nanoparticles were kept in constant climate chamber for 3 months at 30°±2°C and
65±5% relative humidity. Each value represents mean±SD (n=3).
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3.4.4. Transepithelial permeability of LPV loaded nanocarriers across Caco-2 cell
monolayers
All the nanocarriers significantly enhanced apparent permeability (Papp) of
LPV across the Caco-2 cell monolayers (Fig. 40a). LPV loaded ZPEG micelles showed
the highest permeability of LPV (6-fold) compared to free LPV. The apparent permeability
of LPV loaded nanocarriers was found to be in the following decreasing rank order
ZPEG>ZC>ZLF>ZWP>ZLG>ZPL>LPV/r>LPV (Fig. 40a). Results from percent
permeability indicates that percent of LPV permeated after 1 to 2 hours was comparable
between free LPV and nanoformulations (Fig. 40b). However, after 4 hours the
nanocarriers showed significantly higher permeability than the free LPV (Fig 40b)
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Figure 40: Apparent permeability coefficient (Papp) (a) and percent of dose of LPV
3.4.5. Metabolic stability studies
permeated (b) across Caco-2 monolayer from LPV loaded nanocarriers. Each value
represents mean±SD (n=3), *P<0.05.
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3.4.5. Metabolic stability studies
To understand the metabolic stability of LPV in vitro, human intestinal microsomes
was used. Two different concentrations (10 and 20 μM) of free LPV, Kaletra®, and LPV
loaded nanocarriers were incubated with human microsomal enzymes for 15 and 30
minutes. After 15 minutes, 58% of LPV was metabolized when the initial LPV
concentration was 10 μM, while only 20% metabolized when 20 μM LPV was used,
indicating that higher concentration leads to saturation of CYP3A4 enzymes (Fig. 41a).
However, there was no statistically significant effect of incubation time on the metabolic
stability of LPV in the nanocarriers. More than 85% of LPV remained stable in nanocarriers
after 15 minute incubation and was comparable to Kaletra®. After 30 minute incubation,
around 30% LPV was metabolized in Kaletra® with 10 µM LPV, while there was no
change in LPV concentration with 20 µM (Fig. 41b).
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Figure 41: In vitro metabolic stability of LPV in presence of human intestinal
microsomes. Free LPV, Kaletra®, and LPV loaded nanocarriers were incubated for 15
minutes (a) and 30 minutes (b). Each value represents mean±SD (n=3), P<0.05.
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3.4.6. In vivo pharmacokinetics in rats
Based on the results from in vitro permeability study, ZLG, ZWP and ZPEG
nanocarriers were selected for in vivo pharmacokinetic studies in rats. A dose of 52 mg/kg
body weight of free LPV (1 mL water with 2% Tween 20), Kaletra®, ZLG, ZWP and
ZPEG nanocarriers (dispersed in water) was administered by oral gavage to rats. Kaletra®
increased the oral bioavailability of LPV by 3-fold compared to free LPV suspension. The
nanocarriers increased the oral bioavailability of LPV by 5- to 6.5-fold compared to free
LPV suspension. The highest oral bioavailability was obtained with LPV loaded ZPEG
micelles followed by ZWP and ZLG nanocarriers (Fig. 42). Further, the highest plasma
concentration (Cmax) of LPV was achieved with ZPEG micelles, which was 4-fold higher
compared to free LPV. Kaletra® liquid formulation enhanced the oral bioavailability by 3fold compared to free LPV. On the other hand, ZPEG micelles showed 2-fold higher oral
bioavailability compared to Kaletra® liquid formulation (Table 25). The AUC of LPV was
in the following decreasing rank order ZPEG>ZWP>ZLG>Kaletra®>free LPV.
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Figure 42: Plasma concentration of free LPV suspension, Kaletra® and LPV loaded
ZLG, ZWP and ZPEG nanocarriers delivered orally in rats. ZPEG: PEGylated zein
micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate
nanoparticles. Each value represents mean±SD (n=3).
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Table 25: PK parameters of free LPV, Kaletra®, and LPV loaded nanocarriers after oral
delivery in rats.
LPV
suspension

Kaletra ®

ZWP-LPV

ZLG-LPV

ZPEG-LPV

0.52±0.05

1.77±0.20

1.29±0.05 *

1.39±0.13 *

1.98±0.04*

Tmax (hr)

6.00±0.00

3.00±0.00

6.00±0.00

6.00±0.00

9.00±0.00

t1/2 (hr)

5.81±1.28

6.53±1.45

11.72±3.30

11.81±2.07

8.63±3.60

AUC0-t

5.04±0.18

15.86±0.68

18.12±0.28

16.99±0.59

28.11±0.30

5.04±0.18

15.86±0.68

23.63±2.21*

20.75±1.27 *

32.48±1.57 *

MRT (hr)

6.30±0.10

6.70±0.31

16.97±3.51

15.04±1.20

14.26±1.96

F (% rel)

--

Cmax
(μg/mL)

(μg-hr/mL)
AUC0-∞
(μg-hr/mL)

323.71±14.06 149.00±13.95* 130.86±8.01*

204.81±9.91 *

Each value represents mean±SD (n=3) *P<0.05. Cmax: Maximum plasma concentration;
Tmax:- Time to reach maximum plasma concentration; AUC:- Area under plasma
concentration-time curve; MRT:- Mean residence time; t1/2:- Elimination half-life;
Kaletra®:-Lopinavir with a low dose of ritonavir; F (% rel):- Percent relative
bioavailability. F(%rel) for Kaletra® is in comparison to LPV suspension, F(%rel) for
nanocarriers is in comparison to Kaletra®.
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Since ZPEG micelles showed the highest oral bioavailability, this formulation was
used for steady-state pharmacokinetic studies by multiple dosing. The formulations were
administered orally twice a day for two days. The LPV absorption increased after the
second dose of Kaletra® and gradual accumulation of LPV was observed after subsequent
doses of Kaletra® and ZPEG micelles (Fig. 43). Steady state plasma concentration of LPV
was achieved after second dose (24-48 hours) and the PK parameters were comparable
between Kaletra® and ZPEG micelles (Table 26). Steady state Cmax for both Kaletra® and
ZPEG formulations was significantly increased (around 2.5-fold) compared to Cmax
obtained with single dose (Table 25 and Table 26).
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Figure 43: Plasma profile of LPV after multiple dose administration (52 mg/Kg twice
a day for 2 days) of Kaletra® and LPV loaded ZPEG nanocarriers. Each value
represents mean±SD. (n=3).
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Table 26: Steady state PK parameters of Kaletra® and LPV loaded ZPEG micelles after
oral delivery in rats.
Kaletra®

ZPEG-LPV

Css max (µg/mL)

5.50±0.65

4.24±0.49*

Css avg (µg/mL)

4.43±0.73

4.0±0.27*

Css min (µg/mL)

1.06±0.12

1.49±0.32*

Tss max (hrs)

27.00±0.00

30.00±0.00*

AUCo-12 ss (μg-hr/mL)

53.20±8.84

53.16±3.35*

Css max. Maximum concentration during dosing interval at steady state; Css min. Minimum
concentration during dosing interval at steady state; Css

avg.

Average plasma drug

concentration at steady state; ZPEG: PEGylated zein micelles; Each value represents
mean±SD (n=3); *P<0.05 compared to Kaletra®.
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3.5. Discussion
The main goal of this study was to test the feasibility of developing a water
dispersible ritonavir free formulation of LPV using food-grade biopolymers. LPV was
encapsulated in the hydrophobic zein core, while the external hydrophilic shell was used
to increase the water solubility and permeability through the gastrointestinal membrane.
The size and surface charge of LPV loaded nanocarriers were similar to NR loaded
nanocarriers as described in chapter two (Section 2.4.1). The encapsulation and loading
efficiency varied with different shell composition (Table 22). The highest encapsulation
and loading efficiency of LPV obtained with ZPL nanocarriers can be attributed to the
presence of both lecithin and pluronic in the shell. The lecithin in the shell favors the
entrapment of LPV in the ZPL nanocarriers (Chen, Chen, Su, Hong, et al. 2016; Chen,
Chen, Su, Wong, et al. 2016), while addition of pluronic F127 can sterically stabilize zein
nanoparticles (Podaralla and Perumal 2012). Lecithin alone was not able to prevent
aggregation of zein nanoparticles (Podaralla and Perumal 2012). Pluornic stabilizes the
lecithin layer by hydrophobic interaction of polypropylene oxide unit of pluronic with
hydrophobic tail of lecithin and hydrophilic interaction of polyethylene oxide chain of
pluronic with polar head of lecithin (Schubert and Muller-Goymann 2005; Mosqueira et
al. 2000; Zhang et al. 2008). The loading efficiency of LPV in ZC nanocarriers were
comparable to ZPL due to the relatively higher hydrophobicity of β-casein among the milk
proteins used in this study (Patel, Bouwens, and Velikov 2010). Lactoferrin has high
aqueous solubility and thereby contributed to the lowest encapsulation and loading of LPV
in ZLF nanocarrier (Table 22). In general, the results obtained with loading of NR (Section
2.4.1) and LPV in nanocarriers suggest that the encapsulation and loading efficiency

159

dictated by both shell composition and the physicochemical properties of the encapsulated
molecule.
The long-term stability study indicated that LPV remained stable both in free form
and in nanocarriers with a gradual increase in ZLG particle size which may be attributed
by the alteration in β-lactoglobulin (LG) conformation over time (Majhi et al. 2006).
In vitro food compatibility study indicated that LPV loaded nanocarriers can be
mixed with food matrices (milk and applesauce) and also suggest that the formulations
have the potential to be used as food sprinkle. Water, milk and applesauce are commonly
used vehicles to disperse drug formulations. (WHO 2010) Administration of multiparticulate drug formulation by mixing with food or drinks (sprinkles) can improve
organoleptic properties and thereby can increase the acceptability of the formulation
especially for pediatric patients. However, compatibility of the formulation with food
matrix, drug release in food matrix and bioavailability should be taken into account
(MacDonald et al. 2006; den Uyl et al. 2010). Albertini et al. (2014) reported the
compatibility of solid lipid microparticles with milk and yogurt and can be used as sprinkle
for drug administration. The practice of crushing lopinavir/ritonavir (LPV/r) tablet and
mixing with food leads to reduce the total lopinavir and ritonavir exposure by 45% and
47% respectively (Best et al. 2011). In this regard, zein-based nanoformulations are
advantageous to ensure flexibility in dosing. In addition, LPV loaded zein-based
nanocarriers showed compatibility with food matrices due to less drug release and have
potential to mask the bitter taste of drugs and can be used as food sprinkle. However,
further studies needed to confirm the palatability and taste masking using these core-shell
nanoformulations.
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In vitro metabolic stability study demonstrated the protection of lopinavir from
CYP3A4 metabolic degradation. Apparent permeability (Papp) of LPV across Caco-2 cell
monolayers was also significantly increased using nanocarriers compared to free LPV
LPV/r combination. This result signifies that zein-based nanoformulations can be used to
develop ritonavir free lopinavir formulation. The shell composition of nanocarriers play an
important role in the interaction, uptake, and distribution of the nanoparticles. ZC and
ZPEG nanocarriers are taken up by non-specific endocytosis in Caco-2 cells (Alqahtani et
al. 2017). On the other hand, ZLF can be taken up through lactoferrin receptors in the
intestinal epithelial cells by receptor mediated endocytosis (Alqahtani et al. 2017). The
efflux pumps expressed in the intestinal cells limits the drug absorption. The P-gp
inhibitory activity of PEG in ZPEG micelles resulted in higher permeability of LPV across
Caco-2 monolayers (Alqahtani et al. 2017). ZLG and ZWP nanocarriers mainly taken up
by non-specific endocytosis. Taken together, findings from the in vitro studies suggest that
the shell composition influences the cell uptake kinetics and the mechanisms of
transepithelial transport of zein based core-shell nanocarriers.
Results from single-dose Pharmacokinetic study in rat demonstrated that the trough
plasma concentration was 1 μg/mL, which is consistent with the concentration required to
reduce the HIV viral load (Lopez-Cortes et al. 2013). Further, the half-life of LPV using
nanocarriers significantly increased and was found to be useful to improve plasma level of
LPV by gradual accumulation after administration of multiple dose (Fig. 43). The P-gp
inhibitory activity of ZPEG contributed to suppress the interplay between CYP3A4 and Pgp efflux pump to reduce the absorption of LPV. The steady-state plasma concentration of
LPV using ZPEG micelle was obtained after administration of second dose and steady-
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state PK parameters were comparable to Kaletra® indicated the potential of developing
ritonavir free LPV formulation using zein nanocarriers.
The HIV treatment regimen includes 3 different groups of drugs and concomitant
administration increases the chance of drug-drug interaction (Barry et al. 1999). For
example, ritonavir in lopinavir/ritonavir combination can interact with non-nucleoside
reverse transcriptase inhibitors by inducing drug metabolizing enzymes and thereby reduce
the plasma concentration of protease inhibitors (Barry et al. 1999; Piscitelli and Allicano
2001). The potential of developing ritonavir free lopinavir formulation can reduce the
overall drug load and drug-drug interactions.
Overall, the findings from this study demonstrated that food-grade biopolymers can
be used to develop a safe and effective carrier for LPV.
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3.6. Conclusions
The present study demonstrates that zein based core-shell nanocarriers are
promising for enhancing the oral bioavailability of LPV. In vitro studies showed that zein
based core-shell nanocarriers significantly improved the water solubility of LPV, sustained
the LPV release, and increased membrane permeability. Low LPV release in food matrices
(milk and applesauce) indicated that LPV loaded nanocarriers are compatible with food
matrices and have the potential to be used as a food sprinkle. In vitro metabolic stability
study demonstrated that zein based core-shell nanocarriers protected LPV from CYP3A4mediated enzymatic degradation. Results from the pharmacokinetic study showed that the
bioavailability obtained with ZPEG micelles was similar or higher compared to Kaletra®
liquid formulation. Overall the results suggest the feasibility of developing a ritonavir
pediatric formulation of LPV using zein based nanocarriers.

163

CHAPTER FOUR

USE OF CORE-SHELL NANOCARRIERS FOR ORAL DELIVERY OF AN
INVESTIGATIONAL ANTI-CANCER DRUG MOLECULE
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4.1. Introduction
Given the promising outcomes from chapter two and chapter three, the goal of this
chapter is to use zein-based nanocarriers for encapsulation and oral delivery of fenretinide,
an investigational anti-cancer compound. Fenretinide [N-(4-hydroxyphenyl) retinamide (4HPR)] is a poorly soluble and poorly permeable anti-cancer agent (Torrisi et al. 2001;
Wischke et al. 2010; Orienti et al. 2007; Ledet et al. 2015). Further, the compound has poor
chemical stability. Fenretinide has been investigated for its effectiveness against various
cancers in clinical trials including breast (Kazmi et al. 1996), ovarian (Supino et al. 1996;
Sabichi et al. 1998; Formelli and Cleris 1993), lung (Kalemkerian et al. 1995), pediatric
neuroblastoma (Ponzoni et al. 1995; Di Vinci et al. 1994; Maurer et al. 2000), prostate
(Hsieh, Ng, and Wu 1995; Igawa et al. 1994) and colorectal (Ziv et al. 1994) cancer. There
are several mechanisms reported for fenretinide’s anticancer activity including i) formation
of reactive oxygen species (ROS), ii) increasing the level of ceramides, iii) anti-angiogenic
activity, and iv) enhanced NK cell activity (O'Donnell et al. 2002; Maurer et al. 1999;
Oridate et al. 1997; Delia et al. 1997; DiPietrantonio et al. 1998; Batra, Reynolds, and
Maurer 2004; Rehman, Shanmugasundaram, and Schrey 2004; Ribatti et al. 2001; Zhao et
al. 1994).
However, a major challenge in realizing its therapeutic potential is the compound’s
poor oral bioavailability. Fenretinide at a dose of 100 to 400 mg/day has been investigated
as a chemoprevention agent in phase I, phase II and phase III trial using oral gelatin capsule
(Villablanca et al. 2011). In the capsule formulation of fenretinide was dissolved in corn
oil and a surfactant (polysorbate 80) and achieves very low blood concentration.
Fenertinide has been observed to have dose-limited toxicity (Torrisi et al. 1994). A high-
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dose fenretinide (1800 mg/m2/day) when administered in pediatric patients with
neuroblastoma was found to be associated withs hepatic toxicities and pseudotumor cerebri
(Children's Oncology et al. 2006). Further, fenretinide using capsule formulation showed
the high patient variability in plasma concentration (2-5 μg/mL) with rebound
neuroblastoma (Garaventa et al. 2003; Villablanca et al. 2011; Children's Oncology et al.
2006; Schneider et al. 2009). As a result of the poor compliance with fenertinide capsule
formulation, clinical trials have been discontinued (Caruso et al. 1998).

An oral lipid formulation, Lym-X-Sorb® (LXS), has been investigated to enhance
bioavailability of fenretinide with improved patient compliance (Kummar et al. 2011;
Maurer et al. 2013). LXS® oral powder achieved 4-fold plasma and 7-fold tissue fenretinide
concentration in mice compared to fenretinide capsule formulation (Maurer et al. 2007).
LXS®-fenretinide powder formulation was successful in overcoming some of the
difficulties with corn oil capsule (Kummar et al. 2011). However, there is a strong unmet
need for an effective and safe oral formulation of fenertinide, especially for pediatric
patients.

Figure 44: Chemical structure of fenretinide.
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To this end, the goal of this study is to develop and test the feasibility of using zein
based core-shell nanocarriers for enhancing the oral bioavailability of fenretinide. Six
different core-shell nanocarriers that were evaluated in previous two chapters, was used for
this study with the goal of studying the influence of the shell composition on the in vitro
and in vivo functional performance of fenretinide loaded nanocarriers and identifying a
suitable formulation for further development
The specific aims of this study are:
i)

To prepare and characterize fenretinide loaded core-shell nanocarriers.

ii)

Determine the in vitro release of fenretinide in simulated GI fluids and food
matrices (milk and applesauce).

iii)

Determine the apparent permeability (Papp) of fenretinide and fenretinide loaded
nanocarriers across Caco-2 cell monolayers.

iv)

Determine the oral Pharmacokinetics of fenretinide loaded nanocarriers in rats.
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4.2. Materials and methods
4.2.1. Materials
Fenretinide was purchased from LC Laboratories (Woburn, MA, USA). All other
materials and chemicals used in this study were similar to those mentioned in chapters two
and three.

4.2.2. Methods
4.2.2.1. Preparation of fenretinide loaded nanocarriers
Phase separation method used to prepare fenretinide loaded nanocarriers as
described in the second chapter (section 2.2.2.). Briefly, 15 mg of zein was dissolved in 2
mL of 90% ethanol and 1 mg of fenretinide was mixed with zein solution. The
hydroalcoholic phase was added dropwise to aqueous phase containing milk protein (βcasein-C or lactoferrin-LF or β-lactoglobulin-LG or whey protein isolate-WP) or pluroniclecithin under probe sonication. Beta-lactoglobulin (LG) and whey protein isolate (WP)
was preheated at 60°C for 30 minutes followed by slow addition of zein solution as
described in the second chapter (section 2.2.2.). The dispersion was stirred for 3 to 4 hours
at 100 rpm (room temperature) to evaporate the remaining ethanol. Free fenretinide was
removed by centrifugation using centrifugal filters (EMD Millipore). The purification step
was repeated for 3 to 5 times. The resultant formulation was lyophilized for 48 hours, and
the dried powder was stored at 4°C in a desiccator until further analysis.
Around 1 mg of fenretinide was loaded in ZPEG micelles using the same method
as described in the second chapter (section 2.2.2.)

168

4.2.2.2. Characterization of fenretinide loaded nanocarriers
Fenretinide loaded nanocarriers were characterized for particle size, PDI and zeta
potential using Malvern Zeta Sizer Nano ZS (Malvern Instrument Inc., Southborough,
MA). The morphology of fenretinide loaded nanocarriers was visualized using TEM using
the procedure described in chapter two (section 2.2.3.). Differential Scanning Calorimetry
(DSC) analysis was performed to determine the thermal properties of free fenretinide and
fenretinide loaded nanocarriers using the same procedure as described in chapter 3 (section
3.2.2.3.).

4.2.2.3. HPLC analysis of fenretinide
HPLC analysis of fenretinide was performed on a Waters system (Milford, MA)
equipped with an isocratic pump, a degasser, an autosampler and data processing software
(Breeze version 3.30 SPA). The separation of fenretinide was performed on a symmetry®
C18 Column (Waters Corporation, Milford, USA) (5 µm, 4.6 mm X 150 mm). The mobile
phase was a mixture of acetonitrile: water: glacial acetic acid (80:18:2, v/v). The mobile
phase was pumped at a flow-rate of 0.8 mL/min. Fenretinide was monitored at a
wavelength of 340 nm. The calibration curve (peak area versus drug concentration) was
linear (R2=0.999) in the fenretinide concentration range of 0.39–2.5 μg/mL.

4.2.2.4. Determination of encapsulation and loading efficiency of fenretinide
Lyophilized fenretinide formulations were used to determine the encapsulation and
loading efficiency. Briefly, 2 mg of fenretinide loaded nanocarriers was dispersed in 1 mL
of water and centrifuged at 1000 rpm for 10 minutes, the supernatant was discarded, and
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the nanoparticles was reconstituted in 1 mL 90% ethanol. The extracted fenretinide was
filtered through 0.2 µm syringe filter, and 50 µL was injected into the HPLC column. The
concentration of fenretinide in nanocarriers was calculated from the calibration curve of
fenretinide in 90% ethanol. The encapsulation efficiency (EE%) and loading efficiency
(LE%) were calculated using the following equations:
EE% =
LE% =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑖𝑛 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠

x 100
x 100

4.2.2.5. In vitro release of fenretinide from nanocarriers
The release of fenretinide from nanocarriers was performed by dialysis method in
SGF and SIF using the proedure as described in chapter two (section 2.2.5.). Briefly, 50
mg of fenretinide loaded nanocarriers was dispersed in 5mL of SGF or SIF and placed
inside the dialysis tube (Snakeskin dialysis membrane, 10 kDa molecular weight cutoff).
The dialysis sac was placed in a beaker and placed in a temperature controlled shaker at
37°C and agitated at 100 rpm. Around 400 µL of the sample was withdrawn at
predetermined time points, diluted with equal volume of ethanol and 50 µL of the sample
was injected into the HPLC column.
Sequential release of fenretinide was determined by incubating fenretinide loaded
nanocarriers in 2% milk or applesauce and then transferred to SGF followed by SIF.
Briefly, 50 mg fenretinide nanocarriers was dispersed in 5 mL 2% milk or 50% apple sauce
and transferred into a dialysis sac (10 kDa molecular weight cutoff). All other procedure
was similar to sequential release of LPV described in section 3.2.2.6.
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4.2.2.6. Transepithelial permeability through Caco-2 cell monolayers
The transepithelial permeability of free fenretinide and fenretinide loaded
nanocarriers was studied using Caco-2 cell monolayers as described in the earlier chapter
(section 3.2.2.8). Briefly, 5x104 cells were incubated in 12-well plate transwell inserts with
an area of 1.12 cm2 (Transwell®, Corning Costar Corp. Cambridge, MA, USA). The
growth medium was changed every two other days for 15 days. The tight junction integrity
of the Caco-2 cell monolayers was determined using TEER measurements. Prior to
applying the fenretinide formulations, caco-2 cell monolayers were incubated with Hank’s
Balanced Salt Solution (HBSS) for 30 minutes at 37°C to polarize cell monolayers. About
500 μL of free fenretinide suspension (10 μg/mL) or equivalent of fenretinide loaded
nanocarriers dispersed in HBSS buffer was added to the apical chamber and 100 μL of the
sample was collected at predetermined time points (0h, 1h, 2h and 4 h) from the basolateral
chamber. An equal volume of HBSS buffer was added to maintain the volume in the
basolateral compartment. The samples were mixed with an equal volume of ethanol and 50
μL of the sample was injected into HPLC for determination of fenretinide concentration.
The apparent permeability coefficient (Papp) of fenretinide loaded nanoparticle across
Caco-2 cell monolayers was calculated using the equation described in second chapter
(section 2.2.11.).

4.2.2.7. Stability of fenretinide in nanocarriers
The stability of fenretinide loaded ZC, ZLG and ZPL nanocarriers were evaluated.
Briefly, 5 mg of fenretinide loaded nanocarriers was incubated in a constant climate
chamber (Binder, Germany) at 30°C±2°C/65% RH±5% RH for three months (according
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to ICH guidelines) (ICH 2013). Around 1 mg of free fenretinide was used as a control. At
predetermined time points, the particle size, PDI and zeta potential were measured using
the particle sizer (Malvern instrument). Fenretinide content in the nanocarriers was
determined using HPLC.

4.2.2.8. Pharmacokinetic studies in Rats
All the animal experiments were carried out after approval from the IACUC at
SDSU. Male Sprague-Dawley rats (3–4 weeks of age) weighing 115-150g were used for
the study. Rats with surgically implanted jugular vein catheter were purchased from
Charles River (Wilmington, MA) and acclimatized for one week. After fasting for
overnight, 20 mg/kg of free fenretinide (in water with 2% Tween 20) or fenretinide loaded
ZC, ZLG, ZWP, and ZPL nanocarriers were administered by oral gavage. Blood samples
(200 µL) were collected at 0, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 15 h, 18 h and 24 h from
the jugular vein. The plasma was separated by centrifuging at 4000 rpm for 10 minutes.
Fenretinide was extracted from the plasma by adding an equal volume of ethyl acetate and
n-hexane mixture (50:50, v/v) followed by centrifugation at 10000 rpm for 10 minutes. The
supernatant was collected, and the extraction process was repeated three times to ensure
complete extraction. The fenretinide concentration in the plasma was determined by HPLC
method using a calibration plot prepared by spiking known amount of fenretinide (0.1-2.0
µg/mL) in the plasma. The pharmacokinetic parameters including peak concentration
(Cmax), time to reach peak concentration (Tmax), area under the plasma concentration-time
(AUC), and half-life (t1/2) were calculated by non-compartmental analysis using PKsolution software. The percent relative bioavailability (Frel%) of fenretinide was calculated
by using the following formula,
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Frel (%) =

𝐴𝑈𝐶 (𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑛𝑎𝑛𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠)
𝐴𝑈𝐶 (𝑓𝑟𝑒𝑒 𝑓𝑒𝑛𝑟𝑒𝑡𝑖𝑛𝑖𝑑𝑒 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛)

𝑋100

Based on the results from single dose PK study, fenrettinide loaded ZPL nanocarrier
was further used for steady-state pharmacokinetic studies. Based on the half-life of
fenretinide obtained after single dose PK study, the dose interval for multiple dose study
was designed. Fenretinide loaded ZPL nanocarrier (20 mg/kg fenretinide equivalent) was
orally administered once a day for 4 days. Free fenretinde suspension (20 mg/kg) was
administered orally twice a day. Blood samples were collected from the jugular vein at 0,
0.5, 1, 3, and every 3 hours up to 96 hours. All the blood samples were processed as
described above and the plasma concentration of fenretinide was determined by HPLC.
Steady state PK parameters such as Css

max,

Css

min,

AUCss 0-t were calculated using PK-

solution software. Average steady state plasma concentration (Cavg ss) was calculated using
the following equation,
Cavg ss =

𝐴𝑈𝐶0−𝜏
𝜏

Where, τ is the dose interval (12 hours for free fenretinide suspension and 24 hours for
fenretinide loaded ZPL nanocarrier).

4.3. Statistical analysis
All the experiments were conducted in triplicate using three independent batches
of nanocarriers unless noted otherwise. The data is represented as a mean ± standard
deviation. Student t-test and One-way ANOVA was performed to determine statistical
significance at p < 0.05.
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4.4. Results
4.4.1. Development and characterization of fenretinide loaded core-shell nanocarriers
The particle size of the nanocarriers ranged from 100 to 250 nm diameter and had
a uniform size distribution as evidenced from the low polydispersity index (0.08 to 0.3)
(Table 27). The core-shell structure of nanocarriers was confirmed from TEM (Fig. 45)
and the morphology of fenretinide loaded nanocarriers was similar to NR and LPV loaded
nanocarriers (Fig. 15 and Fig. 35). The zeta potential varied from -45.75±0.91 to
32.95±1.48 mV depending on the shell composition and the values are consistent with LPV
and NR loaded nanocarriers (Table 8 and Table 22). The encapsulation efficiency (EE)
for fenretinide was above 70% in all the nanocarriers with zein-β-casein (ZC) nanoparticles
showing the highest encapsulation efficiency (89%) (Table 27). The EE of NR in ZPEG
micelles was about 56%, while EE of fenretinide was 77% indicating that the interaction
between fenretinide and zein core favors the higher entrapment of fenretinide in ZPEG
micelles. The EE of LPV in ZPEG micelles was similar to EE of fenretinide. The EE of
fenretinide in all other nanocarriers was similar to EE of NR and LPV (Table 8 and Table
22). The loading efficiency was further optimized based on the ratio of drug to polymer,
core to shell, and alcohol concentration. Drug to core polymer ratio was found to be
important parameter and by increasing fenretinide from 1 mg to 5 mg resulted in increase
in loading efficiency. The loading efficiency (LE) varied from 3 to 8% based on the shell
composition (Table 27). The highest loading of fenretinide was obtained with ZPEG
micelles, while ZPL nanocarriers showed the lowest loading efficiency. The LE for ZC
nanocarriers (7.5%) was similar to ZPEG micelles. Further, LE of fenretinide was about 2fold higher than LE of LPV in ZPEG micelles (Table 22).
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The encapsulation of fenretinide in the nanocarriers was confirmed by differential
scanning calorimetry (DSC) (Fig. 46). DSC thermogram for free fenretinide showed two
sharp endothermic peaks at around 175°C and 180°C, which indicates the presence of two
polymorphic forms of fenretinide. (Walkling 1986) The absence of melting peak indicates
loss of crystallinity due to entrapment in the nanocarriers.
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Figure 45: Transmission electron microscopy images of fenretinide loaded
nanocarriers. ZC: Zein-β-casein nanoparticles; ZLF: Zein-lactoferrin nanoparticles;
ZPEG: PEGylated zein micelles; ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zeinwhey protein nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Scale bar is 200
nm.
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Table 27: Characteristics of fenretinide loaded nanocarriers.
Zeta
Particle size
Characteristics

PDI

potential

EE (%)

LE (%)

(nm)
(mV)
ZC

148.25±0.77 0.099±0.055

-40.95±1.06

89.32±0.091

7.5±0.09

ZLF

240.1±3.53

0.15±0.02

32.95±1.48

70.11±0.49

3.75±0.035

ZLG

272.2±7.63

0.30±0.01

-23.25±1.0

78.51±3.68

3.5±0.037

ZWP

256.7±0.98

0.08±0.03

-36±3.25

74.68±1.04

3.09±0.012

219.3±22.88

0.33±0.065

-45.75±0.91

76.05±0.918

3.01±0.23

114.43±2.90

0.34±0.018

-11.35±0.07

77.43±0.47

8.33±0.03

ZPL
ZPEG

Values represent mean±SD (n=3). EE (%): Encapsulation efficiency in percent; LE (%):
Loading efficiency in percent; ZC: Zein-β-Casein nanoparticles; ZLF: Zein-Lactoferrin
nanoparticles; ZPEG: Zein-Polyethylene Glycol micelles; ZPL: Zein-Pluronic-Lecithin
nanoparticles; ZLG: Zein-β-Lactoglobulin nanoparticles; ZWP: Zein-Whey Protein isolate
nanoparticles.
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Figure 46: DSC analysis of free fenretinide and fenretinide loaded nanocarriers. ZC. Zeinβ-casein nanoparticle, ZLF. Zein-lactoferrin nanoparticle, ZPEG. PEGylated zein micelle,
ZLG. Zein-β-lactoglobulin nanoparticle, ZWP. Zein-whey protein nanoparticle, ZPL.
Zein-pluronic-lecithin nanoparticles. X-axis showing Temperature (°C) and Y-axis
showing Heat Flow (W/g). Red line: Free fenretinide; Blue line: Fenretinide loaded
nanocarriers; Black line: Blank nanocarriers.
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4.4.2. In vitro release of fenretinide from nanocarriers
The release of fenretinide was sustained both in SGF and SIF for 24 hours (Fig.
47). The release of fenretinide was faster than the release of NR (Fig. 19), while it was
similar to the release of LPV (Fig. 37) from ZC nanocarriers in both SGF and SIF. The
ZLG and ZPEG nanocarriers showed the slowest release of fenretinide (<40% released) in
both SGF and SIF over 24 hours, which was similar to NR and LPV release from these two
nanocarriers. The release profile of fenretinide from ZWP nanocarriers (Fig. 47) was
similar to the release of NR and LPV (Fig. 19 and Fig. 37) in both SGF and SIF. About 40
to 50% burst release was observed with ZLF nanocarriers within first one hour in SGF and
SIF (Fig. 47), while less than 10% burst release was observed in case of NR and LPV. The
release profile of fenretinide from ZPL nanocarriers was similar NR, while the LPV release
was slower both in both SGF and SIF (Fig. 47).
The nanocarriers were stable when incubated with food matrices (milk or
applesauce), and less than 30% of fenretinide was released within two hours when
transferred to SGF. About 60% of fenretinide was released in 24 hours after transferring
from SGF to SIF (Fig. 48). The compatibility with food matrices indicate that the
fenretinide loaded nanocarriers can be used as a food sprinkle.
The release kinetics was consistent with release of LPV from nanocarriers (Table
23 and Table 24). The release of fenretinide from the nanocarriers predominantly followed
Peppas model, except for ZLG nanoparticles (Table 28). This indicates that the release of
fenretinide from nanocarriers depends on polymer swelling, diffusion of fenretinide and
surface erosion of polymer (Sivakumar and Rao 2003). There was slow release of
fenretinide in the presence of food matrices and release kinetics (R2-values) indicates that
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food matrices have less impact on drug release from nanocarriers (Table 29). The release
of fenretinide from all the six nanocarriers followed Peppas model indicating that the
release is mediated by the diffusion due to surface erosion followed by hydrolytic cleavage
or enzymatic degradation of the polymer (Table 28). In SIF, the release of fenretinide from
ZLG nanocarriers was followed by Hixon-Crowell and first order model indicating that the
release is dissolution limited. Similar release pattern (Fig. 48) and kinetics (Table 29) was
obtained in the sequential release study in food matrices (milk and apple sauce) followed
by SGF and SIF indicating that the food matrices had little influence on the release of
fenretinide from the nanocarriers.
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Figure 47: Cumulative percent of fenretinide released from different core-shell nanocarriers
in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). ZC. Zein-β-casein
nanoparticle, ZLF. Zein-lactoferrin nanoparticle, ZPEG. PEGylated zein micelle, ZLG.
Zein-β-lactoglobulin nanoparticle, ZWP. Zein-whey protein nanoparticle, ZPL. Zeinpluronic-lecithin nanoparticles. Each value represents mean±SD (n=3).
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Table 28: Fenretinide release kinetics using different models.
R2

Formulation (Medium)

ZC (SGF)
ZC (SIF)
ZLF (SGF)
ZLF (SIF)
ZPEG (SGF)
ZPEG (SIF)
ZLG (SGF)
ZLG (SIF)
ZWP (SGF)
ZWP (SIF)
ZPL (SGF)
ZPL (SIF)

Peppas
𝐹
= 𝐾 ∗ 𝑡𝑛
0.993
0.991
0.993
0.993
0.978
0.972
0.987
0.981
0.981
0.988
0.986
0.974

Hixson-Crowell
𝐹 = 100 ∗ (1 − (1 − 𝑘
∗ 𝑡)^3)
0.857
0.884
-0.352
-0.417
0.607
0.541
0.844
0.981
0.875
0.845
0.684
0.727

Zero Order
C=C0-K0t
0.878
0.895
0.376
0.312
0.858
0.851
0.944
0.981
0.932
0.931
0.869
0.874

First Order
F=100*(1-exp(k*t))
0.904
0.922
-0.239
-0.263
0.643
0.588
0.856
0.981
0.883
0.868
0.741
0.798

Higuchi
F = k ∗ sqrt(t)
0.973
0.977
0.313
0.183
0.941
0.914
0.982
0.859
0.969
0.987
0.940
0.925

SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF:
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model.
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Figure 48: Cumulative percent of fenretinide released from different core-shell nanoparticles
in milk (A), apple sauce (B) for 1 hour followed by release in simulated gastric fluid (SGF) for
1 hour and followed by release in simulated intestinal fluid (SIF) up to 24 hours. Values
represents mean±SD (n=3).
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Table 29: Fenretinide sequential release kinetics using different models.
R2

Formulation (Medium)

ZC (milk to SGF to SIF)
ZC (apple sauce to SGF to SIF)
ZLF (milk to SGF to SIF)
ZLF (apple sauce to SGF to SIF)
ZPEG (milk to SGF to SIF)
ZPEG (apple sauce to SGF to SIF)
ZLG (milk to SGF to SIF)
ZLG (apple sauce to SGF to SIF)
ZWP (milk to SGF to SIF)
ZWP (apple sauce to SGF to SIF)
ZPL (milk to SGF to SIF)
ZPL (apple sauce to SGF to SIF)

Peppas
𝐹
= 𝐾 ∗ 𝑡𝑛
0.947
0.912
0.793
0.855
0.998
0.994
0.976
0.971
0.970
0.954
0.952
0.948

Hixson-Crowell
𝐹
= 100 ∗ (1 − (1 − 𝑘 ∗ 𝑡)^3)
0.745
0.707
0.567
0.631
0.928
0.995
0.421
0.913
0.884
0.934
0.906
0.941

Zero
Order
C=C0-K0t
0.656
0.750
0.583
0.695
0.957
0.993
0.791
0.941
0.896
0.915
0.851
0.895

First Order
F
=100*(1-exp(-k*t))
0.850
0.789
0.665
0.671
0.946
0.995
0.465
0.920
0.917
0.948
0.948
0.961

Higuchi
F = k ∗ sqrt(t)
0.790
0.897
0.773
0.854
0.974
0.850
0.924
0.932
0.962
0.906
0.946
0.904

SGF-Simulated gastric fluid; SIF-Simulated intestinal fluid; R2 calculated from SigmaPlot 13.0. ZC: Zein-β-casein nanoparticles, ZLF:
Zein-lactoferrin nanoparticles, ZPEG: PEGylated zein micelles, ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein
isolate nanoparticles; ZPL: Zein-pluronic-lecithin nanoparticles. Highlighted values indicate the best fit model.
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4.4.3. Transepithelial permeability of fenretinide loaded nanocarriers across Caco-2
cell monolayers
The nanocarriers enhanced the apparent permeability (Papp) of fenretinide across
the Caco-2 cell monolayers (Fig. 49). The Papp was increased from 1 to 36-fold compared
to free fenretinide. The Papp ranged from 2.09x10-6 to 72.42x10-6 cm/s depending on the
shell composition of the nanocarriers (Fig. 49). ZPL nanocarriers showed the highest
permeability, while lowest permeability was observed with ZPEG micelles. The apparent
permeability of fenretinide loaded nanocarriers was found to be in the following decreasing
rank order ZPL>ZLG>ZC>ZWP>ZLF>ZPEG. The highest Papp values for NR was
obtained with ZLG nanocarriers followed by ZPEG, while NR loaded ZC nanocarriers
showed the lowest Papp value (section 2.2.2.). However, the rank order was different
compared to LPV loaded nanocarriers (section 3.4.3). Unlike fenretinide formulations,
LPV loaded ZPEG micelles showed the highest Papp, while the lowest value was obtained
with ZPL nanocarrier (Fig. 49). Overall, from the results showed that the zein nanocarriers
significantly enhanced the permeability of fenertinide.
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Figure 49: Apparent permeability (Papp) of free fenretinide and fenretinide loaded
nanocarriers across caco-2 cell monolayers. ZC: Zein-β-casein nanoparticles; ZLF:
Zein-lactoferrin nanoparticles; ZPEG: PEGylated zein micelles; ZLG: Zein-βlactoglobulin nanoparticles; ZWP: Zein-whey protein nanoparticles; ZPL: Zeinpluronic-lecithin nanoparticles. Each value represents mean±SD (n=3), *P<0.05.
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4.4.4. Stability of fenretinide in nanocarriers
Fenretinide in ZC and ZLG nanoformulations was chemically stable compared to
free fenretinide in the solid state when tested for three months. Around 45% of fenretinide
degraded in free-form, while more than 90% fenretinide remained stable after
encapsulation in nanocarriers (Fig. 50a). The particle size of fenretinide loaded ZC
nanocarriers increased slightly after two months, while the particle size of fenretinide
loaded ZLG nanocarriers increased by 2-fold (Fig. 50b). The PDI for both ZC and ZLG
nanocarriers increased after two months (Fig. 50c). The zeta potential for ZC nanocarrier
changed gradually from -55 mV to -35 mV, while the charge of ZLG nanocarrier changed
from -40 mV to slightly positive (+4.0 mV) (Fig. 50d). Particles with zeta potential values
around ±30 mV is reported to be stable for overcoming particle aggregation (Bhattacharjee
2016). The change of zeta potential is consistent with the aggregation of ZLG nanocarriers.
Similar results were observed with LPV loaded ZLG nanocarrier (Fig. 39). Overall, the
stability studied indicate that the zein based nanocarriers can enhance the chemical stability
of fenertinide.
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Figure 50: Solid state stability of free fenretinide, fenretinide loaded Zein-β-casein and zein-β-lactoglobulin nanocarriers.
Nanocarriers and free drug were kept in constant climate chamber at 30°C and 65% RH for 3 months. Each value represents mean±SD
(n=3).
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4.4.5. In vivo pharmacokinetics
Based on the results from in vitro permeability studies, ZC, ZLG, ZWP, and ZPL
nanocarriers were selected for in vivo pharmacokinetic studies in rat. Free fenretinide
suspension showed aCmax of 0.21 μg/mL at 3 hours (Tmax). ZPL nanocarrier showed the
highest Cmax (0.61 μg/mL) of fenretinide at 6 hours (Tmax), while fenretinide loaded ZC
nanocarrier showed the lowest Cmax (0.23 μg/mL) at the same Tmax (Fig. 51). ZLG and
ZWP nanocarriers showed a Cmax of fenretinide of 0.49 and 0.58 μg/mL respectively. Free
fenretinide showed a Cmax of 0.21 μg/mL at 3 hours (Tmax). The AUC of fenretinide was
significantly increased with ZWP nanocarriers (~ 8-fold), whereas the AUC for ZLG, ZPL
and ZC nanocarriers were about 6-, 5- and 3-fold higher compared to free fenretinide
suspension (Table 30). All the nanocarriers under investigation increased the elimination
half-life (t1/2) of fenretinide. The t1/2 was increased by 8-, 6-, 5- and 4-fold with ZC, ZLG,
ZWP and ZPL nanocarriers respectively (Table 30). Overall, the relative oral
bioavailability (Frel%) of fenretinide in nanocarriers was increased significantly with all the
nanocarriers. ZWP nanocarriers enhanced the oral bioavailability of fenretinide by 7-fold
followed by ZLG (6-fold), ZPL (5-fold) and ZC (3-fold) nanocarriers.
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Figure 51: Plasma concentration of free fenretinide and fenretinide loaded ZC, ZLG,
ZWP, and ZPL nanocarriers after oral administration to rats. Each value represents
mean±SD, (n=3).
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Table 30: PK parameters of free fenretinide and fenretinide loaded nanocarriers after oral delivery in rats.
Fenretinide suspension

ZC-Fenretinide

ZLG-Fenretinide

ZWP-Fenretinide

ZPL-Fenretinide

0.22±0.0087

0.23±0.005*

0.54±0.001*

0.58±0.01*

0.60±0.02*

3.00±0.00

6.00±0.00

6.00±0.00

6.00±0.00

6.0±0.00

MRT (h)

4.37±0.08

16.61±7.09

11.28±0.53

9.07±0.04

8.49±0.21

Ke (h-1)

0.71±0.60

0.08±0.04

0.09±0.04

0.09±0.02

0.12±0.04

t

1.50±0.06

12.90±6.49*

9.82±3.38*

7.84±2.11*

6.17±1.93*

1.11±0.11

3.26±0.74*

7.03±0.47*

8.82±3.23*

5.57±0.07*

--

294.53±66.75*

633.51±42.68*

673.37±12.08*

502.19±6.58*

C

max

T

max

1/2

(μg/mL)
(h)

(h)

AUC

(0-inf)

F (% rel)

(μg-h/mL)

Each value represents mean±SD (n=3), *P<0.05 compared to fenretinide suspension. Cmax: Maximum plasma concentration; Tmax: Time
to reach maximum plasma concentration; AUC: Area under plasma concentration-time curve; MRT: Mean residence time; t1/2:
Elimination half-life; F (% rel): Percent relative bioavailability.
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Based on results from single dose PK study (Fig. 52), free fenretinide was
administered twice a day, while fenretinide loaded ZPL nanocarriers was given once a day.
Results from multiple-dose PK study show that ZPL nanocarriers increased the steady state
plasma concentration of fenertinide by 5-fold (Fig. 52). It is important to note that the
higher levels achieved with ZPL nanocarriers was achieved with a once-a-day dosing as
opposed twice-a-day dosing with free fenertinide. Around 1.5-fold higher Cmax

of

fenretinide was achieved at steady state with ZPL nanocarriers. However, there was no
significant change in Cmax for free fenretinide suspension after multiple dose. (Table 31).

192

Figure 52: Plasma profile of free fenretinide and ZPL-fenretinide nanocarriers after oral
administration of 20 mg/Kg fenretinide for 4 days. Free fenretinide administered twice
a day, while fenretinide loaded ZPL nanoparticles administered once a day. Each value
represents mean±SD. (n=3).
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Table 31: Steady state PK parameters of free fenretinide and fenretinide loaded ZPLnanocarriers after oral delivery in rats.
Fenretinide suspension

ZPL-fenretinide

Cmax-ss (µg/mL)

0.33±0.01

0.95±0.13*

Cavg-ss (µg/mL)

0.20±0.06

0.66±0.05*

Cmin-ss (µg/mL)

0.11±0.04

0.13±0.03*

Tmax-ss (hrs)

51.00±0.00

54.00±0.00*

Each value represents mean±SD (n=3), *P<0.05 compared to fenretinide suspension. ZPL.
Zein-pluronic-lecithin nanoparticles; Cmax-ss. Maximum concentration during dosing
interval at steady state; Cmin-ss. Minimum concentration during dosing interval at steady
state; Cavg-ss. Average plasma drug concentration at steady state t. Each value represents
mean±SD (n=3).
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At the end of multiple dose PK study, rats were sacrificed and different organs were
collected to deterrmine the distribution of fenretinide in the body. Results show that
significantly higher fenretinide was distributed in liver and kidney compared to other
organs such as brain, lung and spleen (Fig. 53). In general, concentration of fenretinide in
different organs were significantly higher than free fenretinide suspension which is
consistent with plasma concentration of fenretinide.

Figure 53: Organ distribution of free fenretinide and ZPL-fenretinide nanocarriers after
oral administration of 20 mg/Kg fenretinide in rats for 4 days. Free fenretinide
administered twice a day, while fenretinide loaded ZPL nanoparticles administered
once a day. Each value represents mean±SD. (n=3), P<0.05.
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4.5. Discussion
The clinical investigation of fenretinide isfocused on its anticancer activity
especially against pediatric neuroblastoma (Children's Oncology et al. 2006), oral
leukoplakia (Lippman et al. 2006), and ovarian cancer (Garcia. A. A. 2004). However,
fenretinide is reported to have low and variable bioavailability and dose escalation is
required to achieve reasonable therapeutic concentration. One important impediment in the
clinical application of fenretinide is the lack of a suitable delivery system to achieve high
and sustained therapeutic concentration. A corn-oil capsule has been used and achieved
around 5 µg/mL blood concentration of fenretinide with a daily dose of 4000 mg/m2 of
fenretinide (Garaventa et al. 2003). Although a lipid formulation of fenretinide (LYM-XSORB) was reported to achieve 3- to 7-fold higher plasma level of fenretinide compared
to corn-oil capsules, the safety of the lipid matrix in pediatrics especially infant patients is
yet to be clarified (Maurer et al. 2007).
Fenretinide has poor oral bioavailability due to its poor water solubility and
membrane permeability and poor chemical stability. The hydrophobic fenretinide was
encapsulated in the zein core, while the external hydrophilic shell was used to increase the
water solubility and permeability through the gastrointestinal membrane. In addition, the
core-shell nanocarriers sustained the drug release, thus reducing the dose and dosing
frequency in pediatric patients. The long-term stability study demonstrated the enhanced
chemical stability of the zein nanoformulation.
Apparent permeability coefficient (Papp) of fenretinide across Caco-2 cell
monolayers was also significantly increased using nanocarriers compared with free
fenretinide. The uptake of nanocarriers in Caco-2 cells was predominantly by non-specific
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endocytosis. Lecithin favors the interaction with lipophilic cell membrane and results in
higher cell uptake (Zhirnov et al. 2005). In addition, pluronic can inhibit P-gp and evade
the P-gp mediated efflux (Wei et al. 2013). Both lecithin and pluronic in ZPL nanoparticles
contributed to significantly higher permeability across cell monolayers. However, apparent
permeability for all other nanocarriers (except ZPL) was comparable to free fenretinide in
the first two hours, while a significant difference was observed at four hours indicating that
of the cellular uptake and subsequent transport and release play an important role in the
higher permeability observed with ZPL nanocarriers.
Lower plasma concentration of fenretinide with ZC nanocarrier was obtained can
be attributed to thefaster release of fenretinide in SGF and SIF. All other tested nanocarriers
(ZLG, ZWP, and ZPL) significantly enhanced Cmax, AUC, t1/2 and oral bioavailability of
fenretinide compared to fenretinide oral suspension. The enhanced membrane permeability
and intestinal epithelial cell uptake contributed to the increased absorption and
bioavailability of fenretinide using ZLG, ZWP, and ZPL nanocarriers. About 3-fold higher
steady-state plasma concentration of fenreitnide was obtained using ZPL nanocarrier
compared to free fenretinide suggests that lecithin composition in shell may favor the
uptake by lymphatic systems in intestine (Randolph and Miller 2014). However, further
studies are required to confirm the absorption mechanism of ZPL nanocarriers. We used
fenretinide at a dose of 20 mg/kg body weight of rat, which is 18-times lower dose than
reported for the lipid formulation of fenretinide (Maurer et al. 2007). Reported dose of
fenretinide with lipid formulation used as divided dose (twice a day) and ZPL nanocarriers
can be administered once day which is also advantageous in reducing dosing frequency
(Maurer et al. 2007).. Our results demonstrated that fenretinide loaded nanocarriers can
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achieve up to 0.6 μg/mL plasma concentration of fenretinide (Cmax), which is 13-fold less
than maximum plasma concentration reported for the lipid formulation with same dosing
frequency in mice (Maurer et al. 2007). Since the ZPL nanoformulation was able to
significantly increase the fenretinide concentration in the various organs, this can be used
for different types of cancers. A higher dose of ZPL nanoformulation is expected to achieve
equivalent or higher plasma levels compared to the lipid formulation. In addition, the use
of food-grade biopolymers offers significant advantages for developing a pediatric
formulation as a food-sprinkle. Further, the sustained release of fenertinide from ZPL
nanocarriers can reduce the dose and dosing frequency, thus improving the safety and
compliance in pediatric patients.

4.6. Conclusion
The present study demonstrated that zein based core-shell nanocarriers can be used
to enhance the oral bioavailability of fenretinide. In vitro studies showed that core-shell
nanocarriers significantly improved the stability and aqueous solubility/dispersibility of
fenretinide, sustained the release of fenretinide, and increased membrane permeability. The
compatibility with food matrices (milk and applesauce) indicate that fenretinide loaded
nanocarriers can be used as a food sprinkle, especially for pediatric patients. In vivo
pharmacokinetic study demonstrated that the oral bioavailability of fenretinide increased
from 3- to 7-fold using zein nanocarriers. Results from this multiple dose pharmacokinetic
study demonstrated that ZPL nanocarrier can be used to develop a once-a day orally
bioavailable formulation of fenretinide. Overall, the findings from this study can be used
to develop a safe, effective, and food compatible oral pediatric formulaton of fenretinide.
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5. Summary
Six different core-shell nanocarriers were developed using zein (corn protein) as
the core and milk protein (casein, lactoferrin, lactoglobulin, whey protein isolate) or PEG
or pluronic-lecithin as the shell. The shell structure-function relationship of zein-based
nanocarriers were evaluated in-vitro and in-vivo. The results were used to develop orally
bioavailable formulation for two challenging drug molecules. Zein nanocarriers were used
to encapsulate lopinavir, an antiretroviral drug, and fenretinide, an investigational new
chemical entity. Table 32 is a summary of the results from this dissertation and compares
the functional performance of the different zein-based nanocarriers. The particle size of
drug-loaded nanocarriers was 100 to 250 nm diameter with uniform size distribution. The
zeta potential varied based on shell composition. All the carriers were non-immunogenic
and safe for oral administration. Nanocarriers showed above 70% encapsulation efficiency
with 3 to 8% drug loading efficiency. Nanocarriers sustained the release of drug in
simulated gastric fluid, simulated intestinal fluid and in food matrices signifies the potential
of using as food sprinkle and mask the taste of bitter drugs. The release was mainly
dependent on shell the composition, physicochemical properties of encapsulated molecule,
and nature of the release of the medium. As shown in Table 32, ZC and ZPL ranked high
in terms of sustaining drug release. However, in presence of food matrices, these two
systems ranked lower than the other nanoformulations. Among the six formulations,
ZPEG, ZPL and ZLG showed relatively higher permeability than the other three
formulations. Further, the ZPEG also has P-gp inhibitory activity, suggesting the potential
use of this nanocarriers for enhancing the oral bioavailability of drugs that are substrates
for P-gp efflux pump. This was evident from the enhanced oral bioavailability of LPV,
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which was comparable to the oral bioavailability commercial LPV/r liquid formulation. On
the other hand, ZLG and ZWP have high bioadhesive property and may be suitable to
enhance the oral absorption of drugs by increasing the drug retention in the GI tract. These
carriers may also be used for developing colon targeted delivery systems. Although the
dissertation provides a general structure-function relationship for developing zein based
nanocarriers, the findings from this dissertation suggest that the zein nanocarriers have to
be customized based on the drug’s physicochemical properties, the functional properties of
the shell and the disease type. To this end, depending on the physicochemical properties of
the drug, one or more of the functional characteristics of the zein-based nanocarriers
contributes to the enhanced oral bioavailability. In case of LPV, the inhibition of P-gp and
CYP3A4 metabolism are the primary determinants of oral bioavailability. On the other
hand, in case of fenertinide, the enhanced memberane permeability and sustained release
characteristics are important determinants for enhanced oral bioavailbility. Overall, the
results from this dissertation provides a roadmap for rational development of zein-based
nanocarriers in particular and protein based nanocarrier in general for oral drug delivery
applications.
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Table 32: Comparison of zein-based nanocarriers for the feasibility of using for oral drug
delivery applications.
Characteristics

ZC

ZLF

ZLG

ZWP

+++

+

++

+++

++

++

Inhibition of P-gp efflux

+

++

+++

+++

+

+

Sequential release (Food matrix, SGF
and SIF)

++

+++

+++

++

+++

+++

Transepithelial permeability (Caco-2
monolayer)

++

++

+++

+++

+++

++

Gastrointestinal Retention

++

+

+

++

+++

+++

Bioadhesive/mucoadhesive property

++

++

++

++

+++

+++

Oral Immunogenicity

+++

+++

+++

+++

+++

+++

Oral bioavailability of lopinavir

ND

ND

+++

ND

++

++

+

ND

ND

+++

+++

+++

Sustained release

Oral bioavailability of fenretinide

ZPEG ZPL

(+++) Excellent; (++) good; (+) fair. ZC: Zein-β-casein nanoparticles; ZLF: Zeinlactoferrin nanoparticles; ZPEG: PEGylated zein micelle; ZPL: Zein-pluronic-lecithin
nanoparticles; ZLG: Zein-β-lactoglobulin nanoparticles; ZWP: Zein-whey protein isolate
nanoparticles. ND: Not done.
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6. FUTURE STUDIES
Findings from this dissertation open several new opportunities to expand the
application of these nanocarriers for the delivery of other drugs. Future studies should
include the following:
•

The findings from this study should be extended to BCS class II drugs (low
solubility and high permeability) and BCS class III drugs (highly soluble and low
permeability).

•

To understand the role of zein in core-shell nanocarriers, future studies should
include zein nanoparticles as a control.

•

Studies should evaluate the taste masking ability of these nanocarriers by
encapsulating drugs with a bitter taste. Future studies should also focus testing the
compatibility with additional food matrices based on preferences for different age
group of pediatric patients.

•

Mechanistic studies should be performed to understand the segmental absorption
in the gastrointestinal tract. Further studies should be performed to understand the
mechanism involved and identifying the major site of absorption.

•

The ability of the nanocarriers to target M-cells or mesenteric lymph nodes should
be explored to understand the potential of these nanocarriers for the treatment of
metastatic cancer and HIV infection.

•

Future studies should confirm the findings from this dissertation by testing the
formulations in appropriate pediatric animal models such as a juvenile pig model.

•

Future studies should also focus on testing the efficacy of these formulations in
suitable animal models.
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